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ABSTRACT 
Thrombolysis remains the predominant reperfusion strategy for ST segment 
elevation myocardial infarction (STEMI) in the United Kingdom. Although 
primary angioplasty may offer superior outcomes, the logistics of delivering this 
therapy in the UK have not been investigated. This thesis describes the 
development of a pilot primary angioplasty service in North East London. 
Outcomes are compared with the thrombolytic strategy, and platelet activation is 
explored as a possible biological mechanism determining reperfusion. 
The impact of the thrombolytic strategy on revascularisation following STEMI in 
North East London was first investigated. Thrombolytic delivery was effective, 
but necessitated frequent early revascularisation, leading to prolonged hospital 
stay. A primary angioplasty service was developed at the cardiac centre, and 
expanded to serve six network hospitals. Within the limitations of a daytime pilot, 
the service improved clinical outcomes, and was associated with a substantial 
reduction in hospital stay. 
Two admission strategies were compared - direct access to the cardiac centre 
following pre-hospital diagnosis by ambulance crews, and transfer of patients 
presenting to network emergency (A&E) departments after upstream 
administration of abciximab and clopidogrel. Direct access significantly reduced 
reperfusion times. Upstream anti-platelet therapy improved angiographic 
reperfusion prior to primary angioplasty, possibly compensating for inter hospital 
transfer delays. 
A subgroup of STEMI patients underwent platelet activation studies. Lower 
baseline platelet monocyte aggregate (PMA) levels predicted improved 
angiographic reperfusion following primary angioplasty, supporting the concept 
that PMAs may reflect plaque rupture severity, and may promote microvascular 
2 
dysfunction. Early anti-platelet therapy reduced PMAs following intervention, 
which may explain the benefit of early abciximab observed in clinical trials. 
In summary this thesis has demonstrated that primary angioplasty can be 
del ivered safely and eff ectively in North East London. The eff icacy of reperf usion 
may be determined by mechanisms involving platelet activation. Delivery of a 24 
hour seven day service should now be addressed. 
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CHAPTER 1 INTRODUCTION 
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1.1 Background 
Acute Myocardial Infarction (AMI) is a major cause of morbidity and mortality 
worldwide. Recent data from the British Heart Foundation estimate the incidence 
of AMI in the United Kingdom to be 700 per 100,000 population per year, 
leading to an estimated 92,000 events (1). Furthermore, the coronary event 
mortality in two separate UK populations (Belfast and Glasgow 1983-1993 and 
1985-1994 respectively) reported in the WHO MONICA (Monitoring Trends and 
Determinants in Cardiovascular Disease) Project (2) was 48%, and was thereby 
amongst the highest in Europe. Although the rate of cardiovascular death in the 
UK and around the world is falling, this trend is slowing, particularly in younger 
age groups. At present it is estimated that more than 1.2 million men and 
women living in the UK have suffered a heart attack (1). 
It is also noteworthy that age standardised coronary heart disease mortality 
rates in North East London boroughs are amongst the highest in Britain, and 
commensurate with the high levels observed in Northern Scotland and Northern 
Ireland. It is possible that the high proportion of South Asians living in North East 
London may in part contribute to these statistics. It has been demonstrated that 
Indian, Bangladeshi, Pakistani and Sri Lankan individuals (who comprise up to 
40% of the East London population) have a higher premature death rate from 
CHID than average, being 46% higher for men and 51% higher for women (1). 
Furthermore, this is the only ethnic group in which cardiovascular event rates 
are rising. 
It is clear that direction of resources towards primary prevention of coronary 
events through education, lifestyle change, diet, exercise, and smoking 
cessation is warranted. Indeed the latter is represented as a key target 
mechanism to reduce CHD mortality within the National Service Framework for 
Coronary Heart Disease (3). However the size of the existing burden of acute 
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coronary events necessitates strategies to reduce morbidity and mortality 
following clinical presentation with these events. 
This thesis investigates the management of patients presenting with ST 
segment myocardial infarction (STEMI). ST segment elevation on the ECG in 
association with chest pain commonly signifies acute coronary occlusion, and is 
thus the most severe acute coronary presentation. In this setting the immediate 
aim of therapy is to restore effective blood flow through the occluded epicardial 
artery as early as possible following presentation. This fundamental concept of 
reperfusion is based on the fact that ischaernia leading to necrosis is a 
progressive process, with irreversible injury of ischernic myocardium developing 
as a transmural wave front, occurring first in the subendocardium, and ultimately 
becoming transmural (4). Prompt reperfusion limits the degree of myocardial 
damage (4), and in turn improves prognosis (5). There are two traditional 
approaches to achieve coronary reperfusion. Medical reperfusion therapy 
involves the intravenous administration of a thrombolytic (fibrinolytic) agent in 
combination with aspirin. The mechanical reperfusion strategy involves 
immediate coronary angiography, followed by percutaneous intervention (PCI) to 
reopen the culprit vessel without antecedent thrombolysis. This strategy is 
referred to as primary angioplasty or primary PCI (PPCI). There is debate as to 
which should be the preferred reperfusion strategy for STEMI patients in the 
United Kingdom and around the developed world. This thesis examines the 
current provision of reperfusion therapy (thrombolysis) within a metropolitan 
United Kingdom population based in North East London, and studies the 
development, instigation, expansion and impact of a primary angioplasty service 
serving this population. The thesis also explores potential biological 
mechanisms that may determine the ultimate efficacy of reperfusion. 
In this chapter the pathophysiology of the acute coronary syndromes is first 
discussed, with particular emphasis on the role of platelets in thrombosis, 
inflammation and coronary plaque destabilisation. This provides the background 
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for subsequent consideration of the management of STEMI, where the debate 
between medical (thrombolysis) and mechanical (primary angioplasty) 
reperfusion therapies is addressed in detail. The benefits and limitations of both 
strategies are discussed, highlighting both clinical and logistic issues that may 
determine which therapy delivers optimal reperfusion to individual patients. 
Finally the discussion of reperfusion therapy moves beyond the restoration of 
epicardial blood flow to achieving patency of the coronary microvasculature. The 
implications and mechanisms of microvascular dysfunction following reperfusion 
are considered, and once again the influence of platelets is highlighted. 
1.2 Pathophysiology of Acute Coronary Syndromes 
1.2.1 Coronary Thrombosis 
Current understanding of the pathology of acute coronary events has been 
shaped by post mortem studies demonstrating the presence of coronary plaque 
fissuring in association with thrombosis in patients with ischaernic cardiac death 
(6). It has since been elucidated that over 90% of acute myocardial infarctions 
are characterised by the presence of an occlusive thrombus, but that the 
pathology of the underlying plaque varies (7). 65-75% of these thrombotic 
events occur as a result of rupture of an atheromatous plaque. These lesions 
are characterised by a necrotic core, thin fibrous cap, inflammatory cells 
(macrophages and T lymphocytes), and few smooth muscle cells (8). The 
remainder occur as a result of plaque erosion. These plaques are histologically 
quite different, with fewer inflammatory cells, more smooth muscle cells, and 
less necrosis in the core (9). While both situations are associated with coronary 
risk factors (smoking, cholesterol elevation, hypertension, diabetes and family 
history), plaque rupture is more closely linked to cholesterol levels (10), with 
erosion more common among younger patients, and females in particular (9). 
Interest has focused on the identification of thin cap fibroatheromas (TCFAs) as 
a precursor for plaque rupture. These lesions have many features in common 
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with ruptured plaques, including the thin cap (<65gm), a necrotic core, 
macrophage and T cell infiltrates, and loss of smooth muscle cells (11). Despite 
these similarities, there is as yet no direct causal link between the so called 
'vulnerable' plaque and rupture. Vascular, inflammatory and haematological 
mechanisms have been proposed, some or all of which may contribute (12). 
Exposure of the damaged endothelial surface to the blood stream leads to 
platelet adhesion, the first step in the thrombotic process. The platelet 
glycoprotein (Gp) Ib/IX/V complex binds to sub-endothelial von Willebrand 
Factor (vWF) associated with collagen, which in turn leads to platelet activation. 
The glycoprotein (Gp) Ilb/Illa receptor complex [see 1.4.1 Pharmacological 
therapies for Acute Coronary Syndromes] is up-regulated and becomes 
activated allowing binding of fibrinogen and platelet aggregation resulting in a 
platelet rich 'white' thrombus. If allowed to progress, further fibrin deposition 
ultimately results in the trapping of red blood cells leading to formation of red 
thrombus. Tissue factor (TF) produced by macrophages and endothelial cells 
(ECs) further accelerates the formation of thrombus, and plasminogen activator 
inhibitor 1 (PAI-1) released from platelets inhibit fibrinolysis at the rupture site. 
1.2.2 Mechanisms of plaque destabilisation 
Endothelial dysfunction is a prerequisite for the development of coronary 
atherosclerosis. Changes in vascular endothelial function can be demonstrated 
early in the disease process, including increased permeability, expression of 
adhesion molecules, and loss of endothelium dependent vasodilatation. The 
expression of soluble intercellular adhesion molecule 1 (ICAM-1) is associated 
with risk of future myocardial infarction (13), and impaired endothelium 
dependent dilatation can be demonstrated in patients with acute MI in both 
culprit and unaffected coronary vessels (14). However it is unlikely that 
endothelial dysfunction in isolation is the primary cause of acute coronary 
thrombosis. 
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The role of inflammation in initiating plaque events has been studied extensively. 
Acute coronary syndromes are associated with systemic inflammation, with 
elevation of inflammatory markers (including CRP and IL6) at clinical 
presentation (15). Widespread inflammation is detectable throughout the 
coronary tree in patients with acute coronary syndromes (16). This is consistent 
with angiographic (17), angioscopic (18), and intravascular ultrasound (IVUS) 
studies (19) that have demonstrated the presence of multiple complex coronary 
plaques at locations remote from the culprit plaque in the same patient, although 
there is debate as to their prognostic importance (17; 19; 20). HMG co reductase 
inhibitors (statins) reduce inflammatory markers following ACS, suggesting that 
anti-inflammatory mechanisms may explain event reductions in patients treated 
with these agents, over and above their lipid lowering effect (21-24). 
Inflammation may lead to plaque rupture via a number of mechanisms. Oxidised 
low density lipoprotein (LDL) leads to upregulation of cytokines, induction of 
tissue factor (TF), and macrophage over-expression of matrix 
metal loproteinases (MMPs) including MMP-1 and MMP-8, which digest collagen 
weakening the fibrous cap (25). Pro-inflammatory cytokines, including y- 
interferon, Interleukin 1P and TNFa, cause cytotoxic breakdown of smooth 
muscle cells, reducing compensatory collagen production. The imbalance 
between overproduction of MMPs and underproduction of stabilising collagens 
increases the risk of rupture. It has recently been proposed that intra-plaque 
haemorrhage may be a key trigger for plaque destabilisation, due to the rich 
cholesterol content of erythrocyte membranes (26). Infection has also been 
proposed as a possible precursor to inflammation. However, although agents 
such as Chlamydia pneumoniae and Helicobacter pylori have been localised to 
coronary plaques, no aetiological link has been established (21). 
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1.2.3 Role of platelet activation in acute coronary syndromes 
Increasing evidence supports the role of platelets as not only prothrombotic, but 
also pro-inflammatory particles with respect to acute coronary syndromes 
(ACS). The activation status of individual platelets can be measured using flow 
cytometry. P-selectin expression has until recently been the gold standard 
platelet activation marker (27). Levels are elevated in patients with acute MI 
(28; 29), and it has been demonstrated that differences in P-selectin expression 
may predict the severity of ACS presentation (30). Michelson et al have since 
demonstrated that circulating platelet-monocyte aggregates (PMAs) may be 
more sensitive platelet activation markers than P-selectin (31). Importantly PMA 
elevation also predicts subsequent myocardial infarction in patients with chest 
pain (32). Whereas markers such as creatine kinase (CK) and troponin only rise 
following myocardial damage, PMAs may reflect the severity of plaque rupture 
before necrosis occurs. That platelet activation may be an early predictor of 
plaque behaviour in ACS may suggest that therapeutic intervention to reduce 
their activation might have a plaque stabilising effect, and could thereby improve 
clinical outcomes. 
It is unclear however, whether platelet activation is a reactive process, or 
whether platelets may directly influence plaque behaviour. Recent evidence may 
suggest a potential mechanistic role of platelets in initiating plaque rupture. 
CD40 ligand (CD40L) is a pro-inflammatory cytokine of the tumour necrosis 
family that was first identified on cells of the immune system. CD40L is also 
present on vascular endothelial cells (ECs), smooth muscle cells, monocytes, 
and macrophages (33). Importantly it has now been demonstrated that the 
majority of human CD40L exists in platelet crypts (34). Following activation 
CD40L is rapidly translocated to the platelet surface, and soluble 'sCD40L' 
cleaved and released into the circulation by hydrolysis. CD40L has both 
thrombotic and inflammatory properties. It has a structural domain that allows 
binding to GpIlb/Illa and stabilises arterial thrombi, a property retained by 
sCD40L (35). In addition, ligation of CD40 on ECs induces numerous 
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inflammatory responses including release of chemokines (e. g. 11-6 and 11-8) and 
expression of leukocyte adhesion molecules (34). It has already been 
demonstrated that interruption of CD40L signalling may reduce progression of 
stable atheromatous plaques in animal models (36; 37), and that through 
induction of matrix metal loprotei nase (MMP) expression (33) may be implicated 
as a mechanism of plaque rupture. Endothelial CD40 ligation can also impair EC 
migration by increasing production of reactive oxygen species (ROS) (38), 
another mechanism that may promote plaque instability. Observational clinical 
data support this concept. CD40L is elevated in ACS patients (39; 40), with a 
higher ratio of sCD40L to membrane CD40L in acute MI compared with unstable 
angina (40), which may suggest a continuum of CD40L upregulation and 
hydrolysis related to the size of plaque rupture or thrombus burden. 
1.2.4 Summary - Pathophysiology of Acute Coronary Syndromes 
Acute coronary syndromes result from coronary thrombosis. The majority of 
thromboses causing acute myocardial infarction occur as a result of plaque 
rupture. These lesions are characterised by a thin fibrous cap, a lipid rich 
necrotic core, and inflammatory cell infiltrates. Plaque erosion is less common. 
These lesions also lead to coronary thrombosis, though their histology may be 
quite different. The precise mechanisms leading to plaque rupture and erosion 
have not been fully elucidated. Pathological and clinical trial data support the 
role of plaque inflammation in initiating events, and in particular the presence of 
oxidised LDL. However, evidence is emerging that haernatological factors rather 
than the vessel wall may instigate plaque events. Platelets possess both pro- 
thrombotic and pro-inflammatory properties that may have specific relevance. 
Markers of platelet activation (PMAs) may be early predictors of plaque 
behaviour in ACS. CD40 ligand expression also reflects platelet activation, but 
this molecule may also be mechanistic in the process of plaque destabilisation. 
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1.3 Clinical Presentations of Acute Coronary Syndromes 
The clinical consequences of these plaque events depend predominantly upon 
whether the resulting thrombus becomes intermittently or persistently occlusive 
(although the impact of epicardial arterial occlusion may be modified by factors 
such as collateral isation and myocardial oxygen demand), and whether damage 
to cardiac myocytes ensues. ACS manifest with a spectrum of clinical 
presentations. These can be defined immediately at the time of presentation 
using the clinical history and 12-lead electrocardiogram (ECG), and then further 
refined according to subsequent biochemical evidence of myocardial necrosis in 
the hours and days following presentation. ST segment Elevation Myocardial 
Infarction (STEMI) represents the most severe acute presentation, with ST 
segment elevation on the ECG most commonly signifying complete coronary 
occlusion (41; 42). Recent data from the GRACE registry suggest that STEMI 
represents 25-30% of all ACS presentations (43). The remaining ACS are 
termed Non-ST segment Elevation Acute Coronary Syndromes (NSTE-ACS), 
and are further subdivided into Non-ST segment Elevation Myocardial Infarction 
(NSTEMI) and unstable angina (UA), differentiated by the presence or absence 
respectively of biochemical evidence of myocardial necrosis measured by 
cardiac specific troponins or enzyme release (e. g. creatine kinase), and 
evolution of ECG changes (44). These latter syndromes are not necessarily less 
benign, being associated with a range of clinical risk determined by 
demographic and clinical factors (including age, diabetes, 
hypercholesterolaernia, prior history) in addition to clinical investigations 
including the nature of the ECG changes, and the presence of cardiac specific 
troponin release (45; 46). Clinical presentation with NSTE-ACS is less commonly 
associated with complete epicardial coronary arterial occlusion (47). 
1.4 Management of Acute Coronary Syndromes 
The goal of therapy for ACS is to prevent cardiac muscle damage, treat and 
prevent complications (including arrhythmia and heart failure), stabilise the 
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culprit plaque, and to prevent further cardiac events. There is universal 
acceptance that these syndromes necessitate a combination of 
chemotherapeutic agents, though debate continues as to the role of invasive 
investigation with cardiac catheterisation, and revascularisation, and further 
whether these interventions should be performed immediately, early (within 
hours to days), or delayed. The distinction between STEMI and NSTE-ACS is a 
critical step in determining not only the type of therapy administered, but also its 
timing. This thesis focuses on the immediate management of patients presenting 
with STEMI, where the immediate aim of therapy is the restoration of effective 
blood flow through the occluded coronary artery at the earliest opportunity. 
Before specifically considering reperfusion therapies, the role of relevant 
pharmacological and anti-platelet therapies will first be discussed. 
1.4.1 Pharmacological therapies for Acute Coronary Syndromes 
Aspirin 
Aspirin is essential in the treatment of ACS. It prevents the synthesis of 
thromboxane A2, a strong platelet agonist, through the selective acetylation of 
the hydroxyl group of the serine residue at position 529 in the polypeptide chain 
of platelet prostaglandin H synthase (48). Aspirin therapy has independent 
prognostic value in the treatment of STEMI, similar to that of thrombolysis alone, 
with an additive benefit when administered in combination (49). Similarly aspirin 
has been demonstrated to improve prognosis in patients with NSTE-ACS (50- 
53). 
Beta Blockers 
Beta blocker therapy is sympatholytic, reducing cardiac workload and 
myocardial oxygen demand. Beta blockade reduces the risk of progression to 
acute MI in patients with unstable angina (54), and improves prognosis following 
acute MI, through reduction of arrhythmic death and possible protection against 
myocardial rupture (55). 
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Statins 
The role of HIVIG co reductase inhibitors (statins) in reducing recurrent events 
following ACS is also firmly established (56-59). The pleiotropic effects of statin 
therapy may have particular relevance over and above their lipid lowering effect, 
and have been briefly discussed above [see 1.2.2 Mechanisms of plaque 
destabilisation]. The anti-inflammatory effects of atorvastatin 80mg were 
demonstrated in the MIRACL study, with an enhanced decline in C reactive 
protein (CRP) following discharge (though not interleukin-6) in the treatment 
group. In addition, high event rates associated with elevated plasma levels of 
soluble CD40L were abolished by atorvastatin (60; 61). 
ACE-inhibitors 
Angiotensin converting enzyme inhibitors (ACEI) were first demonstrated to 
reduce mortality following STEMI in the presence of clinical heart failure and 
with evidence of systolic LV dysfunction (62; 63). However, STEMI patients 
without LV damage also benefit from ACEI therapy (63; 64), and more recent 
data support their efficacy in improving clinical outcomes for a wide range of 
patients with established coronary disease, or risk factors such as diabetes 
(65; 66). 
Myocardial Infarction National Audit Project (MINAP) data demonstrate that 
between January and December 2003, at least 88% of people discharged from 
hospital following a heart attack in England and Wales were prescribed aspirin, 
67% beta blockers, 83% statins and 73% ACE inhibitors (1). The role of these 
therapies in the setting of ACS is firmly established, and will not be directly 
investigated in this thesis. In contrast, new anti-platelet, anti-thrombotic, 
thrombolytic, and anti-inflammatory pharmacological strategies for ACS continue 
to evolve, and for both STEMI and NSTE-ACS the optimal therapeutic agents 
and combinations are as yet not fully defined. 
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Theinopyridines 
The theinopyridines (ticlopidine and clopidogrel) irreversibly inhibit the binding of 
adenosine diphosphate (ADP) to the P2Y12receptor on the platelet surface. This 
interferes with platelet activation, degranulation, and inhibits the conformational 
change of the glycoprotein GpIlb/Illa receptor required for aggregation. 
Because of its superior side effect profile clopidogrel has become standard 
therapy in combination with aspirin for patients undergoing percutaneous 
coronary intervention with coronary stenting. This combination radically reduces 
the risk of acute vessel closure and subacute stent thrombosis (67; 68). The role 
of clopidogrel in the medical treatment of NSTE-ACS is strongly supported by 
the CURE study, which demonstrated a reduction in event rates in patients 
randomised to the treatment arm for a period of 3-9 months (69). NSTE-ACS 
patients undergoing PCI also derived additional benefit over and above the use 
of clopidogrel to cover the intervention (70). Most recently, the addition of 
clopidogrel to aspirin with fibrinolysis has been proven effective in reducing the 
risk of death, or recurrent myocardial infarction (or an angiographically occluded 
infarct vessel) with no increment in bleeding (71). In addition to the inhibition of 
ADIP binding, the clinical benefits of clopidogrel may be mediated by anti- 
inflammatory properties. It has recently been demonstrated that clopidogrel 
reduces platelet-leucocyte aggregate formation and sCD40L release in patients 
presenting with ACS (72). 
Platelet glycoprotein Ilb/Illa receptor antagonists (GPRAs) 
The glycoprotein Ilb/Illa receptor complex is the most densely expressed 
component of the platelet surface, with between 50 000 and 80 000 receptors on 
each individual platelet. 80% of GpIlb/Illa exists on the platelet surface in its 
resting state, with 20% internalized in the surface connecting system (SCS) and 
(x-granules. Upon stimulation GpIlb/Illa is exteriorized and undergoes 
conformational change to its active form. This allows binding of its primary ligand 
soluble fibrinogen. The process of fibrinogen bridging allows platelet-platelet co- 
adhesion, and is the final common pathway for platelet aggregation. As such, 
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inhibition of this receptor provides potent inhibition of aggregation. Abciximab is 
a monoclonal antibody fragment (Fab) directed against the receptor, directly 
blocking fibrinogen binding. Cross reactivity of abciximab with other integrins 
such as the (X503 (vitronectin) receptor and the MAC-1 (CD1 1 b/CD1 8) leucocyte 
receptor may provide additional anti-inflammatory mechanisms of action that 
may have relevance in the setting of ACS. Other GPRA therapies include the 
small molecule agents eptifibatide and tirofiban. Unlike abciximab these agents 
are competitive Gp Ilb/Illa inhibitors, and do not cross react with MAC-1 or CC503 
((73; 74). 
GP Ilb/Illa receptor antagonists (GPRAs) have become established as adjuvant 
therapy following high-risk percutaneous interventions, with reductions in major 
adverse events in both elective and acute cases (75-78). In the setting of PCI for 
NSTE-ACS, significantly reduced event rates have been demonstrated with 
upstream GPRA therapy using either abciximab or tirofiban, although the benefit 
appears restricted to those patients with elevated cardiac troponins (79; 80). 
While there is also some evidence to support the role of GPRA therapy as 
purely medical treatment for NSTE-ACS, the benefit is predominantly confined 
to those who then undergo a PCI (81), and indeed GPRAs are probably 
detrimental in low risk NSTE-ACS patients not undergoing intervention (82). In 
addition, there are data supporting the role of GPRA therapy for STEMI, 
facilitating primary PCI (83; 84), with subgroup analysis of one study suggesting 
a greater benefit in those treated as early as possible prior to intervention (83) 
[see 1.6.4 Pharmacological facilitation of Primary Angioplasty]. 
As is the case with clopidogrel, the anti-platelet effects of GPRA therapy may 
not be limited to the prevention of platelet aggregation, but also may reduce 
platelet activation. GPRA agents have been demonstrated to inhibit the release 
of sCD40L in vitro (85; 86). A recent study has now confirmed that GPRA 
therapy similarly reduces sCD40L release in vivo following PCI for NSTE-ACS 
patients (87). Furthermore, a retrospective analysis of the 
CAPTURE study 
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demonstrated that baseline elevation sCD40L predicted benefit from GPRA 
therapy (abciximab) independently of troponin in NSTE-ACS patients 
undergoing PCI (88). The effects of GPRA therapy on platelet-leucocyte 
aggregate formation have been more variable, with differential effects of GPRA 
agents (abciximab and eptifibatide) in vitro (89; 90). However, the latest clinical 
data suggest that platelet leucocyte aggregates are also reduced in ACS 
patients undergoing PCI treated with both these GPRA agents (87). Importantly 
the reductions in both sCD40L and aggregate formation were independent of the 
effects of clopidogrel. The mechanisms for these effects are undetermined. 
Platelet-leucocyte interaction predominantly occurs through platelet P-selectin 
binding leucocyte PSGL-1. Secondary binding may also occur through 
fibrinogen cross-linking GpIlb/Illa to leucocyte surface MAC-1, which would be 
affected by abciximab. 
1.5 Medical Reperfusion Therapy for ST Elevation Myocardial Infarction 
Intravenous thrombolysis remains the predominant reperfusion strategy for 
STEMI in the United Kingdom, and throughout the developed world. Large 
multi-centre randomised controlled trials in the 1980s and early 1990s have 
demonstrated that in combination with aspirin thrombolysis significantly 
improves mortality compared to aspirin alone (49; 91-94). Since the advent of the 
first generation of thrombolytic agents whose efficacy were proven in these 
studies (including streptokinase and recombinant tissue plasminogen activator 
(rt-PA)) newer preparations (e. g. tenecteplase and reteplase) have been 
bioengineered to be more clot specific, and are also easier to administer (in 
bolus form). Superior angiographic infarct related artery (IRA) patency has been 
demonstrated with the use of these agents, although prognostic benefits have 
remained unchanged (95-97). 'Fibrin - platelet lysis' (the co-administration of a 
GPRA with a reduced dose of thrombolysis) reduced recurrent ischaernia, ST 
segment elevation, and improve IRA patency in the GUSTO V study, but again 
did not influence mortality (98; 99). 
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1.5.1 National Service Framework for Coronary Heart Disease and 
Reperfusion Therapy 
The National Service Framework (NSF) for Coronary Heart disease in England 
(3) has thus far supported the use of thrombolytic therapy as the preferred 
reperfusion strategy for STEMI, setting explicit'door to needle' (DTN) and 'call to 
needle' (CTN) targets to ensure rapid drug delivery. The need for rapid access 
to pre-hospital care is emphasised in order to facilitate this. 
Standard 4 of the NSF states: 
'Patients with symptoms of heart attack must receive help from trained 
personnel with access to defibrillation within 8 minutes of a call for helpq. 
Standard 5 states 
'People thought to be suffering from a heart attack should be assessed 
professionally and, if indicated, receive aspirin. Thrombolysis should be 
given within 60 minutes of calling for professional help. 
Standard 6 states: 
'NHS Trusts should put in place agreed protocols1systems of care so that 
people admitted to hospital with proven heart attack are appropriately 
assessed and offered treatments of proven clinical and cost effectiveness 
to reduce their risk of disability and death'. 
The first report from the Royal College of Physicians Myocardial Infarction 
National Audit Project (MINAP) demonstrated that only 28% of hospitals 
supplying data treated the target 75% of eligible patients inside 30 minutes of 
arrival at hospital (100). However this has improved radically with each 
subsequent report such that delivery of thrombolytic therapy in the UK is now 
highly efficient, with 89% of hospitals now achieving the 30 minute target, which 
translates to 86% of all eligible patients receiving therapy within this time frame 
(101). 
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1.5.2 Limitations of Thrombolysis 
The goal of reperfusion therapies is to restore normal flow in the infarct related 
artery. Thrombolysis in Myocardial Infarction (TIMI) flow grade describes 
reperfusion angiographically (102). TIMI grades 0 and 1 flow are characterised 
by little or no penetration of angiographic contrast beyond the culprit lesion, with 
TIMI 2 flow indicating complete opacification of the vessel with contrast, though 
less briskly than neighboring unaffected vessels. TIMI grade 3 describes optimal 
epicardial blood flow, where the culprit vessel can be completely opacified with 
contrast similarly to unaffected vessels. Achieving TIMI 3 flow is associated with 
improved short and long-term prognosis following reperfusion therapy for 
STEMI. French et al demonstrated that out to 12 years following randomisation 
to streptokinase, 72% of patients with TIMI 3,67% of those with TIMI 2 and 54% 
of those with TIMI 0-1 flow survived (p = 0.023) (103). 
However, prompt thrombolytic therapy in the setting of randomised controlled 
trials only achieves TIMI-3 flow in the IRA in 50-70% of patients receiving 
therapy (95; 96; 98). Furthermore, the rate of early re-occlusion remains high (6- 
13% early, and up to 30% by 30 days) (104; 105). In addition, a significant 
proportion of patients in clinical practice are ineligible for treatment (through 
legitimate contraindications such as recent surgery, stroke, or bleeding 
diathesis), and perhaps more importantly, a significant number of eligible 
patients are denied treatment. The MIR and MITRA registries (21,092 patients) 
demonstrated that 48% of STEMI patients did not receive reperfusion therapy - 
29% being ineligible, and 19% with no obvious contraindication (106). This 
finding is confirmed by more recent data from the GRACE registry (the largest 
international ACS registry to date including patients from 94 centres in 14 
countries) demonstrating that up to 30% of STEMI patients still receive no 
reperfusion therapy at all (107). 
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1.5.3 Alternative Thrombolytic Strategies - Pre Hospital Thrombolysis, 
Failure to Reperfuse, and Rescue Angioplasty 
Thrombolysis is most effective when administered early (5; 108). This fact has 
led to the development and investigation of mechanisms to administer therapy 
prior to arrival at hospital. In the UK significant funds have been invested in 
equipping ambulance vehicles with 12-lead ECG and telemetry capabilities, 
alongside paramedic personnel training in ECG recognition and drug delivery. 
Early trials (109-111) demonstrated significant time savings can be achieved 
(median 30 -130 minutes) compared to hospital thrombolysis, though none 
translated the time saved into a mortality benefit. Earlier (pre hospital) 
thrombolytic administration does not avoid the problem posed by failure to 
achieve patency of the infarct related artery. The 'Comparison of Angioplasty 
and Pre-hospital Thrombolysis in Acute Myocardial Infarction' (CAPTIM) study 
(112) illustrates this issue. In 840 patients randomised to either pre-hospital 
thrombolysis or primary angioplasty the two strategies appeared equally 
efficacious. All patients in the study were taken by a physician-manned mobile 
intensive care unit directly to a cardiac centre with PCI facilities, where 26% of 
those randomised to thrombolysis underwent PCI specifically for failure to 
reperfuse. By 30 days, 70% of thrombolysis patients had undergone an 
unscheduled PCI, 33% undertaken as emergency procedures. Thus the pre- 
hospital thrombolysis strategy necessitated the backing of an emergency PCI 
strategy (termed 'rescue angioplasty') for those who failed to achieve clinical 
evidence of reperfusion. 
The rescue strategy (angioplasty following thrombolysis where failure to 
reperfuse has been diagnosed) has been implemented to varying degrees in UK 
cardiac centres. However data supporting this strategy are limited. Of nine 
randomised rescue PCI trials prior to 2004, only 4 were prospective 
comparisons with conservative therapy, and these included only 368 patients 
(113). Across these studies the non-invasive criteria employed to diagnose 
failure to reperfuse were not uniform. In practice up to 40% of all patients 
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receiving thrombolysis fail to reperfuse following thrombolysis (113-115). This 
presents an important management dilemma. 
Two recent randomised studies have now been performed in the UK, but have 
yielded contradictory results. In the Middlesborough Early Revascularisation to 
Limit Infarction (MERLIN) study (116), rescue PCI did not improve mortality, or 
left ventricular function at 30 days, and had a higher complication rate than a 
conservative approach (stroke 4.6% rescue vs. 0.6% conservative, P=0.03, 
transfusion required 11.1 % rescue vs. 1.3% conservative, p<0.001). However, 
the need for unplanned revascularisation was significantly reduced (6.5% rescue 
vs. 20.5% conservative, p<0.01), again highlighting the necessity for early 
revascularisation in a significant proportion of patients receiving thrombolysis 
even when not performed immediately. In contrast 6-month data from the 
Rescue Angioplasty versus Conservative Treatment or Repeat Thrombolysis 
(REACT) study demonstrated that the rescue strategy did reduce the event rate 
(a composite of death, re-infarction, stroke, and severe heart failure) by half 
compared with a repeat dose of thrombolysis (TL), or heparin (HP) alone (31% 
TL and 30% HP respectively vs. 15% p=0.0009 and p=0.002 respectively) (117). 
Again there was no mortality benefit. 
It is important to recognise that provision of rescue angioplasty for all patients 
with failure to reperfuse necessitates 24-hour PCI facilities for a sizeable 
proportion of STEMI patients. This infrastructure becomes relevant when 
comparing the thrombolytic strategy to alternative reperfusion strategies. 
1.5.4 Summary - Thrombolytic therapy in the United Kingdom 
Thrombolytic therapy is effective in the treatment of STEMI, with a marked 
reduction in mortality compared with aspirin alone. This therapy 
is the current 
preferred reperfusion strategy in the UK, with NSF targets directed towards rapid 
delivery of therapy. However, up to 30% of STEMI patients do not receive 
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therapy, only 50-70% of patients treated achieve effective reperfusion (TIMI 3 
flow), and the rate of recurrent infarction may be high. There is no consensus as 
to the optimal therapy for those who fail to reperfuse following thrombolysis. 
Studies investigating the systematic use of rescue angioplasty have been 
equivocal. Importantly, these trials demonstrate a frequent requirement for 
invasive investigation and revascularisation following thrombolysis. At present 
revascularisation is not currently considered to be an integral part of the 
thrombolytic strategy for STEMI in the NSF guidelines. The extent of invasive 
investigation and revascularisation and their impact on resource utilisation has 
not been quantified in the NHS setting. This thesis addresses this issue. 
1.6 Mechanical Reperfusion Therapy for ST segment Elevation Myocardial 
Infarction - Primary Angioplasty 
Primary angioplasty is defined as immediate percutaneous intervention in the 
setting of STEIVII, without administration of antecedent thrombolysis. This 
strategy can achieve IRA TIMI 3 flow in up to 95% of cases (118), and treats 
both the occlusive thrombus and the ruptured plaque. It is 12 years since the 
PAIVII and Zwolle groups first demonstrated a mortality benefit and reductions in 
recurrent ischaemia and reinfarction respectively, in patients treated with 
primary angioplasty compared with thrombolysis (119; 120). A quantitative 
review of the short-term results (between hospital discharge and 30 day follow 
up) of 10 randomised controlled trials conducted prior to 1997 demonstrated a 
mortality of 4.4% with angioplasty versus 6.5% using thrombolysis (p=0.02), with 
the composite endpoint of death or non fatal IVII of 7.2% vs. 11.9% respectively 
(p<0.001) (121). Stroke was also significantly reduced (0.7% vs. 2.0%; P=. 007). 
Long-term follow up data from ZWOLLE group (122) demonstrated an absolute 
mortality reduction of 11% (13% angioplasty vs. 24% streptokinase) after a 
mean of 5 years. There is consensus that primary angioplasty is the preferred 
reperfusion therapy in patients presenting with cardiogenic shock (123). The 
Shock study (Should we Emergently Revascularize Occluded Coronaries for 
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Cardiogenic Shock) demonstrated an absolute reduction in one-year mortality of 
13.2% among STEMI patients presenting in cardiogenic shock receiving early 
revascularisation (46.7% survival compared with 33.6% in those treated with 
initial medical therapy, P<0.03) (124), although it should be recognised that only 
55% of the revascularisation group actually underwent angioplasty, with 37.5% 
undergoing coronary bypass surgery. Importantly primary angioplasty is the only 
reperfusion strategy for those ineligible for thrombolysis. 
Since the publication of these studies percutaneous coronary intervention (PCI) 
has evolved. Stenting following primary angioplasty reduces six month major 
adverse cardiac events (MACE) when compared with balloon angioplasty alone 
(POBA) through reductions in target vessel revascularisation (125), and further 
improvements in 30 day and 6 month mortality and non fatal myocardial 
infarction have been achieved with the addition of glycoprotein receptor 
antagonist (GPRA) therapy (126), without an associated increase in 
haernorrhagic stroke. A recent quantitative review of 23 trials comparing primary 
angioplasty and thrombolysis (127) included trials employing current 
interventional techniques (12 using stents and 8 using GPRA therapy). This 
suggested a significant mortality reduction following PCI compared with 
thrombolysis (whether or not cardiogenic shock patients were included), with 
significant reductions in stroke and non-fatal MI (figure 
1.1). This was 
contemporary primary angioplasty in a wider group of patients than previously 
described. 
36 
Figure 1.1 Clinical Outcomes following Primary Angioplasty compared 
with Thrombolysis for the treatment of ST Segment Elevation Myocardial 
Infarction 
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outcomes at 4-6 weeks (127). 
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1.6.1 Primary Angioplasty - Models of delivery 
These data support primary angioplasty as the preferred reperfusion strategy for 
STEMI. However, the majority of the studies included in these analyses 
performed primary PCI in experienced cardiac centres with on-site angioplasty 
facilities. In the United Kingdom (and elsewhere) the vast majority of STEMI 
patients do not present to cardiac centres, but district general hospitals (DGHs) 
without PCI facilities. Although models of primary angioplasty in district hospitals 
without on site surgery have been demonstrated safe and effective (128), they 
present logistic and clinical problems. While the number of UK district hospitals 
with cardiac catheterisation laboratories is increasing, only the minority have 
developed coronary intervention programmes. The number of district hospital 
labs performing diagnostic catheterisation increased by over 20% (to 83) from 
2003-2004, while the total number of PCI centres rose by only 5% (to 77) during 
the same period (129). Most district centres would f ind it diff icult to staff or f und 
a 24 hour service for their respective catchment populations. Furthermore, 
individually these centres could perform too low a volume of primary angioplasty 
procedures to ensure clinical effectiveness. Canto et al (130) introduced the 
concept almost 10 years ago that clinical outcomes may be compromised in low 
volume primary angioplasty centres in the United States. In-hospital mortality 
was 28% lower in high volume centres, although high volume itself was 
described as greater than 33 procedures per annum, and low volume varied 
between only 5 and 11 primary angioplasty procedures, which may have less 
relevance to current clinical practice. 
The desire to deliver primary angioplasty as the preferred reperfusion strategy 
for all STEMI patients has resulted in the development and investigation of 
hospital network models of primary angioplasty, allowing systematic transfer of 
STEMI patients from centres without PCI facilities to a cardiac centre serving as 
a regional or network heart attack centre. A meta analysis of six randomised 
controlled trials investigating this approach concluded that even where transfer 
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is necessary PPCI remains superior to immediate on site thrombolysis (131), 
driven predominantly by the reduction in non fatal MI, but with a trend towards 
reduced mortality. Two of these studies in particular have focused attention on 
the transfer strategy, and warrant further discussion. 
The Danish Multicentre Randomized Trial on Thrombolytic Therapy versus 
Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) study 
(132) randomised both regional centre and DGH patients to on-site thrombolysis 
with rt-PA or primary angioplasty with stenting in most cases (93%). This was a 
high-risk group of patients with >4mm ST elevation and with symptoms for up to 
12 hours. The composite endpoint of death, reinfarction, or stroke was 
significantly reduced in the PCI group (13.7% versus 8.0% p=0.0003), driven 
predominantly by the reduction in non fatal MI. Remarkably, this outcome was 
observed even with transfer times (time from first presentation to arrival at the 
cardiac centre) of up to 3 hours (although the majority (96%) were transferred 
within two hours). The results are all the more striking as primary angioplasty 
was not available in 2 of 5 participating centres prior to the study, and operators 
were trained during a pilot period. 
The PRAGUE-2 study (133) randomised DGH patients only to on-site 
thrombolysis with streptokinase or transfer for PCI. The combined end-point of 
death, reinfarction or stroke at 30 days occurred in 15.2% of the thrombolysis 
(TL) group vs. 8.4% of the PCI group (P<0.003). Although the mortality reduction 
(10% TL vs. 6.8% PCI) was not significant across all patients, it became 
significant in patients who presented greater than 3 hours following onset of 
symptoms (15.3% TL versus 6% PCI P<0.02). This is in keeping with data from 
the Zwolle group demonstrating an exponential increase in mortality following 
thrombolysis with increasing symptom duration, which was significantly 
attenuated in patients undergoing primary PCI (134). 
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1.6.2 Influence of Time to Reperfusion 
DANAMI-2 and PRAGUE 2 have already influenced clinical practice in Europe 
and the United States. In Denmark and the Czech Republic where the two 
landmark trials were performed, thrombolytic therapy is no longer utilised for the 
majority of STEMI patients. However, the systematic transfer of unselected 
patients for primary angioplasty inevitably prolongs the time to reperfusion. In 
PRAGUE-2 the transfer strategy was highly efficient. The median time from 
randomisation to reperfusion (balloon inflation) was 94 minutes, including 
transport duration of 48 minutes. In contrast the time from randomisation to 
administration of thrombolysis was only 12 minutes. Allowing for the fact that 
reperfusion may not occur for up to 60 minutes following administration of 
thrombolysis, the transfer strategy still delayed reperfusion by 22 minutes in this 
trial. Similarly in DANAMI-2 the time from randomisation at a DGH to balloon 
inflation was 116 minutes, compared with randomisation to thrombolysis of 20 
minutes, causing a reperfusion delay of 36 minutes. Despite allowing longer 
transfer times by protocol, the actual median transfer time in DANAMI-2 was 
only 32 minutes. Although the DANAMI-2 trialists concluded that an initial 
strategy of transfer for primary PCI should be superior to thrombolysis 'when 
transfer time is less than 3 hours', it is conceivable that longer transfer times 
could disadvantage patients that would have received prompt thrombolysis. This 
raises a question as to whether there may be a time limit to the efficacy of the 
systematic transfer strategy, or whether there is a need for adjunctive therapy in 
transferred patients. 
An analysis (135) of 21 trials included in the quantitative review by Keeley et al 
(127) has explored the impact of transfer delay. It concluded that the mortality 
benefit of primary PCI may be lost if the delay to the invasive strategy (defined 
as the time difference between the administration of on site thrombolysis and 
that of primary angioplasty, or'door to balloon minus door to needle time (DTB - 
DTN)) exceeds 60 minutes. In terms of MACE (death, reinfarction or stroke), 
the two strategies reached equivalence when DTB-DTN was 93 minutes. The 
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analysis has some caveats. The relation between time delay and outcome was 
assessed on a group basis for each study rather than by individual patients, the 
analysis did not include trials with prolonged (DTB-DTN > 60minutes) transfer 
delays, and importantly the authors assumed a linear association between delay 
and outcome. Nevertheless this finding has had a direct impact on health policy. 
The most recent published ACC/AHA Guidelines for the Management of 
Patients With ST-Elevation Myocardial Infarction (136) state that thrombolysis 
should be the preferred treatment where DTB-DTN is expected to exceed 60 
minutes. 
1.6.3 Influence of Symptom Duration 
It is possible however that this guideline is over simplistic, as the relationship 
between the time delay to primary angioplasty and outcome is likely to be non- 
linear. Gersh and Anderson (108) have constructed a theoretical model 
demonstrating the relationship between mortality reduction, myocardial salvage 
and time from onset of symptoms to reperfusion (figure 1.2). This has an initial 
time-dependent phase within the first 2-3 hours where the potential percentage 
mortality reduction and myocardial salvage following reperfusion therapy is high, 
but then falls rapidly. Subsequently, a mortality benefit is still present but of 
decreasing magnitude over time such that treatment delay may exert less 
influence on outcomes. Importantly, this model suggests that delaying definitive 
reperfusion therapy through transfer to another centre may disadvantage 
patients presenting within the first few hours of pain, such that they are on the 
flat part of the curve by the time that primary angioplasty is performed (figure 
1.2). This hypothetical construct is further complicated by the fact that the 
duration of the early time dependent period may vary for individual patients as a 
result of multiple factors including the duration of coronary occlusion, the 
intermittency of the occlusion, the presence of collateral circulation, and 
myocardial oxygen demand. 
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Figure 1.2 Hypothetical construct of the relationship between symptom 
duration prior to reperfusion, mortality reduction, and the extent of 
myocardial salvage 
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Adapted from Gersh et al, JAMA 2005 (137). 
The mortality benefit of reperfusion therapy is maximal in the first 2-3 hours 
following onset of symptoms, as a result of myocardial salvage. After this period 
the mortality benefit is reduced, and as the curve flattens, the time to reperfusion 
is less critical. 
If successful reperfusion at a non PCI centre could be achieved with thrombolysis 
at point A, transfer for primary angioplasty may be harmful if this achieves 
reperfusion at points B or C. For a patient undergoing primary angioplasty at 
point C, pharmacological facilitation may have the potential to significantly 
improve mortality if reperfusion can be achieved at point A, but not at point B. 
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The influence of symptom duration at the time of presentation is therefore highly 
relevant to the delivery of primary angioplasty. In the Controlled Device 
Investigation to Lower Late Angioplasty Complications (CADILLAC) study 
shorter DTB times had the greatest impact in patients presenting within the first 
two hours of symptoms (138). Meanwhile, as discussed earlier, the mortality 
benefit of transfer for PPCI over thrombolysis in PRAGUE-2 was confined to 
those presenting beyond 3 hours from symptom onset (133). In addition, in the 
CAPTIM study mortality was reduced in patients receiving pre-hospital 
thrombolysis within 2 hours of symptoms compared to PCI, but thereafter the 
trend favoured primary angioplasty. Finally the Myocardial Infarction Triage 
Intervention (MITI) trial (139) demonstrated that the mortality of patients treated 
with thrombolysis in the first 70 minutes following symptom onset was 1.2% 
compared with 8.7% thereafter. Infarction size was limited to 4.9% vs. 11.2% of 
the left ventricle. 
The implication of these data is that thrombolysis and primary angioplasty are 
both highly effective in the first few hours following onset of symptoms, and that 
the speed of delivery may be more important than the therapy delivered during 
this period. However, beyond the first 2-3 hours, during which period up to 60% 
of patients may present (140) the time to reperfusion is less critical, and 
therefore primary angioplasty becomes more effective, owing to its superiority in 
achieving epicardial patency. 
1.6.4 Pharmacological facilitation of Primary Angioplasty 
Thrombolysis and primary angioplasty are not necessarily mutually exclusive. 
Facilitated primary angioplasty in the setting of STEMI describes a strategy of 
initial therapy with a thrombolytic agent or a glycoprotein Ilb/Illa receptor 
antagonist (either alone or in combination) followed by immediate angiography 
and angioplasty where appropriate. The rationale for this approach is to achieve 
reperfusion at the earliest opportunity before definitive mechanical treatment. 
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TIMI grade 3 flow prior to primary angioplasty may be expected spontaneously 
in 15-20% of cases, and is associated with improved procedural success, 
reduced LV dysfunction and reduced mortality (141; 142) 
Despite the intuitive value of this approach, early trials comparing routine 
angioplasty following thrombolytic therapy with a conservative ischaemia driven 
revascularisation strategy were disappointing, with no demonstrable 
improvement in left ventricular function (143-146), trends toward increased 
mortality (145), and significantly more bleeding (144). However, these studies 
predated the use of stents, smaller arterial sheaths, and low profile guiding 
catheters, and may therefore be less relevant to current clinical practice. In 
addition the trials were performed at a time when adjuvant anti-thrombotic 
therapies were evolving, prior to the routine use of theinopyridines, and in an era 
where high dose of heparin was routinely prescribed. 
A series of more recent small studies investigating facilitated primary 
angioplasty have combined contemporary PCI techniques with reduced dose 
thrombolytic regimens. In the Plasminogen Activator Angioplasty Compatibility 
Trial (PACT), facilitation with half dose rt-PA increased pre procedural TIMI-3 
flow from 15% (without thrombolysis) to 33% pre procedure, but had little effect 
on clinical outcomes (114). The Bavarian Reperfusion Alternatives (BRAVE) 
study (147) randomised DGH patients to facilitation with half dose reteplase in 
combination with a GPRA (abciximab) versus abciximab alone, followed by 
transfer to a PCI centre (147). There was no difference in the primary endpoint 
of left ventricular infarct size (using myocardial perfusion imaging), and no 
difference in MACE, although there was a non significant increase in bleeding in 
those receiving combined therapy. 
The BRAVE study was successful in terms of efficient service delivery. The 
median DTN time for pre transfer therapy was 30 minutes (combined reteplase 
and abciximab) and 24 minutes (abciximab alone), and the median transfer time 
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was 35 minutes in both the groups. However, median symptom duration at 
presentation was 130 and 140 minutes respectively, meaning that drugs were 
administered approximately 2.5 hours following symptoms, and may have only 
achieved reperfusion by 3-3.5 hours. The lack of clinical benefit may therefore 
have been the result of missing the early 'time dependent' window for 
reperfusion discussed above (Figure 1.2). 
The use of upstream GPRA therapy alone to facilitate primary angioplasty has 
also been explored. These agents are already established in reducing MACE 
following high risk PCI (75; 78), and have been proven more effective when 
administered prior to intervention in the setting of NSTE-ACS (148). The 
ADMIRAL study provided support for upstream abciximab prior to primary 
angioplasty with stenting (83), demonstrating that administration of abciximab 
prior to primary angioplasty with stenting improved TIMI flow grades pre and 
post procedure, with lower six month MACE (7.4% abciximab vs. 15.9% placebo, 
p=0.02), and improved LV recovery. Importantly, the 25% of patients in the 
abciximab arm who received the drug earlier (in a mobile intensive care unit or 
the emergency department) derived the greatest benefit. In contrast however, 
tirofiban (a small molecule GPRA) did not have any impact on either TIMI 3 flow 
pre procedure or clinical and angiographic outcomes in the Ongoing Tirofiban in 
Myocardial Infarction Evaluation (On-TIME) trial (149). 
Thus at present, the key questions of whether, and which therapy should be 
utilised to facilitate primary angioplasty remain unanswered. As yet the ability to 
achieve improved patency before intervention has not translated into clinical 
benefit. However, the studies to date have occurred in parallel with the evolution 
of percutaneous technologies and adjunctive pharmacology. In addition the trials 
have been small. A number of ongoing studies may provide answers to this 
question including the Facilitated Intervention with Enhanced Reperfusion 
Speed to Stop Events (FINESSE) study, and the Assessment of the Safety and 
Efficacy of a New Thrombolytic (ASSENT IV) trial. However, the results of these 
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will need to be interpreted in the context of symptom duration at the time of 
presentation. 
1.6.5 Summary - Primary Angioplasty 
Primary Angioplasty has been proven superior to thrombolysis in 23 randomised 
controlled trials. It offers improved infarct related arterial patency treating both 
the thrombus and the culprit plaque. It is the preferred treatment for STEMI with 
cardiogenic shock, and the only reperfusion option for patients with 
contrai ndi cations to thrombolysis. However, results vary with operator 
experience, and the majority of patients present to centres without PCI facilities. 
The systematic transfer of DGH patients with STEMI to a cardiac centre for 
primary PCI is safe and feasible. However, the time to reperfusion may be 
prolonged compared to on site thrombolysis. Data suggest that the transfer 
strategy could lose its efficacy when the delay to PPCI exceeds 60 minutes 
(DTB-DTN > 60 minutes), and have been incorporated into clinical guidelines. 
However, this may be over simplistic as clinical outcomes are more closely 
related to the duration of symptoms at the time of presentation than the speed of 
delivery of therapy. Furthermore this relationship is non linear, such that the 
speed of delivery may be more relevant for patients presenting early, and indeed 
this subgroup may be disadvantaged if transfer for PPCI prolongs reperfusion 
time. This provides a rationale for the pharmacological facilitation of primary 
angioplasty, to achieve reperfusion at the earliest opportunity in all patients. 
However, as yet the questions of both the optimal combination and timing of 
therapy remain undetermined, with the results of ongoing clinical trials awaited. 
The challenge faced by health providers is to deliver the optimal therapy for all 
STEMI patients. While it is clear that a PCI strategy is a necessity in treating 
STEMI (even where thrombolysis is the preferred first line treatment), the model, 
mechanism and timing may need to vary within STEMI populations. To date 
there has been no National Service Framework or National Health Service 
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strategy to investigate the provision of optimal reperfusion therapy with primary 
angioplasty in the United Kingdom. 
1.7 Optimising Reperfusion 
1.7.1 The Concept of Microvascular Perfusion 
In comparing treatment strategies for STEMI, the discussion thus far has been 
based on the supposition that early restoration of optimal epicardial patency 
(TIMI grade 3 flow) is the primary objective of reperfusion therapy. However 
TIMI-3 flow does not guarantee perfusion at tissue level. Up to 40% of patients 
do not regain microvascular and myocyte perfusion despite achieving TIMI-3 
flow in the infarct related artery (118; 150). 
The concept of the 'no-reflow' phenomenon has been demonstrated in animal 
models of ischaernia and reperfusion, and describes impaired tissue perfusion in 
the territory of the infarct related vessel despite restoration of epicardial flow 
(151). This impairment of microvascular flow does not occur until the duration of 
ischaernia is sufficient to cause myocardial necrosis, but increases thereafter as 
ischaernia is prolonged. In the experimental setting, where ischaernia and 
reperfusion are achieved using ligatures of non-diseased animal coronary 
vessels, the anatomical area of no-reflow is confined to areas of already 
irreversibly damaged myocardium. In clinical practice this process is more 
complex. Plaque disruption and thrombus formation in the epicardial artery lead 
to the risk that following reperfusion (particularly with primary angioplasty but 
also following thrombolysis) athero-thrombotic material may be propagated to 
the distal coronary bed (152). As the restored blood flow is preferentially 
diverted to areas of lower vascular resistance, this process may result in 
reperfusion related damage to myocardium that may not have been affected if 
the vessel had remained occluded. 
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1.7.2 Assessment of microvascular perfusion following STEMI 
Experimental models of ischaemia and reperfusion predict that the degree of 
microvascular dysfunction should correlate with the extent of myocardial 
damage, and clinical measures of microvascular perfusion following reperfusion 
therapy have confirmed this finding (153-156). Microvascular injury is associated 
with adverse left ventricular remodelling (150; 157; 158), heart failure (154; 158) 
and worse prognosis (159; 160), relationships which persist even when 
controlling for infarct size (161). Angiographic no-reflow (or 'slow-reflow') is a 
severe manifestation of microvascular dysfunction in the setting of STEMI, and 
describes the persistence of contrast in the epicardial vessel despite removal of 
the initial obstruction. However this refers only to one extreme of a spectrum of 
microvascular injury. Numerous clinical methods for quantifying the extent of 
microvascular compromise following myocardial infarction have been described, 
including ECG ST segment analysis (153; 155; 156; 160), angiographic blush 
scores (154; 158-160), coronary f low velocity (160; 162; 163), myocardial contrast 
echocardiography (MCE) (150; 157), nuclear perfusion imaging and magnetic 
resonance imaging (MRI) (161). At present there is no gold standard for the 
clinical measurement of microvascular perfusion, and only the minority of these 
modalities are applicable in routine clinical practice. 
Myocardial blush grade (MBG) is an angiographic method of grading 
microvascular patency, by scoring the density and persistence of contrast in the 
myocardial territory of the infarct related artery. As such it can be measured 
immediately following percutaneous intervention, but cannot determine the 
subsequent evolution of microvascular function (without serial cardiac catheter 
studies). Nevertheless, it is well validated, has strong prognostic value, and is 
readily available in clinical practice (154; 159; 160). 
The analysis of ST segment resolution (STR) is a surrogate measure for 
microvascular perfusion. However, its clinical and prognostic value has been 
proven repeatedly since its introduction (153; 159; 160). Whereas angiographic 
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blush measures microvascular patency, ST resolution reflects cell membrane 
integrity and myocyte function (164). This technique is simple, reproducible, and 
again readily available at the time of reperfusion and throughout the post 
reperfusion period. Its prognostic value is additive to angiographic blush scores 
(158; 159), and a recent study suggests that ST resolution has the greater 
independent long term prognostic value (160). 
1.7.3 Mechanisms of Microvascular Dysfunction in STEMI 
Microcirculatory dysfunction following reperfusion is caused by a number of 
mechanisms including ischaemia induced loss of endothelial integrity, red blood 
cell extravasation, neutrophil plugging, platelet microembolisation, and vascular 
spasm. Ischaemic endothelial injury impairs production of endothelium derived 
vasodilators such as nitric oxide, while vasoconstrictors such as endothelin and 
oxygen free radicals may be produced in excess. In addition reperfusion itself 
may cause a paradoxical worsening of cardiac function (165), damaging not only 
the cardiac myocytes, but also microvascular endothelial cells (166). This 
process of reperfusion injury is also characterised by an exacerbation of the 
imbalance between production of reactive oxygen species and nitric oxide (NO) 
(167). In addition reperfusion is associated with recruitment of neutrophils into 
the infarct zone (168), which leads to microvascular plugging (169; 170). The 
recruited neutrophils are also another major source of reactive oxygen species, 
which cause further direct myocyte and endothelial toxicity (168). Platelet 
microembolisation has been the target of pharmacological anti-platelet therapies 
(83; 84) and mechanical anti-embolic strategies (171; 172) aimed at improving 
outcomes following PPCI. Post mortem studies support the importance of this 
mechanism of microvascular compromise, with a high incidence of platelet 
aggregates found in the small intra myocardial vessels of patients suffering 
sudden ischaemic cardiac death (173). Finally, cellular oedema (of myocytes 
and endothelial cells) in response to the insults of both ischaemia and 
reperfusion may result in extrinsic capillary compression. 
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1.7.4 Prevention and Treatment of Microvascular Dysfunction 
Clinical strategies for treating microvascular dysfunction have targeted a number 
of the contributory mechanisms discussed above. Pharmacological therapies 
investigated include potassium channel (KATp) opening with NO donation 
(nicorandil) (174; 175), calcium channel inhibition (verapamil) (176), complement 
inhibition and neutrophil adhesion antagonism (anti-CD18) (177; 178). While 
adenosine and nicorandil have shown some promise, the clinical benefits have 
not been sufficient for these therapies to enter routine clinical practice. 
In the context of primary angioplasty anti-embolic strategies have dominated 
clinical studies directed at improving microvascular perfusion, including 
pharmacological anti-platelet therapy (glycoprotein Gp Ilb/Illa receptor 
antagonists (GPRAs)), and mechanical prevention of distal embolisation using 
thrombectomy catheters and distal protection devices. The role of GPRA agents 
has been discussed earlier, both as adjuvant therapy for all high risk ACS [see 
1.4.1 Pharmacological therapies for Acute Coronary Syndromes], and in the 
context of facilitated primary angioplasty for STEMI specifically [see 1.5.4 
Summary - Thrombolytic therapy in the United Kingdom]. The clinical 
benefits of GPRA therapy may be partly mediated by improved microvascular 
perfusion. This has been demonstrated in studies employing angiographic 
perfusion scores, invasive coronary flow, and myocardial contrast 
echocardiography (163; 179), although a recent post hoc analysis of myocardial 
blush scores in 1301 patients randomised to primary angioplasty with or without 
abciximab was less supportive (180). The precise mechanism for this benefit 
remains uncertain. GPRAs may reduce distal micro emboli, and inhibit the 
formation of platelet micro-particles that can be deleterious to the 
microvasculature through endothelial binding (181). In the case of abciximab, 
additional cross- reactivity with theOC5P3(vitronectin) receptor may also contribute 
to the reduction in platelet-endothelial binding (181). 
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The use of mechanical distal protection and thrombectomy devices for STEMI is 
not yet clearly defined. While they have the potential to prevent deterioration in 
microvascular perfusion, none have yet delivered an improvement in clinical 
outcome. In the EMERALD study (Enhanced Myocardial Efficacy and Removal 
by Aspiration of Liberated Debris) the PercuSurge GuardWire distal protection 
system (Medtronic, Santa Rosa, CA, USA) used during PPCI less than 6 hours 
after presentation with STEMI did not improve angiographic perfusion scores, 
ST segment resolution, final infarct size or clinical endpoints when compared to 
the results from a randomized control group (171). More concerning are the 
results of the recently presented AIMI study (172) where rheolytic thrombectomy 
(Angiojet, Possis) not only failed to improve the quality of reperfusion (despite a 
prior supportive study (182)), but was also associated with a significant increase 
in mortality when compared with routine PPCI alone. 
A number of explanations could account for the disappointing results of 
microvascular treatment strategies. Pathophysiologically, thrombus removal 
from the epicardial vessel may not be sufficient to improve microvascular 
dysfunction as this process does not affect the endothelial damage, oedema, 
neutrophil interactions, and release of vasoactive factors that contribute to the 
insult. Clinical study design may also be relevant. Neither AIMI nor EMRALD 
specifically selected patients with angiographically evident thrombus, a design 
which may have been more intuitive. However, it is likely that any effort to 
improve microvascular perfusion will be influenced by the duration of symptoms 
prior to reperfusion, and that the therapeutic time window may be narrow. 
Patients who present early (within 3 hours) have an excellent prognosis with 
minimal microvascular injury and are therefore unlikely to benefit from additional 
microvascular therapies. Those who present later sustain more microvascular 
injury, but may have less myocardium to salvage and the microvascular damage 
may not be reversible, such that the measurable benefit may be minimal (183). 
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1.7.5 Summary Microvascular Perfusion 
Epicardial infarct artery patency (TIMI grade 3 flow) does not guarantee 
perfusion at tissue level. Damage to the coronary microvasculature is associated 
with larger infarct size, adverse left ventricular remodeling and worse prognosis. 
The microvascular insult is mediated by a combination of platelet and athero- 
thrombotic embolisation, ischaemic endothelial damage, neutrophil plugging, 
vasospasm, and cellular oedema. While there is no gold standard method to 
assess the coronary microvasculature, angiographic myocardial blush grade and 
ST segment resolution on the ECG are well validated reproducible techniques 
that provide complementary information, and are readily available at the time of 
coronary intervention. 
Among the 90% of patients achieving TIMI-3 flow following primary angioplasty 
only half achieve complete ST resolution and angiographic microvascular 
patency (myocardial blush grade 2 or 3) (184). Thus there is a need to find 
strategies to further optimise microvascular perfusion following primary 
angioplasty. To date adjunctive therapies targeting the microvasculature have 
been disappointing, although study design and a narrow therapeutic time 
window could explain these results. Of all these microvascular strategies, anti- 
platelet agents (specifically glycoprotein Gp Ilb/Illa receptor antagonists 
(GPRAs)) have been most promising, though their precise mechanism of action 
with respect to microvascular dysfunction is not determined. 
1.8 Platelet Activation, Primary Angioplasty, and Microvascular Perfusion 
The role of platelet activation in the pathogenesis of acute coronary syndromes 
has been discussed above [see 1.2.3 Role of platelet activation in acute 
coronary syndromes]. Platelet activation is associated with an 
increased risk 
of developing an ACS, and the degree of activation may determine 
the type of 
clinical presentation. Enhanced platelet monocyte aggregate 
(PMA) formation 
predicts the extent of subsequent myocardial damage 
before it occurs (32) 
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which may suggest that PMAs directly affect plaque behaviour. Similarly it has 
also been discussed that CD40L may be implicated in the process of plaque 
rupture (33). The prothrombotic and pro-inflammatory properties of CD40L 
(including thrombus stabilisation, interaction with ECs, expression of leucocyte 
adhesion molecules, release of chemokines, induction of reactive oxygen 
species) (185) make it attractive as a potential mediator of microvascular 
compromise and reperfusion injury. To date the effects of platelet activation on 
the efficacy of reperfusion and microvascular function following primary 
angioplasty for STEMI have not been investigated. 
It is important to note that the interaction between platelet activation and 
reperfusion is likely to be reciprocal. Reperfusion itself may further activate 
platelets. Re-oxygenation of anoxic platelets in response to reperfusion 
increases platelet aggregation, and induces the production of reactive oxygen 
species from the platelets themselves, mediating further microvascular and 
myocyte damage (168; 186; 187). In addition there appears to be a reciprocal 
interaction whereby platelets activate neutrophils and vice versa (188). Activated 
platelets also enhance the production of reactive oxygen species by neutrophils 
(189). 
Primary angioplasty will itself influence platelet activation, which may in turn also 
affect the success of reperfusion. As the primary angioplasty process includes a 
combination of aspirin, clopidogrel, abciximab, and heparin in addition to the 
procedure itself, the consequences for platelet activation will be the sum of all 
their effects. Elective PCI (with or without stenting) enhances platelet expression 
of activation markers (31; 190; 191). To date however, there has been only one 
study of platelet activation in STEMI patients undergoing primary angioplasty 
(29). Platelet activation measured by P-selectin expression fell 4-8 hours 
following the procedure, returning at 24-48 hours -a finding that was not 
apparent in elective patients. There was an associated fall in platelet count and 
micro-particles were generated following primary angioplasty, which may signify 
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platelet sequestration rather than deactivation. This study may not be relevant to 
current practice, predating the use of coronary stents and GPRAs, and the 
availability of more sensitive measures of platelet activation. Nevertheless the 
study did demonstrate a significant difference between platelet behaviour 
following elective and primary angioplasty that may reflect differences in plaque 
pathology. Whereas elective PCI disrupts a stable plaque enhancing platelet 
activation, in the setting of STEMI an inflammatory and thrombotic process is 
already established at the site of the culprit plaque prior to intervention. 
The influences of GPRA therapy and clopidogrel on platelet activation have also 
been discussed above [see 1.4.1 Pharmacological therapies for Acute 
Coronary Syndromes]. GPRA therapy appears to reduce sCD40L release and 
platelet-leucocyte aggregate formation in patients undergoing PCI following a 
NSTE-ACS, an effect which is independent of clopidogrel (87). It is possible to 
speculate that the modification of platelet activation (measured by PMA 
formation and CD40L) may also provide a mechanism for the benefit of GPRA 
therapy in improving microvascular dysfunction following primary angioplasty. To 
date these markers have not been investigated in patients with STEMI 
undergoing primary angioplasty, and their relation to microvascular perfusion 
has not been explored. This thesis examines the influence of primary 
angioplasty on platelet activation measured by P-selectin expression, CD40L 
expression, sCD40L release, and platelet-monocyte aggregate formation. In 
addition the influence of these activation markers on microvascular perfusion 
(measured by ST resolution and myocardial blush grade) is addressed 
1.9. Summary 
ST segment elevation myocardial infarction is a severe and frequent acute 
coronary presentation, usually signifying a freshly occluded epicardial coronary 
artery due to thrombosis. Plaque rupture is the precipitating event in the majority 
of cases, with plaque erosion accounting for most of the remainder. The 
mechanisms determining these processes continue to be the subject of intense 
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investigation. while platelets are critical to the development of thrombosis, 
recent evidence suggests that platelet activation may be mechanistic in initiating 
plaque events. 
The goal of therapy for STEMI is the rapid restoration of arterial patency. There 
is debate as to the optimal reperfusion strategy. The National Service 
Framework for Coronary Heart Disease supports the widespread use of 
thrombolysis, and delivery of this therapy has improved across the UK since its 
publication. However, up to 30% of patients do not receive therapy, and only 
50% of patients treated achieve optimal reperfusion. In addition, reperfusion 
failure, reinfarction and recurrent ischaemia lead to a frequent need for 
revascularisation, often urgent. Primary angioplasty has been proven more 
effective than thrombolysis, provided that it can be performed rapidly in an 
experienced centre. In practice however, the majority of patients do not present 
to a hospital that can provide this treatment. This necessitates transfer 
mechanisms to deliver patients to a distant cardiac centre, which may prolong 
the time to reperfusion, and thereby lose the benefit. Pharmacological therapy 
may be administered prior to transfer to achieve earlier or more effective 
reperfusion. However, it is as yet undetermined whether and which therapy 
should be administered. At present there is no NSF revascularisation strategy 
for patients presenting with STEMI, and the logistics of providing primary 
angioplasty for the majority of UK patients has not been addressed. 
Prognosis following reperfusion therapy for STEMI is determined by the quality 
of blood flow in the epicardial artery. In those achieving complete epicardial 
patency (TIMI-3 flow), outcome is further influenced by patency of the 
microvascular circulation, which can be assessed at the time of reperfusion 
using angiographic and ECG analyses. The causes of microvascular dysfunction 
following reperfusion are multifactorial. To date, therapies directly targeting 
microvascular perfusion have demonstrated limited clinical benefit. Of these, 
anti-platelet strategies (specifically with glycoprotein Ilb/Illa receptor 
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antagonists) have proven most effective, though the precise mechanisms are 
unclear. Thrombo-inflammatory platelet activation markers may be implicated in 
the development of microvascular dysfunction following reperfusion. The 
influence of platelet activation on microvascular reperfusion following primary 
angioplasty has not previously been investigated. 
This research involves the analysis of the existing UK reperfusion strategy 
(thrombolysis) as applied to a metropolitan population based in North East 
London, and describes the development and instigation of a primary angioplasty 
service serving a network of district hospitals. The logistics and efficacy of two 
simultaneous patient transfer strategies are investigated, in tandem with the 
influence of pharmacological facilitation with glycoprotein Ilb/Ilia receptor 
antagonist therapy. In addition to clinical outcomes, the impact of these 
strategies on microvascular perfusion is examined. The potential role of platelet 
activation in determining epicardial microvascular perfusion is studied, and in 
turn the effect of the primary angioplasty process on platelet activation is 
explored. 
1.10 Alms of the Thesis 
To determine the extent and impact of invasive investigation and 
revascularisation following thrombolysis for ST segment Elevation 
Myocardial Infarction in North East London 
To describe the process of development and instigation of a pilot primary 
angioplasty service in North East London, using a network heart attack 
centre model 
To compare a strategy of pre-hospital ECG diagnosis and direct 
ambulance access to the network heart attack centre with that of inter- 
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hospital patient transfer in delivering 
network of hospitals without PCI facilities 
primary angioplasty within a 
To investigate the influence of platelet activation on epicardial and 
microvascular perfusion following primary angioplasty for ST segment 
Elevation Myocardial Infarction 
To investigate the effect of the primary angioplasty process on platelet 
activation in patients presenting with ST segment Elevation Myocardial 
I nfarction 
9 To compare clinical outcome and resource utilisation following the 
instigation of a the pilot primary angioplasty service with outcomes 
following the thrombolytic strategy in North East London 
1.11 Central Hypotheses 
Primary Angioplasty can be delivered safely and effectively in a United 
Kingdom population, with improved efficiency and clinical outcomes 
compared with thrombolysis. 
The efficacy of reperfusion following primary angioplasty can be 
determined by the degree of platelet activation at presentation 
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CHAPTER 2 METHODS 
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2.1 Subjects 
This research involves the comparison of reperfusion strategies for patients 
presenting with ST segment elevation myocardial infarction (STEMI) in North 
East London. STEMI was defined in accordance with the consensus document 
of The Joint European Society of Card iology/Ame rican College of Cardiology 
Committee for the redefinition of myocardial infarction (44) as follows: Ischaemic 
symptoms in association with new or presumed new ST segment elevation at 
the J point in two or more contiguous leads with the cut-off points 0.2 mV in 
leads V1, V2, or V3 and O-1mV in other leads, and a rise in a biochemical 
marker of myocardial necrosis (CK or troponin) according to the local reference 
range. 
2.1.1 Thrombolysis 
Data were collected from consecutive patients allocated to the thrombolytic 
reperfusion strategy following presentation with confirmed STEIVII to five district 
hospitals within the North East London Cardiac Network (April 2003 - January 
2005) (Figure 2.1, hospitals A-E). Data collection was prospective and non 
randomised using dedicated databases at each centre. In addition data from a 
historical cohort of STEIVII patients admitted to hospital E between October 2001 
and October 2002 were also included to enable comparison of outcomes prior to 
the instigation of a daytime pilot primary angioplasty service initiated at the 
regional cardiac centre (Figure 2.1) within the same NHS Trust. In hospital 
outcomes were recorded for all network patients. Follow up data post discharge 
were obtained from both historical and contemporaneous patient cohorts 
allocated to the thrombolytic strategy presenting to centre E, through outpatient 
clinics, recurrent admissions, and contact with general practitioners [see 
chapter 3.3 METHODS]. 
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Figure 2.1 Map demonstrating the location of District Hospitals and the 
Regional Cardiac Centre within the North East London Cardiac Network 
Chase Farm 
Ail Hil 
NORTH WEST 
shnner 
sKer4on 
$%mbley 
Park 
sHanviell 
*Ponders d 
98irntt . 04 
luckhurst Hill Jamurst Hill 
Fri Barn# 
/eEdmonton 
o8ofinds Greert NORTHEAST 
nh in, 
0] 
1 0.1 .ý ý'- ,r00,0 01- 
I a= 
0 
Wembley 
*Camden 
S& 
ED 
G]A 
4011lesden k 
Park R St Johns ood . 81 00 
oh Kensi on tm't UE 20 f ENTPAC It 
ofterlok 
K.; 
1t. 
ool ch *ChisvAck 
iRot r%k,, 
Aestminste 
eFul 404 90epff d 
*Green\ých 
GBri Ylon OBarnehur 
, 
oRichmo 0 eLee ORAney eMottingham 
Key 
The London Chest Hospital (Barts and the London NHS Trust). Regional cardiac 
centre functioning as a pilot Network Heart Attack Centre (N-HAC) 
District General Hospital with Accident and Emergency Department 
A Newham University Hospital 
B Whipps Cross University Hospital 
C King George Hospital, Ilford 
D Oldchurch Hospital 
E The Royal London Hospital 
F Homerton University Hospital 
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2.1.2 Primary Angioplasty 
Data were collected from unselected consecutive patients presenting with 
suspected STEMI to a regional cardiac centre functioning as a pilot network 
heart attack centre (N-HAC) between April 2003 and May 2005, utilising primary 
angioplasty as the preferred reperfusion strategy (Figure 2.1). Data collection 
was prospective and non randomised. Demographic, clinical, haernatological 
and biochemical data were recorded and stored on a dedicated database using 
SPSS software (SPSS Inc. Chicago Illinois). In hospital outcomes were recorded 
in those patients with confirmed ST segment elevation myocardial infarction. 
Follow up data were recorded through designated outpatient clinics, recurrent 
admissions and contact with general practitioners. 
2.2 Interventions 
2.2.1 Thrombollysis 
The thrombolytic strategy included the administration of 300mg aspirin orally 
and intravenous thrombolysis in standard doses (streptokinase, recombinant 
tissue plasminogen activator (alteplase - rTPA), reteplase or tenecteplase) for 
eligible patients, administered according to local and National Service 
Framework (NSF) guidelines (3). Patients could be transferred emergently for 
coronary angiography if thrombolysis was contraindicated, for recurrent or 
persistent ST elevation, or for ongoing ischaemia according to local physician 
preference. In addition patients could be transferred non-emergently for 
angiography during the index admission at the discretion of the admitting 
physician. 
2.2.2 Primary Angioplasty 
The development, mechanism of operation, and expansion of the network pilot 
primary angioplasty protocol is described in Chapter 4. 
Patients identified with 
suspected STEMI were admitted directly to the 
WHAC cardiac catheter 
laboratory via two routes. London Ambulance Service (LAS) crews making an 
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independent pre-hospital diagnosis were permitted to bring unselected patients 
directly to the WHAC, bypassing the nearest Accident and Emergency 
department (A&E) ('direct access'). Patients initially presenting to one of the 
participating network A&E departments could also be transferred urgently by 
ambulance to the WHAC ('A&E transfer'). Patients identified by LAS crews or 
ME physicians were transferred to the WHAC without consultation with local 
physicians or the WHAC itself. The WHAC was notified of arrival by London 
Ambulance Control. 
All patients allocated to the primary angioplasty strategy received 300mg aspirin 
orally, theinopyridine therapy (clopidogrel 300mg orally), and intravenous 
glycoprotein Gp Ilb/Illa receptor antagonist therapy (abciximab) prior to 
angiography. Aspirin was administered by London Ambulance Service (LAS) 
crews in those presenting via that route, or at the first hospital of presentation. 
Clopidogrel and abciximab were administered as soon as possible following 
arrival in the WHAC cardiac catheter lab ('direct access' admissions), or prior to 
transfer from ME ('A&E transfers'). 
Patients were assessed, and where appropriate taken directly to the catheter lab 
and angiography performed according to local protocol [see Angiographic 
analyses]. Cardiac catheterisation procedures were performed via the femoral 
or radial route using 6F or 8F catheters. Culprit vessel angioplasty and stent 
implantation were performed in all cases (where appropriate), with non-culprit 
intervention performed at the operator's discretion. 
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2.3. Platelet Studies 
2.3.1 Subjects 
The platelet studies presented in this thesis compare platelet activation in three 
groups of subjects: 
1. Patients with confirmed STEMI undergoing immediate angiography with a 
view to primary angioplasty. Patients were consented shortly following 
arrival at the WHAC prior to coronary angiography 
2. Patients with chronic stable angina admitted to the WHAC for elective 
coronary angioplasty. Subjects with a history of an acute coronary 
syndrome within the preceding six weeks were excluded. 
3. A control group of subjects with no symptoms or prior history of ischaemic 
heart disease recruited through advertisement. Subjects taking aspirin or 
other anti-platelet therapy within a week prior to the study were excluded. 
Ethical approval was obtained from the North East London Regional Ethics 
Commiftee (reference number P/03/024). 
2.3.2 Blood Sampling, Preparation and Analysis 
Samples were drawn from the antecubital fossa with minimal stasis using a 21- 
gauge needle prior to entering the cardiac catheter lab, at 2 hours following 
balloon inflation and at 18-24 hours following coronary angioplasty among those 
undergoing intervention. 
Flow Cytometry 
Flow cytometry (FACS Scan, BD Biosciences, USA) was performed in the 
Department of Haematology at the Royal London Hospital, and data analysed 
using Cellquest (version 3.1, BD Biosciences, USA) and Summit (version 4.0 
DakoCytomation, USA) software. 
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Blood was collected into EDTA, and then transferred into a tube (protected from 
light) containing citrate-theophylline-adenosine-dipyridamole (CTAD). The 
combined EDTA / CTAD tube was stored at 40C and analysed within 6 hours. 
5pl of blood were incubated for 5 minutes at 4*C with 5pl of anti-sera, then 
diluted in 90pl Tyrode's salt solution. This has previously been demonstrated to 
be a reliable method of sample preparation and analysis for ex vivo platelet and 
leucocyte activation assessment (192). 
Platelet Surface markers 
P-selectin expression was measured using fluorescein isothiocyanate (FITC) 
conjugated anti-CD62P (Beckman Coulter UK, IgGl mouse antibody, clone: 
CLB-Thromb/6). CD40L expression was measured using phycoerythrin (PE)- 
conjugated anti-CD154 (Beckman Coulter UK, IgGl mouse antibody, clone: 
MR1). The platelet gate was identified using forward and side scatter 
characteristics, with positive events identified using histograms of count against 
fluorescence intensity (Figure 2.2). The boundary between negative and positive 
events was determined using FITC / PE conjugated isotype controls. 10,000 
platelet events were counted (Figure 2.3). 
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Figure 2.2 Flow cytometry. Identification and gating of platelet events 
using forward and side scatter characteristics. 
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A dot plot of side scatter versus forward scatter characteristics of a whole blood 
sample during flow cytometry. A dark cloud of erythrocytes and white blood cell 
lines appear in the upper right quadrant, being of relatively larger size (forward 
scatter) and granularity (side scatter) than the platelet cloud which appears 
below and the left. A gate has been drawn around the platelet cloud as 
indicated. 
65 
Figure 2.3. Flow cytometry. Histograms gated on platelet events 
demonstrating events fluorescing in the FL1 channel. 
Figure 2.3a. The boundary between positive and negative events is first 
determined using FITC conjugated istotype control antibody, with a cut off 
of 0.1% in region R6. 
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A whole blood sample is analysed for CD62P (P selectin) expression. The 
sample is first incubated with an isotype control antibody linked to the 
fluorophore FITC to assess fluorescence resulting from non-specific antibody 
binding. The histogram plot above demonstrates count versus fluorescence 
intensity in the FL-1 channel for events occurring within the platelet gate 
demonstrated in figure 2.2. A region (R6) is created to determine the boundary 
between positive and negative events, which by convention includes 0.1% of 
events using the isotype control antibody. 
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Figure 2.3b. The experiment is repeated using FITC conjugated test 
antibody (in this case anti-CD62P). The percentage of positive events in R6 
determines the percentage expression of membrane P-selectin (2.7%). 
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Platelet Monocyte Aggregates (PMA) 
Using PE conjugated anti-CD14, (Beckman Coulter UK, IgG2a mouse antibody, 
clone RM052) the monocyte gate was identified on a dot plot of side scatter 
against PE (FL2) fluorescence. Platelet positive monocyte events were identified 
using FITC-anti Gp IX (CD42a), which is constitutively expressed on all platelets 
(Beckman Coulter UK, IgG2a mouse antibody, clone: SZ1). A plot of FL2 versus 
FL1 demonstrated dual positive events denoting aggregates (figure 2.4). Non- 
specific antibody binding was excluded using FITC-IgG2a isotype controls. 1000 
monocyte events were counted. Quantification of PMA formation was quoted as 
a percentage using the ratio of dual positive events (aggregates) to all CD14 
positive events (monocytes). 
All analyses were repeated in triplicate by convention. Results with a coefficient 
of variation greater than 10% were re-prepared and re-analysed. Where the 
coefficient of variation was greater than 10% on two separate analyses, the 
sample was excluded from data analysis. 
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Figure 2.4 Flow cytometry. Measurement of platelet monocyte aggregates 
Left panel: Dot plot of side scatter (SSC-H) vs. FI-2 fluorescence. The gated 
area demonstrates monocytes as a population of CD14-PE positive events. 
Right panel: Dot plot of FL2 vs. FL1 fluorescence demonstrating platelet 
monocyte aggregates (PMAs) as a population of dual positive events in the right 
upper quadrant. These are quantified as the percentage of the total monocyte 
population (right upper quadrant + left upper quadrant) 
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Plasma Assays 
Citrated plasma samples were taken onto ice, and immediately centrifuged for 
15 minutes at 10OOg at 4'C. The supernatant was removed and centrifuged 
again for 10minutes at 10,000g at 40C to remove excess platelets. The plasma 
was aliquotted into cryovials and stored at -800C. All samples were defrosted 
only once. Where necessary, repeat sample analysis was always performed 
using a separate cryovial from the same patient. 
Soluble P-selectin, high sensitivity soluble CD40 ligand (sCD40L), and 
interleukin 6 (IL-6) were measured using enzyme-linked immunosorbent assay 
(ELISA) according to manufacturers instructions (Bender Medsystems, UK). 
Briefly, sample plasma was added to the immunosorbent surface in the ELISA 
plate wells, fixed and then washed. A detection antibody to the antigen 
(sCD40L, P-selectin, or IL-6 as appropriate) was added. Plates were washed 
again to remove unbound antibody. A secondary antibody conjugated to a 
substrate specific enzyme was then added, and plates washed again. Finally the 
specific substrate was added, eliciting a chromogenic response. 
All samples were analysed in duplicate according to conventional methodology. 
In addition to sample plasma, reagents of standard concentrations supplied by 
the manufacturer and six additional internal control samples were included on 
each plate. Optical density was recorded using a GENios microplate reader 
(Tecan, Austria) using a 450nm filter. Samples returning a coefficient of variation 
in optical density greater than 10% were repeated. Repeat samples returning a 
coefficient of variation greater than 10% were excluded from analysis. Standard 
curves were generated using Microsoft XL software (Microsoft, USA), allowing 
derivation of concentrations (Figure 2.5). 
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Serum creatine kinase (CK) level was measured as a marker of myocardial 
infarct size on admission and at 18-24 hours in the biochemistry department at 
the Royal London Hospital. The highest level was recorded as the peak CK 
Figure 2.5 Enzyme linked immunosorbent assay. 
Optical density vs. concentration of P-selectin (ng/ml): An example of a 
standard curve generated using a P-selectin ELISA plate (Bender 
Medsystems, UK) 
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The graph demonstrates optical density against concentration (in ng/ml) for an 
ELISA plate assaying soluble P selectin. The points are derived using reagents 
of standard concentrations supplied by the manufacturer, and an equation 
derived to obtain the P selectin concentration for a given optical density. 
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2.4 ECG analyses 
ST segment resolution on the 12 lead ECG was used as a surrogate marker of 
microvascular reperfusion (155; 184). ST segment analysis was performed on all 
patients assigned to the primary angioplasty strategy, where the ECG was 
interpretable. 
The 12 lead ECG was performed by the ambulance crew (in those presenting 
via this route), on arrival at the first hospital of presentation, at the heart attack 
centre prior to primary angioplasty, at 60 to 90 minutes post procedure on the 
coronary care unit, and at 18-24 hours. The location and extent of maximum ST 
segment elevation was recorded. Recordings were copied and anonymised. 
The ST segments were measured 20ms after the J-point to the nearest 0.25mm 
using calipers by a trained independent observer blinded to the clinical details. 
The summed ST segment recovery (2: STR) was calculated according to the 
validated method employed by Schroeder et al (155) as follows: The difference 
between the sum of ST segment elevation (2: STE) (in leads V146, I and aVL 
for anterior and 11,111, aVF, V5, V6 for non-anterior infarction) at baseline and 
immediately following primary angioplasty was expressed as a percentage of the 
baseline ZSTE. This was repeated for an ECG at 18-24 hours. The pre 
procedural ECG (if different to baseline) was also measured to assess 
spontaneous and pharmacologically facilitated reperfusion. 
2.5 Angiographic analyses 
A full diagnostic study was performed on all patients undergoing primary 
angioplasty as per local protocol. Angiography of the target vessel was 
performed to demonstrate the culprit lesion(s) in at least 2 orthogonal views for 
the right coronary artery and 3 for the left coronary artery (at least 600 of rotation 
or angulation between views) following administration of intracoronary nitrate. 
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Image acquisition for angiographic perfusion imaging was performed to 
demonstrate the myocardial infarct territory with minimal overlap of non-infarcted 
regions. Runs were acquired to demonstrate arterial opacification and contrast 
washout (with filling of the coronary venous system or for 3 cardiac cycles 
following cessation of contrast injection). Intracoronary isosorbide dinitrate (1- 
2mg) was injected prior to initial and final acquisitions to standardise coronary 
vasomotor tone. Image acquisition was performed using a digital image system 
(GE Healthcare, USA) at a rate of 15 frames per second. 
Angiographic perfusion views were obtained on all patients undergoing primary 
angioplasty immediately pre and post procedure, and analyses performed by 
two independent observers blinded to the clinical data. Epicardial flow was 
assessed using the TIMI flow grade (102), and microvascular perfusion was 
assessed using the myocardial blush grade and corrected TIMI frame count 
(cTFC) in the territory of the infarct related artery, as described by Van't Hof et al 
(193), and Gibson et al (194) respectively, as explained below. TIMI thrombus 
burden in the index vessel was also assessed prior to intervention (195). 
2.5.1 TIMI Flow Classification 
TIMI 0 No perfusion. 
TIMI 1 Penetration of angiographic contrast with minimal perfusion. 
Contrast fails to opacify the entire bed distal to the stenosis for the 
duration of the cine run. 
TIMI 2 Partial perfusion. Contrast opacifies the entire coronary bed distal 
to the stenosis. However, the rate of entry and/or clearance is 
slower in the coronary bed distal to the obstruction than in 
comparable areas not perfused by the dilated vessel. 
TIMI 3 Complete epicardial perfusion. Filling and clearance of contrast 
equally rapid in the coronary bed distal to stenosis as in other 
coronary beds. 
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2.5.2 Myocardial Blush Grade (MBG) 
MBG 0 no contrast density or persistent staining of the myocardium with 
contrast. 
MBG 1 minimal contrast density 
MBG 2 moderate contrast density, but less than that obtained during 
angiography of a non infarct related artery. 
MBG 3 normal contrast density comparable to that obtained during 
angiography of a non infarct related artery. 
2.5.3 Corrected TIMI Frame Count 
The number of frames taken for contrast to reach standardised distal landmarks 
was counted. The first frame was counted when contrast fully entered the infarct 
related artery antegradely, with a column of contrast visualised to extend across 
the entire width of the artery. The last frame was counted when dye first 
appeared at the predefined distal landmark. For the left anterior descending 
artery (LAD) this was the distal bifurcation at the apex. For the right coronary 
artery (RCA) the landmark was the first branch of the postero-lateral extension 
after the bifurcation. For the circumflex (Cx) this was the distal bifurcation of the 
vessel where dye travels the furthest but also passes through the culprit lesion. 
The total number of frames counted was multiplied by 2 for standardisation with 
the initial method described (30 frames per second), as has been recently 
validated for use in a modern digital cardiac catheter lab (196). LAD values were 
divided by 1.7 to control for the longer length of the LAD as described in the 
original paper by Gibson et al (194). 
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2.5.4 Angiographically evident thrombus (AET) 
A patient was considered to have AET if TIMI thrombus grades 2 to 5 are 
present. 
TIMI thrombus grade 0 no angiographic characteristics of thrombus are 
present 
TIMI thrombus grade 1 possible thrombus is present, with such angiography 
characteristics as reduced contrast density, haziness, 
irreqular lesion contour, or a smooth convex 
"meniscus" at the site of total occlusion suggestive 
but not diagnostic of thrombus 
TIMI thrombus grade 2 there is a definite filling defect consistent with 
thrombus, with greatest dimensions : 51/2 the vessel 
diameter 
TIMI thrombus grade 3 there is a definite filling defect consistent with 
thrombus but with greatest linear dimension A/2 but 
<2 vessel diameters 
TIMI thrombus grade 4 there is a definite filling defect consistent with 
thrombus, with the largest dimension ý2 vessel 
diameters; and in 
TIMI thrombus grade 5 there is total occlusion. 
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2.6 Clinical Outcomes 
2.6.1 Mortality 
Cardiac death was defined as death due to any of the following: 
Acute myocardial infarction. 
Cardiac perforation/pericardial tamponade. 
Arrhythmia or conduction abnormality. 
Death due to complication of the procedure, including bleeding, vascular 
repair, transfusion reaction, or bypass surgery. 
* Any death in which a cardiac cause cannot be excluded. 
Non-cardiac death was defined as a death not due to cardiac causes (as defined 
above). 
2.6.2 Major Adverse Cardiac Events 
A major adverse cardiac event (MACE) was defined as death, myocardial 
infarction (Q wave and non-Q wave), cerebrovascular accident, or emergency 
revascularisation. 
Non fatal myocardial infarction was defined as typical chest pain with a new 
increase in troponin I or T, with or without ECG changes. 
Emergency revascularisation following discharge was defined as 
revascularisation driven by ischaemic chest pain necessitating recurrent hospital 
admission, with or without a rise in troponin or ECG changes. 
Revascularisation during the index admission and elective revascularisation for 
exercise induced ischaemia following discharge were recorded, but were not 
included in the composite MACE endpoint. 
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2.7 Statistics 
Statistical analyses specific to each chapter are documented in their respective 
methods section. Normally distributed continuous variables are presented as 
means and standard deviations. Skewed distributions are presented as medians 
and inter quartile ranges. All statistical analyses were performed using SPSS 
software version 11 .5 (SPSS Inc. Chicago Illinois). Ap value of 
less than 0.05 
was considered statistically significant. 
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CHAPTER 3 The Burden of Revascularisation following the Thrombolytic 
Strategy for the Treatment of ST Segment Elevation Myocardial Infarction 
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3.1 ABSTRACT 
Thrombolysis remains the predominant reperfusion strategy for ST segment 
Elevation Myocardial Infarction (STEMI) in the United Kingdom with National 
Service Framework targets directed towards delivery of this therapy. Primary 
angioplasty can improve outcomes, but has been perceived to be prohibitively 
expensive, due to the potential increase in revascularisation activity. This 
chapter investigates the existing extent of coronary angiography and 
revascularisation following STEMI treated using the thrombolytic strategy in 
North East London, and its impact on resource utilisation measured by duration 
of hospital stay. 
Subjects: 993 patients with ST segment Elevation Myocardial Infarction 
admitted to five district hospitals without on site coronary intervention within 
North East London. Data collection was prospective and non-randomised. 
Methods: Inter hospital transfers for inpatient coronary angiography (IPA) and 
duration of hospital stay were measured at all centres. A subgroup of 192 
subjects admitted to one centre (centre E) was further investigated with respect 
to inpatient revascularisation and clinical outcome. This cohort was followed for 
a median (IQR) of 20 (10 - 41) weeks. Major Adverse Cardiac Events (MACE) 
included death, non-fatal myocardial infarction (NIFIVII), stroke, and emergency 
revascularisation post discharge. Hospital readmissions, outpatient catheter 
studies and planned revascularisations were also recorded. 
Results: 851 (86%) patients received thrombolytic therapy. 50% (492) were 
transferred for IPA, although there was significant variation between centres 
(36% - 61%, p<0.001). Of these 16% were 
transferred urgently within the first 24 
hours of admission. Inpatient stay at the district hospital was prolonged 
by a 
median of 2 days in patients referred for non urgent 
IPA (median [IQR] 6 [4-11 ] 
vs. 8 [5-15] days, p<0.001). 54% (103) of the subgroup presenting 
to centre E 
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were transferred for IPA, leading to inpatient revascularisation in 38% (73), 88% 
performed percutaneously (PCI). MACE was elevated among patients 
discharged without angiography compared to those transferred for IPA (37% vs. 
10%, p=0.001). Mortality and stroke were both significantly elevated (18% vs. 
5% IPA, p=0.004; 7% vs. 1%, p=0.035 respectively) though this is likely to 
reflect patient selection. NFMI and emergency revascularisation following 
discharge were both higher in those not undergoing IPA, though not reaching 
significance (10% vs. 4% IPA p=0.15; 10% vs. 4% IPA, p=0.15 respectively). 
30% of those not undergoing IPA underwent angiography during follow up, 15% 
following emergency readmission. At the time of follow up 65% had undergone 
angiography, and 45% revascularisation (85% PCI). 
Conclusions: Despite effective delivery of thrombolysis, the majority of STEMI 
patients in North East London require coronary angiography. Of those who 
undergo revascularisation, the majority is performed percutaneously. Inpatient 
transfer for angiography significantly prolongs hospital stay at the non 
interventional centre. Those not transferred for IPA are more frequently 
readmitted with recurrent events leading to further emergency catheterisation 
and revascularisation procedures. The existing burden of revascularisation 
following STEMI necessitates reassessment of the approach to reperfusion 
therapy in North East London, including consideration of primary angioplasty. 
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3.2 INTRODUCTION 
The superiority of primary angioplasty over thrombolysis as reperfusion therapy 
for ST segment elevation myocardial infarction (STEMI) has been demonstrated 
by multiple randomised controlled trials (127). In spite of this there has been a 
perception in the United Kingdom that the benefits of this therapy are not 
sufficient to overcome the financial cost of revascularisation and the logistics of 
treating the majority of STEMI patients that present to hospitals without on-site 
coronary intervention. Recent studies have established that transfer of STEMI 
patients for primary angioplasty from district hospitals to a 'regional heart attack 
centre' (RHAC) with interventional facilities is safe, and may be more effective 
than immediate on-site thrombolytic therapy (132; 133). Additionally, STEMI 
patients treated at non interventional centres utilising thrombolysis may also 
require inpatient transfer for coronary angiography at a cardiac centre for failure 
to reperfuse, recurrent ischaernia, if there are contraindications to thrombolysis, 
or high risk features including an early positive exercise test. The aim of this 
study was to investigate the extent of angiography and revascularisation 
following presentation with STEMI within a network of hospitals in North East 
London all utilising the thrombolytic reperfusion strategy. Comparison was made 
between referral practice between centres, and the impact of transfer on bed 
utilisation was assessed. 
3.3 METHODS 
Patients 
The study included 993 patients with ST segment Elevation Myocardial 
Infarction admitted to five district hospitals without on site coronary intervention 
within North East London. Data collection was prospective and non-randomised. 
Consecutive STEMI patients were entered on separate dedicated databases at 
each centre. Each hospital dataset was collected independently, and then 
combined for analysis. Data from four hospitals (A, B, C and D) relate to 
consecutive admissions between April 2003 and January 2005. 
Centre E was 
the district general hospital located geographically closest to and within the 
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same NHS Trust as a tertiary cardiac centre serving all five district hospitals 
(Figure 2.1). Data from hospital E included 192 patients; 105 admitted 
consecutively between October 2001 and October 2002 prior to the instigation of 
a daytime (0800-1700) pilot primary angioplasty service, and 87 patients 
admitted between April 2003 and April 2004 presenting outside the operating 
hours of the pilot primary angioplasty service. 
Interventions 
Eligible patients were treated with thrombolysis according to National Service 
Framework (NSF) guidelines (3). Inpatient coronary angiography was performed 
following inter-hospital transfer to the regional cardiac centre. The decision to 
refer patients for inpatient angiography was based on local guidelines and 
physician preference. Transfer within 24 hours of admission was used a 
surrogate for emergency catheterisation for failure to reperfuse or early recurrent 
ischaernia. Inpatient revascularisation was performed according to operator 
preference. Patients were discharged according to local physician preference. 
Outcome Measures 
The rate of in-patient angiography and hospital stay were recorded at all 
centres. Hospital stay excluded hospitalisation at the cardiac centre. In-patient 
revascularisation was recorded in 192 patients presenting to hospital E. This 
cohort were followed for a median (IQR) of 20 (10-41) weeks. In hospital 
mortality was 8% (15). Data were available for 160/177 (90%) patients alive at 
discharge, through outpatient clinics, inpatient episodes, and general practitioner 
or patient telephone interview where necessary. Of the 17 patients lost to follow 
up, 3 left the country leaving no forwarding address. The remainder were not 
traceable due to incorrect or inconsistent personal and or general practitioner 
details. Major adverse cardiac events (MACE) included a composite of death, 
non fatal myocardial infarction, stroke, and emergency revascularisation 
following discharge. Non fatal infarction was defined as typical chest pain with a 
new increase in troponin 1, with or without ECG changes. Emergency 
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revascularisation following discharge was defined as revascularisation driven by 
ischaernic chest pain necessitating recurrent hospital admission, with or without 
a rise in troponin or ECG changes. Revascularisation during the index 
admission and elective revascularisation for exercise induced ischaemia 
following discharge were recorded, but were not included in the composite 
MACE endpoint. 
Statistics 
Due to the skewed distribution of data, comparisons of duration of hospital stay 
and rates of referral for inpatient angiography were performed using non 
parametric tests. Mann Whitney U tests were used to compare duration of 
hospital stay between patients transferred and not transferred for inpatient 
angiography. Variation in referral rates for inpatient and urgent angiography and 
length of stay between more than two centres was assessed using Kruskal- 
Wallis tests. Comparison of event rates between patients transferred for 
angiography and those not transferred was assessed using Chi squared tests. 
3.4 RESULTS 
Thrombolytic therapy 
851 (86%) patients received thrombolytic therapy. Table 3.1 demonstrates that 
prescription and delivery of thrombolysis at participating centres was uniformly 
high. 
Transfer for inpatient angiography 
50% (492) were transferred for inpatient cardiac catheterisation during the index 
admission. Of these 16% were transferred urgently within the first 24 hours of 
admission (Figure 3.1). There was significant variation between centres both in 
referral for inpatient angiography (36% centre D- 61% centre C, p<0.001), and 
urgency of transfer (6% centre B -25% centre D, p<0.001). 
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Table 3.1 Percentage of patients receiving thrombolysis, and achieving 
NSF targets at each centre 
% Thrombolysis % DTN<30* % CTN<60* 
A n=141 78 90 65 
B n=141 81 80 44 
C n= 260 89 83 59 
D n= 168 94 90 53 
E n=192 87 97 86 
Mean 86 88 61 
DTN < 30 - percentage of patients receiving therapy within 30 minutes of arrival at the 
referring centre 
CTN < 60 - percentage of patients receiving therapy within 60 minutes of the first call for 
professional help 
*Data do not directly relate to the cohorts investigated in this study. Data supplied from 
each centre are for the study period, as reported in the fourth Myocardial Infarct 
National Audit Project (MINAP) report June 2005 (101). 
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Figure 3.1 Variation in referral rates for inpatient angiography at the 
regional cardiac centre from hospitals A to E 
El No Transfer for Anglogram 
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Hospital Stay 
There were significant differences in median hospital stay between centres 
(Table 3.2) ranging from 5 days (centres A and E) to 8 days (centre B), P<0.001. 
Inpatient stay at the district hospital was prolonged by a median of 2 days in 
patients transferred for angiography beyond the first 24 hours of admission. 
Once again there was significant variation in hospital stay for this subgroup of 
patients between centres such that hospital stay was not prolonged at centre E, 
but was prolonged by 6 days at centre D, with an 8 day difference in median 
stay between these two centres, suggesting differential access to the tertiary 
centre between hospitals. 
Table 3.2 Differences in duration of stay at the district hospital among 
patients admitted with STEMI referred and not referred for inpatient 
angiography. 
Hospital Stay Hospital Stay Hospital Stay 
all patients No IPA IPA > 24hr P (Mann- Hospital 
days median days median days median Whitney) 
[IOR] [IOR] [IOR] 
A n= 141 5 [4-9] 5 [4-6] 8 [5-18] <0.001 
B n= 232 8 [5-12] 7 [5-10] 10 [7-14] 0.002 
C n= 168 7 [5-11] 6 [4-8] 9 [6-15] <0.001 
D n= 260 7 [5-12] 7 [6-10] 13 [6-23] <0.001 
E n=1 92 5 [3-7] 5 [4-8] 5 [3-7.5] 0.12 
Total 993 6 [4-11] 6 [5-9] 8 [5-15] <0.001 
P (Kruskal- 
<0.001 <0.001 <0.001 
Wallis) 
IPA Inpatient anglogram 
IPA>24hr Transferred for inpatient anglography beyond 24 hours following 
presentation 
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Inpatient cardiac catheterisation and revascularisation (Centre E) 
Figure 3.2 demonstrates the invasive management pathway for patients 
presenting to centre E. 54% (103/192) were transferred for inpatient 
angiography, leading to revascularisation in 38% (73/192), of which 88% (64/73) 
was performed percutaneously (PCI). 
Cardiac Catheterisation and revascularisation procedures during follow up 
Patients discharged without undergoing inpatient angiography., 
Follow up data were available for 69/76 patients discharged without undergoing 
inpatient transfer for cardiac catheterisation. 30% (21) subsequently underwent 
angiography, 11 following emergency readmission with an acute presentation. 
17% (13) underwent revascularisation (9 PCI, 4 CABG) of which 9 were 
performed as emergencies (6 PCI, 3 CABG). 
Patients discharged following inpatient angiography. 
Follow up data were available for 91 /101 patients discharged having undergone 
cardiac catheterisation during the index admission. 11 required a repeat catheter 
study, 4 following emergency readmission. 6/59 (10%) of patients undergoing 
PCI during the index admission required a repeat revascularisation procedure 
during follow up, 3 (5%) for target vessel failure (TVF). 5 patients underwent 
PCII 1 CABG. 2 (3%) procedures were performed as emergencies (1 CABG, 1 
PCI). Of 9 patients allocated to CABG following inpatient angiography, only 3 
were performed during the index admission. 1 patient died in hospital prior to 
CABG being performed. 5 patients were discharged pending planned 
readmission for CABG, one of whom was readmitted and revascularised as an 
emergency prior to the date planned. 
At a median (IOR) of 20 (10-41) weeks follow up, 65% of patients had 
undergone cardiac catheterisation, and 45% revascularisation (85% PCI). 
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Patients Lost to Follow up 
17 patients (9%) were lost to follow up. 3/17 returned overseas following the 
index admission and could not be contacted. The remaining 14 patients could 
not be traced for follow up through clinics, the general practitioner, or contact 
addresses. 5/14 were of South Asian origin, a reflection of the local East London 
catchment population of centre E. Some are not British citizens visiting from 
overseas or illegal immigrants. Some may present with different names (or 
spellings), or with varying dates of birth. Many are not registered with a General 
Practitioner. Finally, there is an additional daily daytime population of up to 
200,000 people visiting or working in the City of London that falls within the 
catchment population of centre E. These factors may have contributed to the 
loss to follow up. It is not known whether patients lost to follow up may have had 
major adverse events. 
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Figure 3.2 The Invasive Management Pathway for patients presenting to 
centre E with STEMI 
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3/8 patients stratified to CABG following inpatient angiography were 
discharged pending elective revascularisation 
3/5 repeat PCI procedures were for target vessel failure, the remainder were 
for de novo disease. 
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Major Adverse Cardiac Events 
Figure 3.3 demonstrates that the composite event rate was significantly elevated 
among patients that were not transferred for inpatient angiography relative to 
those who were. The endpoints of death and stroke reached independent 
significance. The rate of non fatal MI and emergency revascularisation following 
discharge without inpatient angiography was more than double that observed 
among those that had been transferred for an angiogram, although not reaching 
significance. Figure 3.4 demonstrates events following hospital discharge. There 
was no significant difference in mortality or stroke among patients surviving 
beyond discharge. Non fatal MI and emergency revascularisation almost 
invariably occurred following discharge, driving a persistently significant 
difference in overall MACE between those that underwent inpatient angiography 
compared with those that did not. 
Cardiac Readmissions 
In total 37 patients were readmitted with chest pain, 11 with non fatal MI as 
defined above. The rate of readmission was lower in those referred for 
angiography than those discharged without an angiogram (17% vs. 25%, p=NS). 
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Figure 3.3 Major Adverse Cardiac Events according to invasive or non 
invasive inpatient management strategy among 175 /192* patients 
admitted to Centre E 
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Figure 3.4 Major Adverse Cardiac Events following hospital discharge 
according to invasive or non invasive inpatient management strategy 
among 160 / 177* patients surviving beyond discharge from Centre E 
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3.5 DISCUSSION 
Transfer for angiography and hospital stay 
This study demonstrates that 50% of patients admitted with STEMI across the 
North East London sector are transferred for coronary angiography during the 
index admission. This occurred despite the proportion of patients receiving 
thrombolytic therapy being substantially higher than that observed in the 
GRACE registry (107), and surpassing current NSF delivery targets. There was 
significant variation in the rate of transfer for angiography from the referring 
centres. Hospital stay also varied between centres, and was significantly 
prolonged for patients requiring non urgent transfer in 4 out of 5 centres 
investigated, suggesting delay in access to the cardiac centre. The extent of 
delay also varied significantly between centres, indicating inequity of access. 
The greatest prolongation of inpatient stay occurred at the centre referring the 
lowest proportion of patients, raising the possibility that delay in access to the 
cardiac centre may itself have been a disincentive to refer patients. That hospital 
stay following acute Ml may be unnecessarily prolonged in the UK and in East 
London specifically has previously been demonstrated (197; 198). However the 
finding that the need for invasive investigation is a significant contributor to this 
process has important implications to service delivery. Transfer of patients with 
non ST elevation syndromes for inpatient cardiac catheterisation has already 
been identified as a cause of prolonged hospitalisation in patients with acute 
coronary syndromes (199; 200), but has not previously been highlighted in the 
setting of STEMI. 
Comparison with published data 
It is also noteworthy that the rate of cardiac catheterisation, and the proportion 
transferred within the first 24 hours of admission were both lower than would be 
predicted by published data. 55% of patients enrolled in the GUSTO-1 
thrombolytic study underwent emergency, elective or protocol cardiac 
catheterisation (201). This trial excluded patients ineligible for thrombolysis or 
with cardiogenic shock, both indications for emergency angiography that would 
93 
be expected to increase this proportion (202). In addition, up to 40% of patients 
who receive thrombolytic therapy demonstrate ECG evidence of failure to 
reperfuse (persistent ST segment elevation 60-90 minutes following therapy) 
(113-115), in whom emergency transfer for rescue angioplasty should be 
considered. In the CAPTIM study (comparing pre hospital thrombolysis and 
primary angioplasty), 26% of patients randomised to thrombolysis underwent 
urgent PCI for this indication (112). The present study did not record the 
indication for transfer or assess ST segment resolution. Thus the actual number 
of patients eligible for rescue cannot be calculated. However, given the expected 
frequency of failure to reperfuse, these data suggest that the majority of patients 
with failed reperfusion were not referred to the cardiac centre. This could have 
been a consequence of equivocal trial data relating to the role of rescue 
angioplasty (113; 116). However, more recent randomised controlled trial data 
have emerged definitively favouring the rescue strategy (117). Another 
explanation may have been a lack of specific guidance governing the indications 
for emergency angiography following STEMI treated with thrombolysis 
throughout the network. Indeed, at present there is no National Service 
Framework guideline governing the treatment of failure to reperfuse. The 
present study suggests that implementation of such guidance would dramatically 
increase the number of urgent catheterisations and revascularisations at the 
tertiary cardiac centre. 
Revascularisation and MACE 
Subgroup analysis of patients presenting to centre E demonstrated that 
following transfer for angiography the majority of patients required 
revascularisation, most performed percutaneously. Event rates at follow up were 
significantly lower in those transferred for inpatient angiography compared to 
those treated conservatively. The significant differences in death and stroke are 
likely to have been a consequence of appropriate selection rather than the 
treatment strategy per se. Some patients will have been moribund at 
presentation or unsuitable for invasive management due to significant 
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comorbidity, and patients developing a disabling stoke following thrombolysis 
would not have been transferred. 13 of 16 deaths among those not transferred 
for angiography occurred in hospital, 6 within the first 24 hours of admission. 
Furthermore, there was no mortality difference between strategies among 
patients surviving beyond hospital discharge. In contrast, the trend towards a 
significant reduction in both non fatal MI and emergency revascularisation does 
suggest a benefit for performing invasive investigation during the index 
admission. These findings are in keeping with the reduction in unplanned 
revascularisations observed in the GRACIA study among patients randomised to 
a strategy of systematic angiography within 24 hours of thrombolysis when 
compared with an ischaemia driven approach (203). In the Merlin study, 
although rescue angioplasty did not improve mortality, there was a significant 
reduction in MACE, driven by the reduction in unplanned revascularisations 
following discharge (116). 
Limitations 
This study does have a number of important limitations. The comparison of 
referral rates for angiography between participating centres assumes that the 
populations compared have similar risk characteristics. However, this was not 
investigated. In fact the degree of ethnic diversity and deprivation may have 
been higher in two of the inner city populations examined (E and A), with a 
higher proportion of South Asian patients relative to the others. This population 
specifically has a higher incidence of coronary disease, may be treated less 
effectively in the acute setting of STEMI due to atypical presentation (204), and 
may require a higher rate of subsequent invasive investigation (205). 
Nevertheless, cohorts with similar population characteristics (C and D) still had 
significantly different rates of transfer for angiography. 
It is proposed that the prolongation of hospital stay at the non 
interventional 
centres was the result of delay in access to tertiary cardiology. 
However this 
may have occurred as a result of delayed referral at the 
district hospital. It is also 
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possible that the need for transfer itself selected out a high risk group requiring 
longer hospital isation, although hospital stay was not prolonged at centre E, and 
this would not explain differences in prolongation of stay between centres. 
Subgroup analysis of cohort E was used to assess revascularisation practice 
and clinical outcomes following STEMI, but for the reasons stated above may 
not have been representative of the entire North East Sector. Importantly, the 
combination of a historical cohort of patients with a more contemporary cohort 
presenting exclusively outside working hours may also have altered the risk 
profile of the population studied, and the approach to treatment. Although the 
rate of transfer for angiography was similar between these cohorts (55% 2001/2 
vs. 51% 2003/4, p=0.43), the rate of transfer within 24 hours was significantly 
lower in the out of hours population (34% 2001-2 vs. referral 14% (p=0.019), 
suggesting a possible bias against urgent transfer out of hours. This warrants 
further investigation, with comparison of urgent transfer activity during working 
and non-working hours at all centres within the network. 
Implications to Service delivery in North East London 
At present NSF targets remain focused on the delivery of thrombolytic therapy. 
However, concentration on immediate infarct management may take the 
emphasis away from subsequent hospital care and clinical outcomes. It is clear 
from this study that effective delivery of thrombolysis does not ensure effective 
patient management. The thrombolytic strategy necessitates prompt access to 
angiography and revascularisation for the majority of patients. In order to 
improve STEMI management while continuing to use thrombolysis, it is 
necessary to improve equity of access to early invasive investigation across the 
North East London sector. In addition, evidence based practice dictates that the 
number of patients transferred should increase, with provision of urgent access 
for up to 40% of patients receiving thrombolysis that fail to reperfuse, and those 
ineligible for therapy. This will itself demand the availability of 24 hour 
angioplasty facilities, with the necessary infrastructure to allow rapid transfer 
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between centres. This questions the concept that adopting primary angioplasty 
as the preferred reperfusion strategy for STEMI would require a substantial 
increase in revascularisation activity beyond that already required. 
3.6 CONCLUSIONS 
Despite effective delivery of thrombolysis, the majority of patients presenting 
within North East London require coronary angiography. Of those undergoing 
revascularisation, the vast majority is performed percutaneously. Half of all 
patients admitted are transferred to the cardiac centre during the index 
admission, leading to prolonged hospitalisation at the non-interventional centre. 
There is inequity of both referral and access to tertiary cardiac services between 
centres. Furthermore, the proportion of STEMI patients transferred, and in 
particular the rate of emergency transfer is substantially lower than trial data 
would predict. Those that are not referred for inpatient angiography are more 
frequently readmitted with recurrent events, necessitating further emergency 
catheterisation and revascularisation procedures. The existing burden of 
revascularisation following presentation with STEMI necessitates reassessment 
of the delivery of reperfusion therapy in North East London, including 
consideration of primary angioplasty. 
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CHAPTER 4 Delivering Primary Angioplasty in North East London: 
Development and Instigation of a Pilot Programme 
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4.1 ABSTRACT 
Randomised controlled trial data support the use of primary angioplasty as the 
preferred reperfusion strategy for ST segment Elevation Myocardial Infarction 
(STEMI). However, the majority of STEMI patients do not present to a cardiac 
centre with interventional capabilities. Models of immediate transfer from non 
cardiac centres have been suggested, but have not been investigated in the 
United Kingdom. This chapter describes the development of a pilot primary 
angioplasty programme in North East London, with the objective of investigating 
the feasibility of delivering optimal evidence based therapy to the majority of 
patients presenting with STEMI within a hospital network. The rationale for the 
service model chosen is described, with key innovations highlighted. The 
mechanisms of service instigation and expansion are described, with emphasis 
on the importance of collaboration with ambulance services and Accident and 
Emergency partners at an early stage. Finally the fundamental outcome 
measures for service evaluation and future directions are described. 
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4.2 INTRODUCTION 
Randomised controlled trial data support the use of primary angioplasty as the 
preferred reperfusion strategy for ST segment Elevation Myocardial Infarction 
(STEMI) (127). Although the majority of STEMI patients do not present to a 
cardiac centre with interventional capabilities, recent studies have established 
that transfer of STEMI patients from district hospitals to a regional cardiac centre 
with interventional facilities may be more effective than immediate on-site 
thrombolytic therapy (132; 133). Application of this model of infarct care has not 
been investigated in the United Kingdom. At present National Service 
Framework (NSF) targets remain directed towards the administration of 
thrombolytic therapy, and successive Myocardial Infarction National Audit 
Project (MINAP) reports have demonstrated highly effective delivery of this 
therapy across England and Wales (100; 101). However, it has been 
demonstrated in Chapter 3 that there is also a significant requirement for 
transfer for invasive investigation and revascularisation following the 
thrombolytic strategy in North East London, which is in keeping with trial data 
(112; 116; 203). At present revascularisation is not recognised as an integral part 
of the thrombolytic strategy for STEMI in NSF guidelines. Designing a primary 
angioplasty service may therefore be challenging in an atmosphere where 
national targets are currently being achieved, and as yet there is no additional 
government funding. This chapter describes the development, instigation and 
expansion of a pilot primary angioplasty programme serving North East London. 
The background, logistics, and service model are discussed, in addition to the 
mechanisms and chronology of service expansion. The outcome measures 
necessary for service evaluation and future directions for the service are 
considered. 
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4.3 BACKGROUND 
4.3.1 Objectives 
The aim of developing a pilot primary angioplasty service in North East London 
was to investigate the feasibility of delivering optimal evidence based therapy to 
the majority of patients presenting with STEMI within a hospital network. A key 
objective was to provide equity of access to emergency specialist care for all 
patients irrespective of postcode or hospital of first presentation. 
4.3.2 Structure of Existing Invasive Cardiac Services in North East London 
The North East London Cardiac Network includes six hospitals with emergency 
departments admitting unselected patients with acute coronary syndromes, and 
without on site coronary intervention facilities. These centres are served by two 
dedicated tertiary cardiac centres without accident and emergency departments 
(ME), performing elective and emergency percutaneous and surgical 
revascularisation, both based within the same NHS Trust in central London. Six 
Primary Care Trusts (PCTs) fund services provided by five NHS Trusts within 
the network for an estimated population of 1.8 million inhabitants (Figure 4.1). 
In addition to providing elective and emergency cardiac services to the hospitals 
within the North East London Network, the cardiac centres also provide services 
to an additional five hospitals in Essex, increasing their referring catchment 
population to 3.8 million. 
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Figure 4.1 Map of North East London Cardiac Network demonstrating the 
expansion of the pilot primary angioplasty service. 
District Hospitals and their respective PCTs are shown. 
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4.3.3 STEIVII presentations within North East London Network per annum 
Table 4.1 demonstrates the number of 'Definite' Myocardial Infarction patients 
presenting to each hospital within the network for the year 1 st April 2003 to 31 st 
March 2004, derived from pooled MINAP data returns from each centre. The 
number of patients identified as a 'definite' myocardial infarction on arrival is 
always less than or equal to the total with a final diagnosis of 'myocardial 
infarction (ST Elevation)'. Although STEMI patients with a classical history and 
ECG changes represent the majority, not all cases are clear at presentation. 
This therefore provides an estimated range of expected presentations per year 
(535 - 694), with a mean of 615, equating to 342 STEMI presentations per 
million population. 
The same dataset demonstrates that STEMI represented 29% of all patients 
discharged with a diagnosis of an acute coronary syndrome during that period 
(including all patients coded as STEMI, Non STEMI, acute coronary syndrome 
troponin positive or negative, and unstable angina) (Table 4.2). This proportion 
is consistent with that predicted by international registry data (43). 
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Table 4.1 Patients Presenting to North East London Centres with ST 
Elevation Myocardial Infarction April 2003-4 
Data from a North East London Strategic Health Authority report 2004 (206). 
Hospital 
No. of Patients with 
Admission Diagnosis of 
'Definite' Myocardial 
Infarction 
No. of Patients with 
Discharge Diagnosis of 
'Myocardial Infarction 
(ST Elevation)' 
A 69 98 
B 90 129 
C 118 118 
D 154 201 
E 72 94 
F 32 54 
Total 535 694 
105 
Table 4.2 Percentage of ACS patients with discharge diagnosis of 
'Myocardial Infarction (ST Elevation)' April 2003-4. 
Data from a North East London Strategic Health Authority report 2004 (206). 
Hospital All ACS STEMI % STEMI 
A 392 98 25% 
B 321 129 40% 
c 466 118 25% 
D 582 201 35% 
E 390 94 24% 
F 222 54 24% 
Total 2373 694 29% 
4.4 SERVICE MODEL DEVELOPMENT 
4.4.1 Tailoring the Service Model to the target population 
Published trial data support a number of models for delivering primary 
angioplasty, either based on transfer of patients from a non-interventional centre 
to a heart attack centre (HAC) (132; 133), or in a district catheter lab without on- 
site surgical cover (128) [see 1.6.1 Primary Angioplasty - Models of 
delivery]. It was clear from the outset that the latter model would not be 
appropriate to the North East London population. This would require substantial 
investment in new cardiac catheter facilities by individual Trusts, with associated 
staffing and training. Importantly, each separate centre would perform 
too few 
primary angioplasty procedures per year (Table 4.1), a predictor of adverse 
outcomes (130). 
While the HAC model was ostensibly more applicable, utilising existing 
resources at the regional cardiac centres, this strategy also 
has limitations that 
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are relevant to service design. It has been proposed that the mortality benefit of 
primary angioplasty over thrombolysis may be lost if the delay to the invasive 
strategy (defined as the time difference between the administration of on site 
thrombolysis and that of primary angioplasty, or 'door to balloon minus door to 
needle time (DTB - DTN)) exceeds 60 minutes (135) [see 1.6.2 Influence of 
Time to Reperfusion]. In the DANAMI-2 study (132), the door (of the hospital of 
first presentation) to balloon times for patients transferred from distant centres 
were comparable to and in some cases shorter than those presenting directly to 
a cardiac centre. Notably patients in that study initially presenting to a cardiac 
centre were first admitted to its A&E, whereas those transferred from distant 
centres were admitted directly to the cardiac catheter laboratory. Thus while 
these data suggest that rapid transfer is achievable, it is also evident that 
presentation to the ME may itself delay access to reperfusion. Therefore our 
own perspective was that the key to providing the earliest possible reperfusion 
would be to combine pre-hospital diagnosis with delivery of patients directly to 
the cardiac catheter lab bypassing the ME completely wherever possible. 
4.4.2 Pre hospital Diagnosis by London Ambulance Service Crews 
Prior to the consideration of a pilot primary angioplasty service, London 
Ambulance Service (LAS) crews in North East London had already undertaken 
considerable training in ECG recognition, demonstrating reliable diagnosis of 
STEMI using on-board 12-lead ECG equipment (207). The NHS plan and the 
NSF have emphasised the critical role of ambulance services in the 
management of acute MI with a commitment to the development of pre hospital 
thrombolysis through paramedic training (3). However, the density of the 
metropolitan population served by LAS in inner city areas of East London was 
such that the mean transit time from the community to the ME was 6.4 minutes 
(208), suggesting that pre hospital administration of thrombolysis may not 
significantly improve (and could potentially delay) access to reperfusion therapy. 
There was however an opportunity to utilise both the diagnostic skills and rapid 
transit times of LAS in delivering patients diagnosed in the community directly to 
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the cardiac catheter laboratory of the regional cardiac centre rather than A&E, 
with a view to immediate angiography. The 'direct access' model was 
consequently developed in collaboration with LAS, cultivating a close working 
relationship from the outset. 
4.4.3 Referral Mechanism 
A key element of the protocol developed was that autonomy would be given to 
referring LAS crews. In order to facilitate rapid access to reperfusion, the 
decision was taken to accept patients without consultation with medical staff at 
the receiving centre or ECG transmission. Inclusion and exclusion criteria are 
shown in table 4.3. Notable exclusions were cardiac arrest and left bundle 
branch block (LBBB) on the ECG. Only patients with established cardiac arrest 
of uncertain aetiology at the time of arrival of an ambulance crew to the scene 
were excluded. Patients going into cardiac arrest following a diagnosis of STEMI 
on route could be taken directly to the HAC. LBBB was excluded based on 
previous local audit data demonstrating that less than half all patients receiving 
thrombolysis for LBBB locally had a discharge diagnosis of STEMI (data not 
shown). Patients with cardiogenic shock were excluded from immediate transfer 
without referral, but could be accepted following consultation with the on call 
physician at receiving centre. 
A dedicated emergency telephone was installed in the cardiac catheter lab, 
receiving calls only from the LAS control room, alerting staff to the expected time 
of arrival. The receiving centre made a commitment to accept and treat all 
patients received. In doing so it was understood that there would be occasions 
where patients with non cardiac pathology might be received. The facility to 
transfer patients from the cardiac centre to the nearest A&E was therefore 
agreed for cases where emergency non cardiac care may be necessary. 
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Table 4.3 Inclusion and exclusion criteria for immediate transfer of STEMI 
patients from the community of A&E to a regional heart attack centre. 
INCLUSION CRITRIA EXCLUSION CRITERIA 
Symptom onset < 12 hours Cardiogenic Shock* 
- ST segment Elevation MI on ECG Intubated / ventilated 
- Orientated, conscious - Established Cardiac Arrest 
No age limit - Confused/ reduced conscious level 
Previous Stroke with dense 
hemiplegia 
Left Bundle Branch Block 
* Patients with cardiogenic shock were included following physician consultation 
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4.4.4 Choice of Site 
In collaboration with the London Ambulance Service it was decided that there 
should be one receiving cardiac centre, to avoid the need for individual crews to 
consult a rota prior to deciding which centre was open for primary angioplasty on 
any given day or week. The centre chosen was that which was geographically 
more accessible to crews from the catchment population (Figure 4.1) 
4.4.5 Estimating Workload 
The key initial issue facing the cardiac centre was the volume and potential 
impact of the incremental interventional activity on existing resources. Beyond 
addressing the quantity of additional procedures required, there were concerns 
that a radical increase in preferential acute revascularisation for STEMI patients 
may be performed at the expense of elective procedures (for which waiting 
times were already under scrutiny, and themselves NSF targets (3)), and 
patients with Non ST segment elevation acute coronary syndromes (NSTE- 
ACS), who were waiting up to two weeks for inpatient transfer for angiography 
and revascularisation. Moreover, the increased activity within North East London 
could disadvantage patients requiring elective and emergency interventions from 
Essex centres, which were not included in the primary angioplasty proposal. 
These concerns were partially addressed by the observation that 50% of 
patients presenting with STEMI within North East London were already being 
transferred for coronary angiography during the index admission, with almost all 
subsequent revascularisation being performed percutaneously [Chapter 3]. 
Moreover, this was occurring at the cost of prolonged hospital stay, and frequent 
readmissions with recurrent events leading to further inpatient 
revascularisations. Finally the existing rate of inter hospital transfer following 
STEMI was itself failing short of evidence based standards, such that an 
increment in coronary intervention for this cohort of patients would become 
inevitable. 
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That the cardiac centre was already delivering an invasive strategy to the 
majority of STEMI patients led to the understanding that a primary angioplasty 
programme would not represent a completely new interventional workload, but 
that invasive management would be moved forward in the treatment pathway. It 
also led to the hypothesis that the impact of undertaking additional immediate 
angiography at the time of acute infarction for all STEMI patients may be offset 
by bed day savings, and a reduction in readmissions, recurrent events and 
emergency revascularisations. Furthermore, removal of the burden of inter 
hospital transfers resulting from the STEMI cohort may be expected to reduce 
rather than exacerbate transfer delays for patients with NSTE-ACS. 
4.5 MECHANISM OF INSTIGATION 
4.5.1 Stepwise approach 
The move from separate hospitals independently administering thrombolysis to 
treating all STEMI patients with a network wide primary angioplasty service 
required a stepwise approach. It was evident that an immediate 24-hour protocol 
would necessitate considerable initial investment and radical changes in working 
practice, in advance of demonstrating safety and efficacy locally. An 
independent report by the North East London Strategic Health Authority (206) 
showed that 48% of all STEMI admissions within the North East sector (April 
2001 -September 2004) presented within working hours 
(0800 and 1700) (Figure 
4.2). This was consistent with data from the Zwolle group, which demonstrated 
not only that the majority of STEMI presentations occurred during working hours, 
but also that the outcome following primary angioplasty was significantly better 
when performed within that period (209). It was therefore accepted that the 
protocol would initially be provided as a daytime weekday service only, with a 
view to providing proof of concept. In addition the service would 
initially be 
offered to LAS crews within the local population only, in order 
for those crews 
with the most extensive ECG training, a greater working 
knowledge of the 
cardiac centre, and short transit times to gain experience with 
the protocol and 
give feedback during the early pilot phase. However 
it was imperative that the 
ill 
protocol lend itself to future application to a wider population on a 24-hour 
seven-day basis. 
Audit data (October 2001-2002) from the initial catchment population (250,000 
inhabitants, 105 STEMI per annum) prior to commencement of the pilot 
demonstrated that 82.5% of STEMI patients arrived at hospital via LAS, 
predicting that 2-3 patients per month would be delivered to the cardiac centre 
during the hours of operation of the pilot service (Appendix 11a) 
Figure 4.2 Timing of presentation of patients admitted with STEMI within 
North East London 2001-2005 
Data from a North East London Strategic Health Authority report 2004 (206). 
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4.5.2 Protocol Following Arrival at the Cardiac Centre 
The protocol was designed so that the incoming LAS crew would be greeted at 
the entrance to the hospital by a designated team consisting of a specialist 
registrar, nurse, technician and senior house off icer and the patient taken 
directly into the catheter lab resuscitation area. The aim was to assess, 
examine, and consent the patient rapidly, aiming for the patient to be on the 
catheter lab table within 15 minutes. Within this period aspirin (if not already 
administered), clopidogrel and upstream intravenous abciximab would be 
administered prior to entering the lab. Following coronary angiography, culprit 
vessel angioplasty with stenting wherever possible would be performed, with 
further revascularisation of non culprit vessels at the operator's discretion. 
Following the procedure patients would be monitored on the coronary care unit 
for a period of 24 hours. Evidence supports discharge of uncomplicated patients 
as early as 3 days following admission (201; 210). There are further data 
suggesting that the event rate for patients who are free from arrhythmic and 
other complications within the first 48 hours remains relatively constant out to 30 
days, such that additional hospitalisation may be unnecessary (211). A decision 
was therefore taken to investigate the safety of feasibility of very early discharge 
at 48 hours for uncomplicated patients (table 4.4) during the pilot period. These 
patients would return to a specifically designed clinic within one week for 
medical review, further education and cardiac rehabilitation. All patients would 
be reviewed medically at 6-8 weeks following discharge. 
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Table 4.4 Criteria for early discharge of uncomplicated patients following 
primary angioplasty for STEMI 
Age <75 
Successful culprit vessel revascularisation 
Moderate or good LV function on left ventricular anglogram or 
echocardiogram 
Freedom from 
o recurrent ischaernia 
o clinical heart failure 
o ventricular arrhythmia 
Reviewed by cardiac rehabilitation team 
4.6 EARLY EXPERIENCE - DEVELOPMENT OF PHASE 1 
The programme commenced in April 2003. Figure 4.3 demonstrates the number 
of patients received via the primary angioplasty protocol at the cardiac centre 
per month form April 2003 to May 2005 inclusive. Only four patients were 
delivered to the cardiac centre during the first four months of operation of the 
protocol, less than half that predicted. This was caused by unnecessary service 
closures (for international conferences, internal audit and training days, or 
technical problems in the cardiac catheter lab). This in turn had a significant 
effect on LAS crews, who lost confidence in whether the service would be 
running on a given day, and delaying the necessary learning curve for LAS 
crews and catheter lab staff to become fully conversant with the protocol. 
Importantly, patients self-presenting to the local A&E were being excluded. To 
fully address these issues, a renewed commitment to avoid closures at the 
cardiac centre was required, in addition to the modification of the protocol to 
include patients presenting directly to A&E. 
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Figure 4.3 Graph demonstrating the number of patients presenting to the 
Network Heart Attack Centre Recruitment during development of the pilot 
service. 
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The arrows demonstrate commencement of the A&E transfer protocol from district 
hospitals A-F. At the time of writing hospital D had not commenced A&E transfer. 
4.6.1 Structured Critical Ambulance Transfer (SCATS) from Accident and 
Emergency 
A rapid transfer protocol from the local A&E was therefore developed (Appendix 
lb). This allowed patients initially presenting to the A&E department and fulfilling 
entry criteria (table 4.3) to be transferred immediately to the cardiac centre, 
again without ECG transmission or physician consultation. However, prior to the 
instigation of this protocol patients waiting (even for emergency) inter hospital 
transfer were given a lower priority by ambulance services than a category A 
(highest priority -8 minute response) 999 call from the community, as they were 
deemed to be under existing medical care. This therefore necessitated the 
development of a 'Structured Critical Ambulance Transfer System' (SCATS) by 
LAS. A SCATS transfer request would commit LAS to an 8 minute target 
response time for STEMI patients in A&E, avoiding unnecessary transfer delays 
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to reperfusion, and providing equity of access with patients diagnosed by LAS 
crews in the community. 
This protocol had a substantial benefit to recruitment (Figure 4.3), not only in 
transferring walk-in patients, but also allowing LAS crews a safety net whereby 
uncertain or complex cases would not automatically be excluded if taken to 
A&E. It also fostered a close working relationship with local ME personnel. 
4.6.2 Pharmacological facilitation prior to transfer from Accident and 
Emergency 
Immediate transfer from A&E also afforded the opportunity to administer 
concomitant anti platelet therapy at an earlier opportunity. Pharmacological 
facilitation with initial thrombolytic therapy or a glycoprotein Ilb/Illa receptor 
antagonist (GPRA) prior to transfer may achieve earlier reperfusion prior to 
definitive mechanical treatment, though at the expense of increased bleeding 
post procedure (144; 145) [see 1.6.4 Pharmacological facilitation of Primary 
Angioplasty]. At present the optimal combination of therapy is undetermined. 
The ADMIRAL study supports the use of upstream abciximab prior to primary 
angioplasty with stenting (83), with the greatest benefit in those patients 
receiving the drug earlier, either in a mobile intensive care unit or the emergency 
department rather than on arrival in the catheter lab. Recent meta analysis data 
provide f urther support for this concept (126). Therefore prior to transf er f rom the 
A&E department it was decided that a bolus of abciximab in addition to aspirin 
and clopidogrel would be administered, provided this did not delay the transfer 
process. 
The utilisation of the A&E transfer protocol in conjunction with upstream anti- 
platelet therapy required additional training for A&E medical and nursing staff. 
This was provided in a series of didactic lectures and practical sessions 
provided by the WHAC team, with repeat sessions provided at times of 
changeover of junior medical staff. 
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4.7 GEOGRAPHICAL EXPANSION OF THE SERVICE 
4.7.1 East Central Sector 
The combined direct access and A&E transfer protocols increased recruitment 
and experience prompting further expansion to the catchments of another two 
district hospitals in East Central London during the same hours of operation 
(Figure 4.3 and Figure 4.4; Appendix Ic). This necessitated further protocol 
refinement. 
4.7.1.1 Implications to LAS 
With geographical expansion, in order to continue utilising the direct access 
protocol, LAS crews making a pre-hospital diagnosis required clearance to 
bypass the nearest ME in favour of delivery to the WHAC catheter lab. This 
represented a fundamental change in working practice by LAS. A wider 
programme of ECG training was required to educate crews at the additional 
stations before the expansion could go live. This was undertaken internally by 
LAS. Once trained, it was important to inform staff at the WHAC that expansion 
to a wider catchment may involve patients presenting directly from further 
distances brought initially by potentially less experienced crews, such that a 
reduction in diagnostic accuracy may be expected. Expansion to direct 
admissions from the East Central Sector was completed in October 2003 
(Figure 4.3, Figure 4.4). 
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Figure 4.4 Chronology of development of the North East London Pilot 
Primary Angioplasty Programme. 
I Presenialon of concept to Tower Hamlets PCr I 
Pilot proposal sent to Nebvork Carcliologists I 
(Appenft Is) 
I 
I Mullclisciplinary Planning meetings at HAC I 
ME transfer Proposal publistied 
(Appendix 1b) 
I 
Oct 2002 
2003 
i DIRECT ACCESS AREA II 
Ea toentralsectorexpansion proposal 
pusblished (appendix lc) 
I 
Presentations to East Central A&Es 
(AE. F) 
I Oct 2003 
I A&E transfer hospital EI 
I DIRECT ACCESS AREA 21 
I Presentations to East Central PCTs I 
First report to North East London 
Cardiac Network Board 
I 
I First business case for 24 hour service 
ubmitted 
I 
First Primary Angioplasty Live Case 
training day hosted at the WHAC 
I 
Second report to North East London 
Cardiac Network Board (Appendix le) 
Proposal for expansion of service to 
North East London Cardiac Network 
(Appendix le) 
I Presentations to Network A&Es (B, C, D) I 
Final busiriess cam for 24 hour wrvice 
submitled 
I 
Invitation to participate in DoH / BCS 
Pilot National Infarct Angioplasty 
Programrne (NIAP) 
I Presentation to CEOs for Network PCTs I 
Funding Agreed for 24 hour Network 
Primary Angioplasty Service 
I 
Jan 
Jun 2005 
I A&E transfer hospille IAI 
I A&Etranster hospital FI 
I DIRECT ACCESS AREA 31 
I A&E transfer hospital BI 
I A&E transfer hospital CI 
Jan 2006 
MMMM--- A&E transfer hospital D 
ýMll 
-, 
planned 
April 2006 
Landmark dates in service expansion are demonstrated on the right side of the figure. 
Landmark dates in service development are demonstrated on the left. 
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4.7.1.2 Implications to Network Hospitals 
From September 2003 - February 2004, following the commencement of the 
local ME transfer protocol, half of all patients delivered were transferred from 
A&E. It was therefore essential to enable the two additional ME departments 
within the East Central sector to participate in the transfer protocol. This involved 
further network collaboration with A&E physicians, general physicians and 
cardiologists across three NHS Trusts (Figure 4.4). Discussions were held with 
all clinical stakeholders including local general physicians, and specific training 
was arranged for A&E medical and nursing staff. 
4.7.1.3 Logistics of Expansion and Funding 
A primary angioplasty working group was convened at the HAC to oversee the 
expansion programme, with the role of directing policy, disseminating 
information within the HAC and the network, and protocol development and 
implementation. Members included a lead consultant cardiologist, a lead 
specialist registrar, the clinical director for cardiac services at the HAC, the 
general manager and finance director for cardiac services at the HAC, the chair 
of the North East London Cardiac Network, and a senior representative from 
LAS with a special interest in cardiology. 
Separate presentations on behalf of the HAC working group were made to 
cardiac representatives from the individual participating PCTs within the East 
Central Sector, and also to healthcare commissioners through the forum of the 
North East London Cardiac Network Board (Figure 4.4). It was made clear that 
the process did not require additional funding during the pilot stage, but had 
been designed to inform future investment in the management of STEMI 
patients, and revascularisation. All stakeholders were updated with the progress 
of the programme through the Cardiac Network Board. 
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This process enabled the pilot protocol to function as a network service for the 
first time, although still within the restrictions of a daytime service. This 
completed phase 1 of the pilot development process. 
4.7.2 North East London Cardiac Network (Phase 2) 
The protocol gained momentum with increasing recruitment from within East 
Central London (Figure 4.3). In October 2004 phase 2 of the pilot was proposed 
(Appendix le), whereby the service would be expanded to serve the entire North 
East London Network, accepting direct LAS admissions and offering the 
immediate transfer protocol to the three additional A&E departments (Figure 
4.4). This expansion added further complexity to the service. 
4.7.2.1 Implications to LAS 
LAS crews traveling from the outskirts of the sector could now be asked to pass 
three separate ME departments with an acute STEMI patient on board, 
travelling a distance of up to 22 miles, taking up to 30 minutes before gaining 
access to specialist reperfusion therapy. This would represent a considerable 
change in attitude and methodology for the participating crews. Importantly, the 
movement of ambulance vehicles over larger distances, and out of their locality 
had the potential to leave those areas short of operational cover, which could 
compromise response times to other emergencies. However LAS agreed to 
continue the learning process within the confines of daytime hours of operation. 
Once more an extended training program was undertaken by LAS, with the 
direct access protocol commencing across the Network in January 2005. 
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4.7.2.2 Implications to Network Hospitals 
Following the publication of the initial proposal for network expansion of the pilot 
protocol in October 2004 (Appendix le), Accident and Emergency physicians 
and cardiologists working in the furthest A&E departments required substantial 
reassurance from the WHAC working group and LAS that transfer times within 
published guidelines were achievable (136; 212). These legitimate concerns 
were also communicated to the respective PCTs. A process of consultation 
between members the WHAC team, physicians at all three additional centres, 
and representatives of one of the PCTs, took place commencing in December 
2004, culminating in unanimous agreement from all departments in April 2005. 
Simultaneously, the A&E education and training process commenced at two of 
the three centres (Figure 4.4) while discussions were in progress, and in 
addition these centres applied for local clearance to administer pre transfer 
clopidogrel and abciximab therapy. At the time of writing, five out of six ME 
departments within the sector are utilising the immediate transfer protocol, with 
the final centre expected to commence in January 2006. LAS continue to 
provide direct access for patients diagnosed pre hospital from all areas of the 
sector. 
4.8 SERVICE EVALUATION 
In tandem with the evolution of the pilot protocol, key targets were identified to 
allow ongoing critical appraisal and evaluation of the service. In terms of service 
delivery it would be necessary to demonstrate that access to immediate 
angiography and reperfusion with primary angioplasty could be satisfactorily 
achieved within the limits of accepted published guidelines, and that clinical 
outcomes are similar to or better than those observed in clinical trials and large 
published registries. Furthermore it would be necessary to establish 
improvements in service delivery and patient experience compared to patients 
treated with thrombolysis within North East London. Specifically, in the light of 
the data presented in Chapter 3, the service would aim improve the patient 
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pathway, leading to a reduction in hospital stay, recurrent admissions, and 
emergency revascularisations. These measures aimed to determine the ultimate 
direction of the service, and in particular whether it should be adopted in its 
current form as a permanent 24 hour network wide service. 
The service design also included key innovations that may inform future practice 
not only within the boundaries of the North East London Network service, but 
may also have implications to other metropolitan populations intending to adopt 
a regional heart attack centre model for delivering primary angioplasty. Firstly, 
the direct access protocol is the first of its kind to offer ambulance crews 
immediate access to interventional cardiology without physician consultation or 
ECG transmission. Chapter 5 compares this access strategy with that of A&E 
transfer (with GPRA facilitation), presenting the impact of each strategy on 
diagnostic accuracy, time to reperfusion, quality of reperfusion, myocardial 
infarct size, and clinical outcome. Secondly the discharge of uncomplicated 
patients at 48 hours following intervention represents the earliest discharge of 
STEMI patients described to date. The safety and efficacy of this strategy during 
the pilot period is presented in Chapter 7. 
The move from a pilot to a substantive service would constitute the final phase 
of the programme (phase 3). Construction of a business case for this service 
was developed from January 2004 (Appendix ld) utilising data from the pilot 
phase presented in this thesis (chapters 3,5, and 7). A finalised business case 
was submitted in April 2005 and approved in November 2005, with a planned 
implementation date of April 2006 (Figure 4.4). 
4.9 MULTIDISCIPLINARY APPROACH 
The key to the progression of the pilot primary angioplasty service has been 
collaboration. From its conception, all members of the cardiac catheter lab team 
were involved in developing the protocol, prior to its commencement. Since its 
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instigation, acute coronary syndrome training days have been attended 
simultaneously by catheter lab staff, ambulance crews, A&E and ward staff to 
promote the team approach. In addition dedicated training days have been 
devised to familiarise LAS crews with angioplasty procedures and the catheter 
lab environment. All stakeholders, including PCTs, commissioners, ME 
departments and cardiac staff have been updated with progress reports and 
have been involved in the expansion of the service. Data have been fed back to 
the North East London Cardiac Network board (Figure 4.4, Appendix le), with 
each stage in the evolution of the protocol receiving scrutiny before backing. 
Importantly the programme has relied heavily on service innovations and 
adaptations made by the London Ambulance Service, who have been prepared 
to change practice radically to meet the needs of this population. 
4.10 CONCLUSIONS 
This chapter has described the process and chronology of development of a 
pilot primary angioplasty service serving patients presenting with ST segment 
elevation myocardial infarction based in North East London. A heart attack 
centre model was developed utilising two access strategies; immediate transfer 
from district hospitals to the cardiac centre, and direct access to the centre from 
trained ambulance crews making an independent pre-hospital diagnosis. The 
service involves multidisciplinary collaboration, crossing traditional geographical 
and organisational boundaries. This service needs to demonstrate safety and 
efficacy, improving both service delivery and patient experience. If this can 
be 
achieved the protocol readily lends itself to temporal expansion to a 
24-hour 
seven-day programme. 
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CHAPTER 5 Service delivery, reperfusion and clinical outcomes following 
Direct Ambulance Access versus Accident and Emergency Transfer for 
Primary Angioplasty in North East London 
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5.1 ABSTRACT 
Delays in transfer of ST Segment Elevation Myocardial Infarction (STEMI) 
patients from district hospital Accident and Emergency (A&E) departments may 
negate the benefit of primary angioplasty. Pharmacological facilitation may 
provide a bridge to mechanical reperfusion, though data supporting this 
approach are equivocal. Direct access to the cardiac catheter lab bypassing 
A&E has the potential to reduce reperfusion times, and may therefore be 
preferable. This chapter compares a direct access (DA) strategy utilising pre 
hospital ECG diagnosis by ambulance crews, with transfer from A&E 
departments (AET) for primary angioplasty. Facilitation with a glycoprotein 
Ilb/Illa receptor antagonist is investigated. 
Methods: 144 consecutive suspected STEIVII patients within a network of 6 
hospitals were delivered to a heart attack centre catheter lab without physician 
consultation or ECG transmission (66 DA, 78 AET). DA allowed bypass of the 
nearest A&E if necessary with patients receiving aspirin only at the time of 
diagnosis. AET included self presentations, and non DA ambulance patients. 
These patients were treated with aspirin, clopidogrel, and a glycoprotein Ilb/Illa 
receptor antagonist prior to transfer. 105 patients with confirmed STEIVII 
underwent coronary angiography. 103 underwent culprit vessel angioplasty with 
stenting. All patients received abciximab prior to intervention. 
Outcome measures 
Accuracy of clinical diagnosis by ambulance crews and A&E departments was 
compared. In those undergoing primary angioplasty, reperfusion times were 
measured from symptom onset (pain to balloon - PTB), call for specialist help 
(call to balloon - CTB), and first hospital arrival (door to balloon - DTB). Peak 
creatine kinase (CK) was measured as a marker of infarct size. Epicardial and 
microvascular blood flow were assessed in each group (TIMI flow grade, 
myocardial blush grade (MBG), corrected TIMI frame count (cTFC)), and ECG 
ST segment resolution. MACE included death, non fatal myocardial infarction, 
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stroke, and emergency revascularisation at a median follow up of 16 (9-28) 
weeks. Incidence of bleeding was recorded. 
Results 
Diagnostic accuracy for STEMI was lower among patients brought directly via 
LAS. DA significantly improved all reperfusion times (PTB, CTB, DTB) compared 
to AET. Peak CK was similar in both groups. TIMI flow, MBG, and cTFC were all 
significantly better prior to intervention in those receiving early abciximab, 
though flow post procedure was similar. ST segment resolution post procedure 
was also similar in both groups. There were no differences in MACE between 
the two groups. 
Conclusions 
Pre hospital diagnosis with direct ambulance catheter lab access significantly 
reduces time to reperfusion although there is scope to improve diagnostic 
accuracy. Both strategies were similar with respect to infarct size and clinical 
outcome, which may be explained by improved epicardial and microvascular 
blood flow prior to intervention in the AET group. These data suggest that early 
facilitation with abciximab may compensate for inter hospital transfer delays 
when this strategy cannot be avoided. The optimal strategy may be to combine 
these approaches, with ambulance crews administering pre hospital abciximab, 
or similar therapy. 
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5.2 INTRODUCTION 
Transfer of ST Segment Elevation Myocardial Infarction (STEMI) patients from a 
district hospital Accident and Emergency (A&E) department for primary 
angioplasty at a heart attack centre has been demonstrated safe and effective. 
However, it has already been discussed that transfer delays may negate the 
benefit of this strategy [see 1.6.2 Influence of Time to Reperfusion]. 
Pharmacological facilitation may improve patency of the infarct related artery 
prior to intervention providing a bridge to definitive mechanical reperfusion, 
though data supporting this approach are equivocal, and at present the optimal 
therapy remains uncertain. In order to avoid delays in reperfusion we designed a 
pilot primary angioplasty service providing direct access (DA) to the cardiac 
catheter lab for ambulance crews making a pre hospital diagnosis [Chapter 4], 
allowing vehicles to bypass the nearest A&E where necessary. Service delivery, 
efficacy of reperfusion and clinical outcomes were compared with a strategy of 
transfer from A&E departments (AET) with utilisation of pharmacological 
facilitation with a glycoprotein Ilb/Illa receptor antagonist (abciximab, ReoProo, 
Eli Lilly and Company). 
5.3 METHODS 
5.3.1 Subjects 
144 consecutive patients were delivered to a network heart attack centre (N- 
HAC) between April 2003 and May 2005, from within the North East London 
Cardiac Network. Patients were recruited from within the local catchment of the 
WHAC (April 2003-August 2003), the East central catchment (August 2003- 
December 2004, and from the entire North East catchment (January 2005-May 
2005) as described in the preceding chapter [see Chapter 4; Figure 4-1]. 66 
(46%) were admitted directly from the community (DA) via London ambulance 
Service (LAS) crews, and 78 (54%) via transfer from five ME departments 
participating in the pilot programme (AET). AET patients 
included self 
presentations to the local A&E, patients developing ST elevation 
in the ME 
department, and patients arriving via LAS crews where there was uncertainty of 
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ECG diagnosis. Patients were accepted at the WHAC without physician 
consultation or ECG transmission. Data collection was prospective and non 
randomised. 
105 (73%) patients were diagnosed with STEMI, 42 (40%) DA, 63 (60%) AET. 
103 underwent primary angioplasty. Of those not treated with primary 
angioplasty, one patient was referred for bypass surgery, and the other was 
treated medically (TIMI grade 3 flow with no residual stenosis). Demographic 
details of the AET and DA STEMI groups were similar, although there was a 
higher prevalence of previous myocardial infarction and prior percutaneous 
intervention (PCI) in the DA cohort (Table 5.1). 
Table 5.1 Demographic 
presenting to the WHAC 
details of patients with confirmed STEMI 
via ambulance transfer from local A&E 
departments (AET)q and through direct LAS access (DA) 
AMBULANCE DIRECT A&E TRANSFER 
P value 
ACCESS(DA) (AET) 
N= 42 N=63 
Age 58(13) 58(12) NS 
Sex 36 Male (86%) 44 Male (70%) NS (0.06) 
Smoker 26(62%) 47(75%) NS 
Hypercholesterolaemia 9(21%) 19(30%) NS 
Diabetic 8(19%) 11(17.5%) NS 
Hypertensive 20(48%) 23(37%) NS 
Prior MI 6(14%) 2(3.2%) 0.034 
Prior PCI 4(9.5%) 0 0.012 
Prior CABG 1(2%) 1(1.5%) NS 
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5.3.2 Interventions 
Loading with oral clopidogrel (300mg) and an intravenous bolus of abciximab 
were administered prior to coronary intervention in all cases. Culprit vessel 
angioplasty with stenting was performed in all cases, with further 
revascularisation of non culprit vessels at the operator's discretion. 
4/55) participating ME departments administered clopidogrel 300mg and a bolus 
of abciximab prior to transfer (AET'). The remaining centre (hospital F; see 
Chapter 4; Figure 4.1) administered clopidogrel only, with abciximab 
administered on arrival at the N-HAC (AET-). This centre was 2.1 miles away 
from the N-HAC, with a journey time of 15 minutes. 
5.3.3 Outcome Measures 
Service Delivery 
Service delivery was compared by assessment of the accuracy of clinical 
diagnosis among all patients delivered to the WHAC, and by the time to 
reperfusion in STEMI patients undergoing primary angioplasty. 
ST segment elevation on the ECG was confirmed by the receiving cardiologist in 
the presence of ý: 2mm in two contiguous anterior leads, and ý: 1 mm in non- 
anterior leads [chapter 2]. A final diagnosis of STEMI was confirmed at 
discharge in the presence of ST elevation at presentation and any of the 
following: a culprit lesion at angiography in the anatomical territory of the ECG 
changes, a regional wall motion abnormality in the anatomical territory of the 
ECG changes, or a rise in troponin I or CK. 
Reperfusion times were measured from symptom onset (pain to balloon - PTB), 
call for specialist help (call to balloon - CTB), and first hospital arrival (door to 
balloon - DTB). The door to needle time (DTN) was defined as the time 
from first 
hospital arrival until the abciximab bolus was administered. 
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Efficacy of Reperf usion 
Efficacy of reperfusion was assessed by coronary angiography and ST segment 
resolution on the ECG among patients undergoing primary angioplasty. 
Comparison was made between 41 DA patients, 52 AET+ patients receiving 
abciximab facilitation, and 10 AET- patients receiving abciximab at the WHAC 
following transfer. 
Angiographic epicardial and microvascular blood flow were assessed in all 
patients using the TIMI flow grade (102), myocardial blush grade (MBG) (154), 
and corrected TIMI frame count (cTFC)) (194). Angiographically evident 
thrombus was assessed using the TIMI thrombus score (213) [see Chapter 2; 
2.5 Angiographic analyses]. 
ECG data sufficient for assessment of ST segment resolution were available for 
80/105 STEMI patients (33 (79%) DA and 47 (75%) AET) at presentation, post 
procedure and at 18-24 hours following admission. 21/37 AET+ patients and 
8/10 AET- patients had sufficient ECG data available for analysis prior to 
angiography both before transfer and on arrival at the N-HAC. ST segment 
resolution was calculated according to the method described by Schroeder et al 
(214) [see Chapter 2; 2.4 ECG analyses]. 
Clinical outcome 
Peak creatine kinase (CK) was measured as a marker of infarct size. Major 
adverse cardiac events (MACE) including death, non fatal myocardial infarction, 
stroke, and emergency revascularisation were recorded after a median follow up 
period of 16 (9-28) weeks. Major bleeding was defined as any of the following: a 
fall in haemoglobin (Hb) > 4g/dl; overt bleeding with a fall in Hb > 3g/dl; the 
requirement for a blood transfusion of 2 or more units; retroperitoneal or 
intracranial haemorrhage. Minor bleeding was defined as overt bleeding not 
meeting the criteria for a major bleed. 
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5.3.4 Statistics 
Comparison of continuous variables between cohorts was assessed using non 
parametric tests where the distribution of data was skewed (Mann Whitney U 
and Kruskal - Wallis tests). Normally distributed variables were compared 
independent samples T-tests. Chi square and Fisher's exact test were used to 
compare categorical variables. 
5.4 RESULTS 
5.4.1 Accuracy of Diagnosis 
105/144 patients presenting via the protocol had a final diagnosis of confirmed 
STEMI [see 2.1 Subjects]. Table 5.2 demonstrates ECG findings, invasive 
management, and the final clinical diagnosis made at the N-HAC for DA and 
AET groups. Diagnostic accuracy was significantly higher among patients 
transferred from ME compared with those admitted via LAS directly. 
A total of 39 subjects did not have confirmed STEMI (24 DA, 15 AET) (table 
5.3). Of these 46% did have ST segment elevation on the presenting ECG which 
was ultimately of another aetiology. 62% of patients without a final diagnosis of 
STEMI underwent an inpatient cardiac catheterisation procedure, and 18% 
underwent a PCI procedure. 15% (6) had a final diagnosis of myocarditis or 
pericarditis. The discrepancy in diagnostic accuracy was related to an excess of 
patients with both Non-ST segment elevation acute coronary syndromes (NSTE- 
ACS) and non ischaernic cardiac presentations in the DA group (table 5.3). The 
majority of NSTE-ACS patients were troponin positive, and would ultimately 
have required invasive coronary investigation at the cardiac centre. Those with 
non ischaernic cardiac pathology had either acutely decompensated left 
ventricular function in the setting of chronic heart failure, or a pre-existing 
cardiornyopathy with ST elevation but no cardiac pain. No subject required 
transfer for acute non-cardiac intervention. 
131 
Table 5.2 ECG and Clinical diagnosis following arrival at the WHAC 
Direct Access 
DA n=66 
A&E Transfer 
AET n=78 
P value (X2) 
ECG ST segment elevation 51(77%) 72(98%) 0.011 
Final diagnosis STEMI 42(64%) 63(81%) 0.021 
Cardiac Catheter 54(82%) 64(82%) NS 
Percutaneous Intervention (all) 45(68%) 63(81%) 0.021 
Primary Angioplasty for STEMI 41(62%) 62(79%) 0.034 
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Table 5.3 Final diagnosis among patients delivered to the WHAC that did 
not have STEMI 
Direct Access A&E Transfer 
(n=24) (n=15) 
DIAGNOSES 
NSTE-ACS troponin positive 7(29%) 2(13%) 
NSTE-ACS troponin negative 2(8%) 3(20%) 
Pericarditis / Myocarditis 1(4%) 5(33%) 
Other Cardiac 8(33%) 1(7%) 
LVF 4 
DCM 1 
HCM 1 
0 Arrhythmia 2 
ACHD 0 1 
Other Non Cardiac 6(25%) 4(27%) 
Non cardiac chest pain 4 2 
Collapse cause unknown 0 2 
Subdural haernatorna 1 
Asymptomatic 1 
INVESTIGATION and MANAGEMENT 
ECG ST segment elevation 9(37.5%) 9(60%) 
Cardiac Catheter 13(54%) 11(73%) 
PercutaneouS Intervention 4(17%) 3(20%) 
Kev 
LVF Acute Left ventricular failure 
DCM Dilated Cardiomyopathy 
HCM Hypertrophic Cardiomyopathy 
ACHD Adult Congenital Heart Disease 
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5.4.2 Time to reperfusion 
Among those patients with confirmed STEMI, the duration of symptoms at the 
time of first presentation was similar in both groups (table 5.4). The DA strategy 
reduced all reperfusion times (PTB, CTB and DTB), with a significantly higher 
proportion achieving both the 2 hour target DTB time recommended by the 
European task force for primary percutaneous intervention and the 90 minute 
target recommended by ACC/AHA Guidelines for the Management of Patients 
With ST-Elevation Myocardial Infarction [1.6.2 Influence of time to 
reperfusion] (table 5.4) (136; 212). Median (IQR) transfer time (time from arrival 
at the first centre to arrival at the N-HAC) was 69 (51-88) minutes. 
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Table 5.4 Comparison of reperfusion times according to access strategy 
AH PATIENTS DIRECT ACCESS A&E TRANSFER 
(DA) (AET) P value 
N= 42 N--63 
Symptom duration at 
presentation (min) 112 [62-236] 105 [53-175] NS 
Med [IQR] 
Symptom duration at 
63% 79% NS 
presentation <180 
Transfer time (min) 
NA 69(51-88) 
Med [IOR] 
PA 77ENTS 
DIRECT ACCESS A&E TRANSFER 
UNDERGOING 
(DA) (AET) P value 
PRIMARY 
n=41 n=62 
ANGIOPLASTY 
Pain to balloon PTB 
(min) 172 [102-256] 216 [170-349] 0.01 
Med [10R] 
Call to balloon CTB 
(min) 83 [70-105] 135 [120-163] < 0.001 
Med [IQR] 
Door to balloon DTB 
(min) 40 [32-48] 106 [93-133] < 0.001 
Med [IQR] 
door to balloon <120 99% 65% <0.001 
Door to balloon <90 94% 22% <0.001 
135 
5.4.3 Abciximab facilitation 
Symptom duration at presentation was similar between DA patients, and both 
AET+ and AET- groups (Table 5.5). Despite the prolongation of pain to balloon 
time in AET' cohort relative to DA (58 minutes), the peak CK was similar in both 
these groups. The door to needle time (time from arrival at the first centre to 
administration of abciximab) was significantly longer in the AET+ group than at 
the WHAC (DA). Nevertheless there was still a significant difference (53 
minutes) in the time from abciximab administration to balloon inflation (needle to 
balloon time - NTB) between AET+ and DA patients. It is also noteworthy that the 
median transfer time was 23 minutes shorter among the 10 AET- patients. This 
may have been a result of the proximity of this centre to the WHAC relative to 
the other referring centres [see Chapter 4; Figure 4.1], but could also imply that 
delays were incurred at other centres in administering abciximab. Peak CK was 
also higher in this cohort, although this did not reach significance in this small 
subgroup. 
Table 5.5 Impact of pharmacological facilitation with abciximab - timing of 
therapy and Enzyme (CK) rise 
A&E Transfer A&E Transfer 
Direct Access 
Abciximab pre abciximab post P (DA vs. 
(DA) 
transfer (AET+) transfer (AET-) AET+) 
N=41 
N=52 N=1 0 
Symptoms 112 (62-236) 100 (58-174) 135 (33-356) NS 
Door to needle 18(10-35) 37(19-63) 71(41-83) 0.002 
Pain to needle 153 (74-251) 142 (90-251) 191 (117-443) NS 
Transfer time 74(57-102) 51(43-65) 0.02* 
Needle to 21 (1-33) 74(65-86) 21(11-38) <0.001 
balloon 
Pain to 172 (102-256) 230 (172-337) 198 (120-483) 0.009 
balloon 
Pe Wk- -CK 721 (370-1451) 800 (423-1887) 1 1239 (743-1735) NS 
*P value = AET+ vs. AET- 
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5.4.4 Angiographic reperfusion and ST segment resolution 
TIMI flow grade, myocardial blush grade (MBG), and corrected TIMI frame count 
(cTFC) prior to intervention were superior among AET+ patients relative to DA 
(Table 5.6). There was no difference in angiographic thrombus burden between 
groups. Among the AET- patients the rates of TIMI 3 flow, and TIMI grades 2 or 
3 flow prior to intervention were almost identical to those of the DA group, 
although when compared with the AET+ the difference was not significant (owing 
to the small AET- sample size). This observation suggests that improved 
patency prior to intervention in AET' patients was likely to be the result of 
abciximab therapy rather than spontaneous recanalisation occurring during the 
period of transfer. There was no difference between cohorts in epicardial or 
microvascular flow following intervention. 
There were no differences between patient groups in ST resolution post 
procedure, or at 18-24 hours, in keeping with the angiographic data. Although 
not reaching statistical significance, there was a trend (p=0.08) towards 
improved ST resolution pre procedure in those AET patients pre treated with 
abciximab (AET' vs. AET-), which would be consistent with the angiographic 
findings (Table 5.7 and Table 5.8). 
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Table 5.6 Abciximab facilitation and angiographic reperfusion pre and 
post procedure 
A&E Transfer A&E Transfer 
Direct Access + abciximab + abciximab 
(DA) pre transfer post transfer 
P (DA vs. 
N=41 (AET+) (AET-) 
AET+) 
N=52 N=l 0 
PRE PCI 
TIMI 3 8(19%) 22(42%) 2(20%) Chi2 0.019 
TIMI 2/3 16(38%) 31(58%) 4(40%) Chi2 0.048 
MBG 2/3 8(20%) 24(46%) 3(30%) Chi2 0.007 
Mean TIMI 
Thrombus 3.8(l. 7) 3.4(l. 7) 3.1(2.1) NS 
burden 
Median cTFC 100 (43-100) 45(18-100) 79(32-100) 0.03 MW-U 
POST PCI 
TIMI 3 36(86%) 51(96%) 9(90%) Ch12 NS (0.07) 
TIMI 2/3 39(93%) 53(100%) 10(100%) Chi2 0.048 
MBG 2/3 25(64%) 35(70%) 4(40%) NS 
Mean TIMI 
Thrombus 0.1(0.2) 0.1(0.7) 0.1(0.3) NS (0.057) 
burden 
Median cTFC 14(12-24) 15(10-21) 14(10-20) NS 
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Table 5.7 Abciximab facilitation and ST segment resolution post 
procedure 
Direct Access A&E Transfer A&E Transfer P (DA vs. 
(DA) Abciximab pre Abciximab AET+) 
N=33/41 transfer post transfer 
(AET+) (AET-) 
N=35/52 n=l 0/10 
60-90 min 
STR median 
68%(41-84) 69%(49-83) 70%(33-77) NS 
(IOR) 
STR > 50% 22(67%) 25(71%) NS 
STR > 70% 16(48%) 18(51%) NS 
18-24 hours 
STR median 
79%(50-89) 75%(58-89) 75%(48-86) NS 
(IOR) 
STR > 50% 26(79%) 29(83%) NS 
STR > 70% 22(67%) 22(63%) NS 
Kev 
STR ST Segment Resolution 
Table 5.8 Abciximab facilitation and ST segment resolution pre procedure: 
comparison of AET+ and AET- patients 
A&E Transfer A&E Transfer 
Abciximab pre Abciximab post P value 
transfer (AET+) transfer (AET-) 
n=21/35 n=8/1 0 
STR median (IOR) 43 (-8 to 79) 17 (-7 to 28) 
NS 
STR > 50% 10 1 NS 
(0.08) 
STR > 70% 5 1 
NS 
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5.4.5 Clinical Outcomes 
Bleeding 
There were two major bleeding complications (both in AET' patients). One 
patient required a transfusion of 2 units. This patient had a background of 
chronic anaemia due to gastric angiodysplasia. The patient remained 
haemodynamically stable. A second patient developed a small haemorrhagic 
stroke (confirmed by CT scan) following a fall in platelet count (< 20x109), 
characterised by transient confusion but no persistent neurology. 
3 other patients developed thrombocytopenia (1 with a platelet count < 20x109, 
2 <50x 109). 1 of these subjects developed minor bleeding (a small femoral 
haematoma). 4 other patients developed small femoral haematomas. There was 
no other minor bleeding. 
Major Adverse Cardiac Events 
Major adverse event rates at follow up were similar among AET and DA patients 
(Figure 5.1), with overall MACE for both cohorts falling within the boundaries of 
previously published randomised and registry data (127; 215). Although there 
may appear to be an excess of deaths driving a higher event rate in the direct 
access group, the small sample size makes further interpretation of these data 
unsafe. There were in total only 4 deaths among these patients, 3 occurring in 
the direct access group. 
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Figure 5.1 Major adverse cardiac events (MACE) according to admission 
strategy 
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5.5 DISCUSSION 
5.5.1 Service Delivery 
This study demonstrates effective delivery of primary angioplasty using two 
separate access strategies within a metropolitan population. The proportion of 
patients with confirmed ST segment elevation on the ECG, and a final diagnosis 
of STEMI were lower among patients presenting directly via LAS crews. A small 
study undertaken locally prior to commencement of the pilot service had 
established that recognition of ST segment elevation by trained paramedics was 
similar to that of senior house officers in ME (207). The present study 
demonstrated that the reduction in diagnostic accuracy was not the result of 
failure to recognise ST elevation, but predominantly due to an excess of patients 
delivered with evidence of coronary ischaemia but no ST segment elevation. 
This is likely to have been the consequence of a number of factors. The 
distinction between ST elevation as a mechanism of diagnosing a heart attack, 
and ST elevation as a pre requisite for deriving a benefit from primary 
angioplasty may not initially have been made clear. Thus there may have been a 
desire among some crews to bring all patients diagnosed with possible AMI. The 
geographical expansion of the service [chapter 4] will have further compounded 
this training issue, as each sector embarked on its own learning curve with the 
immediate referral protocol. Also, given the number of crews operating in the 
North East LAS sector, and the hours of operation of the pilot service, the 
opportunity for individual crews to gain repeated exposure to the protocol will 
have thus far been limited. While it is clear that ongoing training and direct 
feedback in the catheter lab environment are essential, it is also reassuring that 
the majority of DA patients without STEMI did have a cardiac diagnosis, and 
would ultimately have required invasive investigation. This demonstrates that 
LAS crews are sufficiently skilled to diagnose acute coronary syndromes 
independently and without consultation, but that dissemination of the specifics of 
the protocol with respect to ST elevation must be improved. In tandem with this, 
alternative strategies including ECG telemetry could also be considered in order 
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to avoid unnecessary mobilisation of the STEMI team in future, particularly with 
expansion to a 24 hour protocol. 
The advantage of the DA strategy was the significant reduction in the time to 
reperfusion. The majority of patients in both groups achieved reperfusion times 
(DTB) within the recent European task force recommendations (212). However, 
the majority of AET patients fell outside the 90 minute target specified in the 
most recent North American guidelines (136). While the latter was not 
specifically targeted at patients transferred from distant centres, this highlights 
the disparity between strategies. Notably the median time from admission to 
A&E to arrival at the N-HAC was over an hour, which may have been longer 
than expected given the relatively short distances to travel [see chapter 4; 
figure 4.1]. It is possible that there may have been delays waiting for ambulance 
transfer from the A&E departments, although the finding that door to needle time 
was significantly prolonged in AET compared with DA suggests that delays may 
have been incurred prior to requesting ambulance transfer ('SCATS') [chapter 
4]. While more detailed audit of the referral and transfer process prior to arrival 
at the N-HAC is warranted with ongoing service development, there does 
appear to be scope to improve the efficiency of A&E transfer. This may have 
particular relevance as the symptom duration at the time of presentation was 
less than 3 hours in 79% of AET patients. As discussed in chapter 1 [1.6.3 
Influence of Symptom Duration] this patient subgroup did not derive a 
mortality benefit from transfer for primary angioplasty in the PRAGUE-2 study 
when compared with on site thrombolysis (133). Nevertheless the median delay 
to primary angioplasty (DTB-DTN) in this study was 69 minutes, which is only 
narrowly beyond the 60 minute target in the North American guidelines (136), 
and well inside the 93 minutes required to derive a benefit in MACE, as 
described in the original analysis of transfer delay by Nallamothu et al (135). 
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5.5.2 Pharmacological facilitation 
Despite the delay in transfer, clinical outcomes and infarct size measured by 
peak CK rise were similar utilising both strategies. This finding is of interest 
considering that as stated above, the majority of patients presented within the 
first 3 hours of symptom onset, the period where the outcome following 
reperfusion is most time dependent (216). It is tempting to speculate that the 
administration of abciximab to the majority of AET patients prior to transfer could 
have compensated for transfer delay. However, it is important to recognise that 
this small study was not sufficiently powered to detect differences in clinical 
outcome. 
Previous studies have demonstrated improved outcomes among patients 
receiving abciximab during primary angioplasty (126), with superior 
microvascular perfusion post procedure compared to those treated without a 
GPRA. In addition the ADMIRAL study (83) demonstrated further benefit among 
patients receiving therapy earlier. All patients in this study received abciximab 
prior to intervention, and therefore the finding that reperfusion following the 
procedure was similar in both AET+ and DA groups may have been intuitive. 
However, epicardial and microvascular patency were significantly improved prior 
to intervention among those receiving abciximab prior to transfer (AET+) 
compared with DA patients. Earlier reperfusion may account for the benefit of 
very early abciximab therapy observed in studies such as ADMIRAL. Whether 
this effect of early therapy compensates for transfer delay could only be 
addressed with a randomised study of pre transfer abciximab versus abciximab 
on arrival specifically in patients transferred to the HAC from distant centres. It 
should be noted however that thrombolytic agents also improve arterial patency 
prior to intervention when used to facilitate primary angioplasty, but have not 
thus far demonstrated improved clinical outcomes [see chapter 1; 1.6.4 
Pharmacological facilitation of Primary Angioplasty]. Indeed the recently 
presented ASSENT 4 study (217) demonstrated that administration of 
tenecteplase (TnK) prior to primary angioplasty was inferior to primary 
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angioplasty alone, with increased mortality in the TnK arm that was not 
explained by bleeding complications. Additional anti-platelet and anti- 
inflammatory mechanisms may therefore be relevant, and are the subject of 
further investigation in chapter 6 of this thesis. 
The potential benefit of early administration of abciximab observed among AET 
patients does not exclude the possibility that DA patients might also derive 
additional clinical benefit with pre hospital abciximab therapy if it were available. 
A randomised study comparing pre hospital paramedic administration of 
clopidogrel and abciximab with therapy on arrival at the N-HAC specifically 
among DA patients could be designed to answer this question. While this 
strategy would necessitate further training for LAS crews, proof of concept for 
paramedic drug delivery has already been provided by successful programs of 
pre hospital thrombolysis elsewhere in the UK (218; 219). 
5.5.3 Limitations 
The data presented here reflect outcomes of a developing rather than an 
established service. The non randomised nature of this study raises the 
possibility of selection bias. Although demographics were similar, it is possible 
for example that self presentation to A&E may select a lower risk cohort with 
less severe presentations than patients presenting directly via ambulance, such 
that transfer delay may have had less impact. In addition, the study was not 
designed to directly compare the 10 AET- patients transferred from one 
institution with the remaining AET+ patients, and cannot provide an indication of 
the efficacy of abciximab facilitation per se. Finally these results cannot be 
generalised to patients presenting outside working hours, when potential 
transfer delays in real world practice may be exacerbated. However, the data 
can serve to inform future development of a 24 hour service. 
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5.6 CONCLUSIONS 
Pre hospital diagnosis with direct ambulance catheter lab access (DA) 
significantly reduces time to reperfusion among STEMI patients undergoing 
primary angioplasty compared with Accident and Emergency transfer (AET). 
However, there is scope to improve the diagnostic specificity of ambulance 
crews, and the efficiency of abciximab administration and transfer from 
participating A&Es. Both strategies were similar with respect to infarct size and 
clinical outcome, which may be explained by improved epicardial and 
microvascular blood flow prior to intervention in the AET group. These data 
suggest that early facilitation with abciximab may compensate for inter hospital 
transfer delays when this strategy cannot be avoided. The optimal future 
strategy may be to combine these approaches, with ambulance crews 
administering pre hospital abciximab. 
146 
CHAPTER 6 Platelet Activation and its Relation to Outcome following 
Primary Angioplasty for ST Segment Elevation Myocardial Infarction 
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6.1 ABSTRACT 
Platelet monocyte aggregates (PMA) and CD40 ligand (CD40L) are platelet 
activation markers that possess thrombotic and pro-inflammatory properties. 
These may influence the effectiveness of reperfusion therapy for ST segment 
elevation myocardial infarction (STEMI) This chapter describes the effect of the 
primary angioplasty process on platelet activation, and investigates the influence 
of platelet activation on reperfusion following primary angioplasty. The impact of 
early facilitation with anti-platelet therapy is also examined. 
Subjects 
25 STEMI patients underwent immediate cardiac catheterisation at a network 
heart attack centre (N-HAC). 23 underwent primary angioplasty. All received 
aspirin (ASA), clopidogrel (CLP) and abciximab (ABX) prior to intervention. 
Aspirin was administered by ambulance crews. 15 patients transferred from 
district hospitals received CLP and ABX prior to transfer to the WHAC ('early 
therapy - ET). 10 patients brought directly to the WHAC by ambulance from the 
community received CLP and ABX on arrival but prior to catheterisation (1ate 
therapy' -LT). Median time from CLP and ABX therapy to balloon inflation was 
70 min (63-90) ET vs. 33 min (20-43) LT, p=0.004. ISChaemia duration was 
similar in the two groups. Results were compared with 23 patients with chronic 
stable angina (CSA) of whom 21 underwent elective coronary angioplasty, and a 
control group of 11 subjects with no history of coronary disease (CTL). 
Methods 
PMA, P-selectin and CD40L surface expression were measured by flow 
cytometry in peripheral venous blood on arrival (T=O), 2 and 24 hours post 
balloon inflation. Plasma P-selectin, soluble sCD40L, and IL-6 were measured 
by ELISA. Peak creatine kinase (CK) within 24 hours was measured for infarct 
size. TIMI flow grade, Myocardial Blush Grade (MBG), corrected TIMI frame 
count (cTFC), and thrombus scores were assessed pre and post primary 
angioplasty. ECG ST segment resolution was measured post procedure. 
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Results 
Baseline PMA levels were significantly elevated among STEMI patients relative 
to CSA and CTL (26.4% ± 4.4 vs. 16.2% ± 2.1 and 16.7% ± 1.5 respectively, 
p=0.042). Levels remained elevated 2 hours following coronary intervention in 
STEMI patients, but fell by 49% and 32% (p=0.006 and 0.036) to similar levels 
by 24 hours in both STEMI and CSA cohorts. PMA levels fell more rapidly after 
intervention (by 35% at 2 hours, p=0.001) in CSA patients. P-selectin expression 
also fell significantly by 24 hours following intervention in both STEMI and CSA 
cohorts, with no significant differences between the two groups. CD40L and 
sCD40L remained unaffected by the angioplasty process in both settings. IL-6 
increased significantly at each time point in both angioplasty groups. 
PMA expression < 20% (median) at presentation was associated with TIMI 
grade 3 flow (9/9 vs. 4/8, p=0.015) and MBG 3 (7/9 vs. 2/8, p=0.03) post 
procedure, but not ST segment resolution. Peak CK was lower in patients with 
PMA < 20% (500 [283-1015], 1462 [837-1945] p=0.046). No association was 
demonstrated between CD40L or P-Selectin and reperfusion. 
PMA fell by 34% at 2 hours following primary angioplasty (p=0.01 3) in the ET 
cohort, but remained elevated in the LT group. P-selectin increased significantly 
at 2 hours in the LT group (by 118%, p=0.01 2). CD40L and IL-6 were unaff ected 
by the timing of anti-platelet therapy. 
Conclusions 
Primary angioplasty for ST segment elevation myocardial infarction did not 
increase platelet activation. Low PMA levels at presentation predicted improved 
reperfusion, supporting the concept that PMAs reflect the severity of plaque 
rupture, and may promote microvascular dysfunction. Early anti-platelet therapy 
reduced platelet activation 2 hours following intervention. This mechanism may 
contribute to the clinical benefits of early anti-platelet therapy in STEMI patients 
treated with primary angioplasty described in clinical trials. 
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6.2 INTRODUCTION 
Thus far this thesis has discussed the rationale and mechanism for the delivery 
of primary angioplasty as the preferred reperfusion strategy for patients 
presenting with ST segment elevation myocardial infarction (STEMI) in North 
East London. In the preceding chapter, effective clinical outcomes have been 
demonstrated utilising two complementary access strategies - direct access to 
the catheter laboratory by ambulance crews following pre-hospital diagnosis, 
and transfer from the accident and emergency departments of district hospitals 
following administration of pre-transfer anti-platelet therapy. It has been 
proposed that early administration of adjuvant anti-platelet therapy may 
compensate for prolongation of ischaernia in patients transferred from district 
centres. 
Platelet activation plays a key role in the pathogenesis of acute myocardial 
infarction. Platelet activation measured by P-selectin expression increases in 
patients with acute coronary syndromes (ACS), and differences in expression 
may predict the severity of clinical presentation (30). Platelet monocyte 
aggregates (PMA) and CD40 ligand (CD40L) may be more sensitive markers of 
platelet activation (31; 34), and are themselves associated with plaque instability, 
thrombus formation and inflammation (33; 220). These properties may influence 
the effectiveness of reperfusion therapy, and may also implicate these markers 
as therapeutic targets. This chapter investigates whether the outcome following 
primary angioplasty may be determined by mechanisms involving platelet 
activation. 
6.3 Aims 
As discussed in Chapter 1 [1.8 Platelet Activation, Primary 
Angioplasty, and Microvascular Perfusion], coronary angioplasty in 
the setting of a stable atheromatous plaque may itself activate platelets 
(31; 191; 221; 222). This study aims to compare platelet activation following 
coronary angioplasty in the setting of plaque rupture 
(primary angioplasty 
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for STEMI) with platelet activation following stable plaque angioplasty 
(elective angioplasty for chronic stable angina). 
2. To investigate the influence of platelet activation at presentation on 
epicardial and microvascular reperfusion following primary angioplasty for 
STEMI 
3. To investigate the effect of early administration of combined anti-platelet 
therapy with clopidogrel and abciximab on platelet activation following 
primary angioplasty for STEMI 
6.4 Hypotheses 
1. Coronary angioplasty in the setting of plaque rupture does not lead to 
further platelet activation 
The degree of platelet activation at presentation predicts reperfusion 
following primary angioplasty for STEMI 
I Early administration of anti-platelet therapy improves outcome following 
primary angioplasty through a reduction in platelet activation. 
6.5 METHODS 
6.5.1 Subjects 
The study was a prospective observational investigation of platelet activation 
among patients undergoing coronary intervention at the WHAC. The timing, 
doses and choice of anti-platelet therapy, as well as the timing and extent of 
revascularisation in each study group were determined by clinical protocol 
and/or operator preference at the WHAC and were not designed specifically for 
platelet studies. The logistics of performing flow cytometry within six hours of 
venesection at multiple time points (detailed below) in addition to restricted 
availability of access to flow cytometry limited sample sizes to those presented 
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in this chapter. The results of these studies must therefore be viewed in the 
context of these limitations. 
Of 105 confirmed STEMI patients presenting to the Network Heart Attack Centre 
(N-HAC) during the study period (January 2004 - May 2005), 25 patients were 
recruited on arrival at the WHAC into the platelet study. 23/25 underwent 
primary angioplasty with stenting, 1 was listed for coronary artery bypass 
surgery (CABG), and 1 was treated medically (TIMI grade 3 flow at presentation 
with no residual coronary stenosis). 
During the same study period, 23 patients with a history of chronic stable angina 
(CSA) were recruited into the platelet study, prior to a planned elective 
angioplasty and stenting procedure. 21/23 actually underwent angioplasty (1 
underwent angiography only and did not proceed to PCI, and the other had a 
failed attempt at opening a chronic total occlusion without balloon inflation). 
Subjects with a history of ACS within 6 weeks of the study were excluded. 
A control group of 11 volunteers with no prior history of ischaernic heart disease 
were also recruited through advertisement (CTL). This latter group was recruited 
from among health care professionals and other NHS workers as it was deemed 
unethical by the North East London Regional Ethics Committee to approach 
unaffected relatives and friends of the patients recruited. As a result the CTL 
group was not matched for age and sex with the two angioplasty groups which 
may be a confounding factor. However existing data suggest that gender and 
age do not affect either platelet aggregation (223) or activation (measured using 
soluble CD40L) (224) in healthy subjects. Baseline demographic and procedural 
characteristics are demonstrated in table 6.1. 
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Table 6.1 Baseline demographic and procedural characteristics 
P value (STEMI STEMI (n=25) CSA (n=23) CTL (n=1 1) 
vs. CSA) 
Demographics 
Age mean (sd) 60(12) 65(7) NS 47(17) 
Male Sex 68% 79% NS 36% 
Smoker 84% 53% 0.026 55% 
Diabetic 17% 12% NS 9% 
Procedure 
Abciximab 100% 48% <0.001 - 
Number of 
vessels treated 1.1(0.5) 1.2(0.5) NS - 
Mean (sd) 
Number of 
lesions treated 1.4(0.8) 1.2(0.6) NS - 
Mean (sd) 
Number of 
stents used 1.75(1-1) 1.5(1-0) NS - 
Mean (sd) 
Kev 
STEMI ST segment Elevation Myocardial Infarction 
CSA Chronic Stable Angina 
CTL Control 
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6.5.2 Interventions 
Primary angioplasty for STEMI 
All STEMI patients were treated with aspirin, clopidogrel and GpIlb/Illa receptor 
antagonist (GPRA) therapy (abciximab) prior to coronary intervention. Aspirin 
300mg was administered orally in all cases at the earliest opportunity (either in 
the ambulance or at the first hospital of presentation). 15/25 patients were 
transferred to the network heart attack centre (WHAC) from the ME 
departments of 5 district hospitals within a hospital network, having received 
'early' anti-platelet therapy (ET) with oral clopidogrel 300mg and a weight 
adjusted intravenous bolus of abciximab prior to transfer. The remaining 10 
patients were admitted to the WHAC directly from the community following pre 
hospital diagnosis by the ambulance crew. Ambulances could bypass the 
nearest network A&E department in favour of admission to the WHAC. These 
patients received 'late' clopidogrel and abciximab therapy (LT) immediately 
following arrival at the WHAC cardiac catheter lab, but prior to coronary 
intervention. Figure 6.1 demonstrates the patient pathway, and the timing of 
administration of anti-platelet therapy in each group. 
Elective coronary angioplasty for chronic stable angina 
All patients received an oral loading dose of clopidogrel 300mg greater than 6 
hours prior to intervention, and were already established on aspirin 75-300mg 
daily according to the standard elective angioplasty protocol at the N-HAC. 
Importantly adjuvant GPRA therapy with abciximab was used in 48% of elective 
cases, administered during or immediately after (but never before) the 
procedure according to operator preference (table 6.1). GpIlb/Illa antagonists 
(abciximab, eptifibatide and tirofiban) have been reported to inhibit the release of 
sCD40L in vitro (85; 86) and abciximab also inhibits agonist-induced formation 
of monocyte platelet aggregates in vitro (90). In vivo GPRA therapy has been 
demonstrated to reduce both sCD40L and PIVIA formation in ACS patients 
undergoing PCI (87). In addition GPRAs reduced circulating PMAs in stable 
patients undergoing PCI (225) although that study did not have a non-GPRA 
154 
control arm. Therefore the administration of abciximab to a proportion of patients 
in the CSA group may be an important confounding factor when comparing 
platelet responses following angioplasty in the setting of CSA relative to STEML 
This issue is specifically addressed in section 6.6.4 [6.6.4 Influence of 
abciximab therapy on platelet activation following elective coronary 
angioplasty for chronic stable angina]. 
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Figure 6.1 Patient pathways for patients presenting with STEMI entered in 
platelet studies 
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6.5.3 Blood sampling 
Peripheral venous blood samples were obtained using a standardised sampling 
protocol [see Chapter 2; 2.3.2 Blood Sampling, Preparation and Analysis]. 
Samples were taken on arrival at the WHAC among STEMI patients or 
immediately prior to entering the catheter lab for chronic stable angina patients 
(t=O), and then at 2 hours following balloon inflation (t=2) and 18-24 hours 
following balloon inflation (t=24). PMA, CD40L and membrane P-selectin 
expression were measured by whole blood flow cytometry, and plasma sCD40L 
and P-selectin were measured by enzyme linked immunoassay (ELISA). Peak 
CK within the first 24 hours of admission was measured as a marker of 
myocardial infarct size. Plasma Interleukin 6 (IL-6) was measured by ELISA as a 
marker of inflammation. Among the STEMI cohort, ET patients had received 
abciximab and clopidogrel at the time of initial sampling (t=O) whereas LT 
patients always received therapy after the first sample had been taken. 
Complete data for all biomarkers were available for analysis from all chronic 
stable angina (CSA) and control (CTL) patients (n=23 CSA, n=21 undergoing 
elective angioplasty, n=1 1 CTL). 
Complete ELISA data were available from all STEMI patients (sCD40L, soluble 
P-selectin, IL-6) (n=25 STEMI, n=23 undergoing primary angioplasty). 
Complete flow cytometric data were available from 21/25 STEMI patients for 
membrane P-selectin and CD40L (n=21 STEMI, n=19 undergoing primary 
angioplasty). 
Complete flow cytometric data were available from 18/25 STEMI patients for 
PMAs (n=18 STEMI, n=17 undergoing primary angioplasty). The remaining 
samples were excluded from analysis as a result of either insufficient data (too 
few monocyte events counted), or inconsistent results (coefficient of variability> 
10% on more than 2 separate analyses of the same sample). 
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6.5.4 Outcome measures 
Hypothesis 1 
Comparison of platelet activation markers at baseline was made between the 
three patient cohorts (STEMI, CSA and CTQ. Serial changes in platelet 
activation following intervention were analysed in those STEMI patients 
undergoing a primary angioplasty procedure and chronic stable angina patients 
(CSA) undergoing elective angioplasty between sampling time points (0-2 hours, 
0-24 hours, 2-24 hours). 
Hypothesis 2 
Platelet parameters were correlated with epicardial and microvascular perfusion 
at initial angiography in all STEMI patients, and post reperfusion therapy in 
those undergoing primary angioplasty. Angiographic measures included TIMI 
flow grade, Myocardial Blush Grade (MBG), TIMI thrombus burden and 
corrected TIMI frame count (cTFC) [see Chapter 2; 2.5 Angiographic 
analyses]. Angiographic data were available for all patients. ST segment 
resolution on the 12 lead ECG was assessed pre and post procedure and 
additionally at 18-24 hours [see Chapter 2; 2.4 ECG analyses]. ECG data were 
available for 18/25 subjects. 
Hypothesis 3 
Platelet parameters were compared between STEMI patients undergoing 
primary angioplasty treated with early and late anti-platelet therapy. All STEMI 
patients received aspirin, clopidogrel and abciximab therapy prior to intervention. 
Platelet responses in CSA patients treated with or without glycoprotein GpIlb/Illa 
receptor antagonist therapy were also compared. 
6.5.5 Statistics 
Due to the skewed distributions of biological markers, differences within and 
between patient cohorts and serial changes over time were compared using non 
parametric tests. The Mann Whitney U test was used to compare marker 
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expression between any two patient cohorts; the Kruskal - Wallis test was used 
to compare marker expression between all three patient groups; the Wilcoxon 
rank sum test was used to compare changes in platelet markers following 
intervention. Differences in categorical variables were compared using Chi 
square or Fisher's Exact tests. 
6.5.6 Ethics 
Ethical approval for platelet studies was granted by the North East London 
Regional Ethics Committee in March 2003 (reference number P/03/024). 
6.6 RESULTS 
6.6.1 Platelet activation following coronary angioplasty and stenting: 
stable versus ruptured / thrombotic plaque 
Baseline differences in platelet activation between patient cohorts are 
demonstrated in table 6.2. The data shown represent all patients presenting with 
STEMI and CSA, including those who did not subsequently undergo a coronary 
angioplasty procedure. PMA levels were significantly elevated in patients with 
STEMI compared with chronic stable angina patients and controls. CD40L was 
significantly higher among both patient cohorts than in the control group. 
However, in contrast to PMA, CD40L expression was significantly lower in 
STEMI patients than the chronic stable angina cohort. There were no 
differences in plasma sCD40L, membrane P-selectin expression or plasma P- 
selectin release between cohorts at baseline sampling. 
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Table 6.2 Comparison of Platelet and Inflammatory markers at baseline 
sampling 
Cohort PMA (%) CD40L (%) sCD40L Membrane Plasma IL-6 (pg/ml) 
(ng/ml) P Selectin P Selectin 
N (ng/ml) 
STEIVII 26.4 ± 4.4 12.4 ± 1.5 0.53 3.9 ± 0.7 20.4 ± 2.9 4.8 1.4 
n=25t (n=18) (n=21) 0.13 (n=21) 
CSA 16.2 ± 2.1 17.0 ±11.3 0.77 ± 3.5 ± 0.5 18.9 ± 2.4 2.7 0.43 
n=23 0.26 
CTL 16.7 ±11.5 3.7 ± 0.34 0.76 1.9 ± 0.4 15.3 ± 4.3 0.6 ± 0.3 
n=I 1 0.21 
P values 0.042* <0.001 All ISIS All ISIS All ISIS 0.003* 
0.029** 0.035** NS** 
0.031 t 0.002t 0.006t 
ISIS tt <0.001 tt <0.001 tt 
All data expressed as mean * SEM. 
Kruskal Wallis comparison of STEMI vs. Chronic Stable Angina vs. Control Group 
Mann Whitney U test: STEMI vs. Chronic Stable Angina 
Mann Whitney U test: STEMI vs. Control Group 
tt P value by Mann Whitney U: Chronic Stable Angina vs. Control Group 
n=25 except where otherwise stated 
Effect of percutaneous intervention 
Among STEMI patients undergoing primary angioplasty (ruptured plaque 
angioplasty), PMA levels and membrane P-selectin expression remained 
elevated 2 hours following balloon inflation, but fell significantly (by 49% in both 
cases) by 24 hours. Similarly plasma P-selectin levels fell by 30% at 24 hours 
(Figure 6.2a-c). 
In contrast, PMA expression fell significantly (by 35%) 2 hours following balloon 
inflation among CSA patients undergoing elective angioplasty (stable plaque 
angioplasty), remaining unchanged by 24 hours, with similar 
final levels to those 
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following primary angioplasty. Membrane P-selectin levels also fell (by 38%) at 2 
hours, and were unchanged at 24 hours, although this was not significant. 
Meanwhile, plasma P-selectin increased significantly by 32% (Figure 6.2a-c). 
Platelet surface and soluble CD40L were unaffected by the angioplasty 
procedure in the setting of both primary angioplasty for STEMI and elective 
angioplasty for CSA (Figure 6.2d-e). 
Interleukin 6 levels increased significantly at 2 and 24 hours following balloon 
inflation in both angioplasty cohorts (primary angioplasty 65% 0-2hrs, 239% 0- 
24 hrs; elective angioplasty 27% 0-2hrs, 137% 0-24hrs). 11-6 appeared higher in 
STEMI patients than in stable patients at all time points but did not reach 
statistical significance (Figure 6.2f). 
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Figure 6.2 Comparison of platelet activation following primary angioplasty 
for STEMI (ruptured plaque angioplasty) and elective angioplasty for 
chronic stable angina (stable plaque angioplasty) 
Data expressed as mean ± SEM 
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PMA levels fall significantly by 2 hours following elective angioplasty (i. e. in the setting of 
stable plaque), but not following primary angioplasty (i. e. in the setting of plaque rupture). 
Levels fall significantly by 24 hours in both groups. (6.2a). Membrane P selectin 
expression demonstrates a similar pattern but does not reach statistical significance 
(6.2b). CD40L and sCD40L appear unaffected by the angioplasty process in both settings 
(6.2d and e). Angioplasty results in an increase in inflammation in both settings (6.2f). 
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6.2b Membrane P-selectin Expression (flow cvtometrv) 
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6.2d Platelet Surface CD40 Ligand (flow cytometry) 
All p=NS (0-2 hours, 0-24 hours, 2-24 hours) 
All p=NS (0-2 hours, 0-24 hours, 2-24 hours) 
6.2e Plasma Soluble sCD40 Li-qand (ELISA) 
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6.2f Inflammation- Plasma Interleukin 6 (ELISA) 
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6.6.2 Influence of platelet activation on reperfusion and infarct size 
following primary angioplasty for STEMI 
Platelet activation markers were not predictive of angiographic epicardial or 
microvascular flow pre-procedure. However, PMA expression below the median 
(20%) at presentation was associated with a significantly increased rate of TIMI 
grade 3 flow and myocardial blush grade (MBG) 3 post procedure among those 
patients undergoing primary angioplasty (Table 6.3a). There was no association 
with thrombus score or corrected TIMI frame count (cTFC). PMA formation 
below 20% was also associated with a significantly lower peak serum creatine 
kinase level (CK). There was no relation between the duration of ischaernia and 
PMA at presentation. 
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T=O T=2 T=24 
No significant association was found between CD40L expression and 
angiographic reperfusion (Table 6.3b). There was no association with sCD40L, 
and neither was related to CK release. 
No association was detected between angiographic measures of reperfusion 
and either membrane P selectin expression or plasma P selectin release. 
Platelet markers were not associated with the degree of ST segment resolution 
on the 12 lead ECG post procedure or at 24 hours. 
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Table 6.3 The Influence of baseline platelet marker expression on 
epicardial and microvascular reperfusion following primary angioplasty 
a. Platelet Monocyte Aggregate expression at baseline sampling (n=17): 
Above versus below median 
I PMA < 20% n=9 PMA > 20ý-ý P W) 
Pre Procedure 
TIMI 3 3 1 NS 
MBG 3 4 2 NS 
Post Procedure 
TIMI 3 9 4 0.015 
MBG 3 7 2 0.03 
Peak CK median 
(IQR) 
500 (283-1015) 1462 (837-1945) 0.046* 
* Mann Whitney U test 
b. Platelet surface CD40 Ligand expression at baseline sampling (n=19): 
Above versus below median 
I CD40L: 5 13% n=l 0 CD40L > 13% n=9 P (XI 
Pre Procedure 
TIMI 3 1 3 NS 
MBG 3 2 4 NS 
Post Procedure 
TIMI 3 6 8 NS 
MBG 3 3 6 NS 
Peak CK median 
(IOR) 
1111 (559-2358) 727 (394-1294) NS 
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6.6.3 Influence of early versus late anti-platelet therapy on platelet 
activation following primary angioplasty for STEMI 
Table 6.4a compares baseline characteristics of patients treated with 'early' and 
'late' anti-platelet therapy. Demographic and procedural details were matched. 
ET patients presented earlier relative to those treated with LT, such that the 
duration of symptoms at the time of blood sampling (t=O) and the total duration 
of ischaernia (pain to balloon time) were similar in both groups (Table 6.4b). ET 
was administered (median) 37 minutes earlier than LT. In keeping with data from 
a larger cohort of patients presented in the preceding chapter [see Chapter 5; 
5.4.4 Anglographic reperfusion and ST segment resolution], TIMI 3 flow and 
MBG 3 were more frequent pre-procedure in the ET cohort compared with the 
LT group, although this did not reach significance in this platelet sub study. 
There was no difference in TIMI flow, MBG or ST resolution post procedure. 
Thrombus burden and cTFC did not differ significantly pre or post procedure 
(Table 6.4c). 
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Table 6.4 Comparison of patients undergoing primary angioplasty 
receiving early versus late anti-platelet therapy with clopidogrel and 
abciximab 
Table 6.4a. Demographics and procedural characteristics 
Early Anti-platelet therapy Late Anti-platelet therapy 
N=15 (14 primary N=10 (9 primary P Value 
angioplasty) angioplasty) 
Demographics 
Age 58(11) 64(13) NS 
Sex 9 male 8 male NS 
Smoker 14 7 NS 
Diabetic 2 2 NS 
Cholesterol 5 2 NS 
Prior MI 1 1 NS 
Prior Revasc 0 0 ISIS 
Procedure 
Culprit Vessel LAD 6 
LAD 5 
Cx 3 
Cx 3 
RCA 5 
RCA 2 
Vein graft 1 
No Vessels 
1.0(0.4) 1.2(0.6) NS 
Mean (sd) 
No lesions 
1.3(0.7) 1.6(l. 0) ISIS 
Mean (sd) 
No Stents 
1.5(0.85) 2.3(1.2) ISIS (0.07) 
Mean(sd) 
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Table 6.4b. Symptom duration, time to reperfusion, and time to 
administration of anti-platelet therapy in patients treated with primary 
angioplasty: early versus late anti-platelet therapy with clopiclogrel and 
abciximab. 
Early Anti-platelet Late Anti-platelet 
therapy therapy 
P Value 
N=1 5 (14 primary N=10 (9 primary 
angioplasty) angioplasty) 
Symptoms at 107 (43-175) 181 (142-541) 0.036 
presentation med (10R) 
Symptoms at t=O 168 (104-243) 201 (142-541) 
NS 
sampling median (IOR) 
Pain to balloon 247 (141-306) 248 (175-610) 
NS 
median (10R) 
Abciximab to balloon 70(63-90) 33(20-43) 0.004 
median (10R) 
Peak CK median (IOR) 
727 (382-1948) 1111 (382-1294) NS 
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Table 6.4c Epicardial and microvascular reperfusion in patients 
undergoing primary angioplasty: Early versus late anti-platelet therapy 
Early Anti-platelet Late Anti-platelet 
therapy therapy 
P Value 
N=1 5 (14 primary N=10 (9 primary 
angioplasty) angioplasty) 
Pre-angioplasty 
Mean TIMI flow (sd) 1.9(1.3) 1.4(1.1) NS 
TIMI grade 3 flow 7 1 ISIS (0.054) 
Mean MBG (sd) 1.8(1.4) 0.6(1.1) NS 
MBG 3 8 1 0.027 
Mean cTFC (sd) 51(39) 63(39) NS 
Mean Thrombus 
3.0(1.7) 3.3(1.0) ISIS 
score (sd) 
Post-angioplasty 
Mean TIMI flow (sd) 2.9(0.4) 2.4(1.0) NS 
TIMI 3 flow 12 6 NS 
Mean MBG (sd) 2.3(1.1) 1.9(1.3) NS 
MBG 3 9 4 NS 
Mean cTFC (sd) 28(26) 36(31) NS 
Mean Thrombus 
0.3(0.5) 0.2(0.4) NS 
score (sd) 
ST Resolution 60min 
71(15) 66(24) NS 
% (sd) 
ST Resolution 24hr 
80(12) 76(20) NS 
% (sd) 
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PMA levels did not differ significantly between ET and LT cohorts at initial 
sampling. PMA expression fell significantly (by 34%) at 2 hours following balloon 
inflation in the ET group, but remained elevated in those receiving LT (figure 
6.3a). Notably however, PMA expression at 2 hours was significantly lower 
among those patients achieving TIMI grade 3 flow post procedure (36% ± 9.5 
vs. 16% ± 3.4, p=0.032), raising the possibility that arterial patency per se may 
have influenced the fall in PMAs rather than early anti-platelet therapy itself. 
Final TIMI flow post angioplasty was not associated with any of the other platelet 
markers, but was associated with lower peak CK (1685 iu [1182-2358] TIMI flow 
<3 vs. 578 iu [302-1243] TIMI 3, p=0.039) and IL-6 (9.8 pg/ml [6.6-40.6] vs. 4.1 
pg/ml [2.7-8.9], p=0.037) at 24 hours. 
Membrane P-selectin expression also fell (by 37%) at 2 hours following primary 
angioplasty in the ET group (though not reaching statistical significance, 
p=0.16), and increased significantly (by 118%, p=0.012) following LT (figure 
6.3b). Plasma P-selectin followed an inverse pattern to that of Membrane P 
selectin and PMAs, remaining elevated at 2 hours in the ET cohort, and falling 
by 28% at 2 hours following therapy in the LT cohort, though this did not 
approach statistical significance (p=0.8, Figure 6.3c). 
CD40L and sCD40L remained unaffected by the timing of anti-platelet therapy 
(figure 6.3d, e). Baseline IL-6 was significantly higher at baseline sampling in 
patients receiving late anti-platelet therapy, and rose thereafter in both groups 
(although this was statistically significant only in the early therapy group) (figure 
6.3f). 
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Figure 6.3 Influence of Early versus Late Anti-Platelet therapy with 
Clopidogrel and Abciximab on Platelet Activation following Primary 
Angioplasty for STEMI 
6.3a Platelet Monocyte Aggregate (PMA) Expression 
p=0.01 3 early therapy (0-2 hours); p=NS 2-24 hours 
p=0.01 2 early versus late therapy at T= 2 hours 
p=NS Late therapy (0-2 hours) 
PMA levels fell significantly 2 hours following primary angioplasty in patients receiving 
early anti-platelet therapy, but remained elevated in those receiving late therapy, before 
failing to similar levels at 24 hours (6.3a). Membrane P-selectin increased 2 hours 
following intervention in patients receiving late therapy (6.3b). CD40L and sCD40L were 
unaffected by the timing of anti-platelet therapy (6.3d and e). Inflammation increased in 
both groups (6.3f). 
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6.3d Platelet surface CD40 Ligand Expression (flow cytometry) 
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6.6.4 Influence of abciximab therapy on platelet activation following 
elective coronary angioplasty for chronic stable angina 
There were no significant differences in baseline platelet activation among CSA 
patients undergoing elective angioplasty treated with or without adjuvant 
abciximab. Furthermore abciximab did not appear to affect platelet activation 
following intervention in this cohort (Figure 6.4a-c). IL-6 was not significantly 
different between these groups, but increased significantly following angioplasty 
in both groups (figure 6.4d). 
Figure 6.4 Influence of abciximab on platelet activation and inflammation 
following elective coronary angioplasty for chronic stable angina 
Data expressed as mean ± SEM. All P=NS 
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6.4b Membrane P selectin Expression (flow cytometry) 
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6.7 DISCUSSION 
This study highlights important differences in platelet responses to coronary 
angioplasty in two clinical and pathological settings, in addition to differences in 
expression of the separate platelet activation markers in each situation. 
Platelet Monocyte Aggregates 
Ruptured vs. Stable Plaque 
The study demonstrated elevated PMA levels among patients with STEMI when 
compared with patients with stable coronary disease, and subjects with no 
history of ischaemic heart disease, a finding consistent with previous published 
data (31). In response to coronary angioplasty PIVIA levels fell significantly at 24 
hours to similar levels in both the acute and stable settings. The fall was more 
rapid in patients with CSA, becoming apparent at 2 hours following the 
procedure. PIVIA levels remained elevated within the STEMI cohort at this time 
point. Furman et al have suggested that PMA elevation may be an early marker 
of subsequent myocardial infarction among patients presenting with ACS, 
potentially indicating the severity and thrombogenicity of plaque rupture (32). 
Thus while the angioplasty procedure did not appear to activate platelets, the 
persistence of PMA elevation in the STEMI group could imply continuing plaque 
disruption related to the underlying pathology that remains unaffected by the 
angioplasty procedure. 
Efficacy of Reperfusion 
Importantly, the PMA level at presentation also predicted the quality of 
reperfusion following primary angioplasty. Lower PMA levels were associated 
with improved epicardial and microvascular flow and smaller ultimate infarct 
size. This is also consistent with the theory that PMAs indicate plaque 
thrombogenicity. The fact that PIVIA levels were not associated with the degree 
of angiographic thrombus at presentation may imply that PMAs are a more 
sensitive indicator of the presence of thrombus than angiography. However this 
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may be over simplistic. It is more likely that PIVIA formation points to the severity 
of the ongoing pathological process within the plaque, or indeed may be directly 
mechanistic in mediating microvascular dysfunction. This could occur through a 
number of thrombotic and pro-inflammatory mechanisms. Sarma et al have 
demonstrated that monocyte binding to platelets occurs primarily through P- 
selectin and P-selectin glycoprotein ligand 1 (PGSL1 -) interaction, and that 
PMAs may be disaggregated using a monoclonal antibody to PGSL-1 (226). 
This mechanism has also independently been demonstrated to reduce 
myocardial reperfusion injury in cat model of ischaemia and reperfusion (227). In 
addition the process of P selectin binding itself promotes cytokine, tissue factor, 
and CID1 1 b/CD1 8 expression by monocytes (228-230). These data lend support 
to the concept that there may be a therapeutic benefit to reducing PMA levels. 
Influence of Anti-platelet Therapy 
The primary angioplasty process in this study included a combination of aspirin, 
clopidogrel, and abciximab in all cases, in addition to the procedure itself. 
Therefore the effects of the procedure on platelet activation are inevitably the 
sum of all their effects. However, subgroup analysis of the STEMI cohort 
demonstrated that early administration of clopidogrel and abciximab therapy 
reduced platelet activation measured at 2 hours post balloon inflation, thereby 
altering the PMA response to resemble that of a stable plaque. That PMA 
remained elevated in those receiving later therapy is noteworthy as these 
patients had similar durations of ischaemia and still received therapy 33 minutes 
(median) prior to balloon inflation. Furman et al have established that PMA 
formation early after intervention can be reduced by administration of GPRA 
therapy among ACS patients undergoing coronary angioplasty, and 
independently of the effect of clopidogrel (87). The data presented here may 
suggest that in the presence of STEMI with a ruptured thrombotic plaque, the 
timing of therapy may be critical in order to achieve this result. Moreover, the 
reduction in PMA expression may provide a novel mechanism contributing to the 
benefit of early abciximab therapy for STEMI patients undergoing primary 
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angioplasty observed in clinical trials (83; 126). It is possible to speculate that 
modification of PIVIA levels to resemble the response of a stable plaque could 
itself imply plaque stabilisation. However, it is also possible that the fall in PIVIA 
level was purely a reactive phenomenon. 2 hour PIVIA levels were also 
significantly lower among those achieving TIMI 3 flow post procedure, 
suggesting this may have been the effect of improved reperfusion rather than 
the therapy per se. Finally it must be recognised that subgroup analysis of the 
STEMI cohort was performed on small numbers of patients (particularly in the 
case of PIVIA analyses where there were 11 patients in the early anti-platelet 
therapy group and only 6 patients in the late anti-platelet therapy group). It is 
possible therefore that the absence of a fall in PIVIA formation at 2 hours in the 
late therapy group may have been a consequence of type 11 error. 
P-selectin 
Membrane P selectin expression behaved similarly to PMA formation following 
coronary intervention in the setting of STEMI, remaining unchanged at 2 hours 
and falling significantly by 24 hours. Plasma P selectin levels also fell 24 hours 
following primary angioplasty but increased significantly following intervention in 
CSA patients. However, P-selectin surface and plasma levels had no influence 
of epicardial or microvascular reperfusion pre or post procedure. Early anti- 
platelet therapy for STEMI resulted in a similar fall in P selectin expression 2 
hours post procedure to that of PMAs, though not significant. Among patients 
receiving late therapy membrane P selectin levels increased. 
The similarity in platelet responses between PMA and membrane P-selectin 
may be explained by the fact that PMA formation depends on a P-selectin 
dependent mechanism (220). This would also imply that P selectin expression 
and monocyte binding are in equilibrium. PMA levels appeared more sensitive 
than P selectin, in keeping with observations described by Michelson et al (31). 
This could explain the lack of correlation of P selectin expression with the 
efficacy of reperfusion. The differences in P selectin response to early and late 
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anti-platelet therapy lend further support to the notion that the benefit of early 
therapy may be mediated by beneficial effects on platelet activation. 
CD40 Ligand 
Baseline surface CD40L expression was elevated in both STEMI and CSA 
patients relative to controls. Interestingly CD40L was highest in stable patients 
and significantly lower in the setting of STEMI. There were no differences 
between cohorts in soluble sCD40L. In addition, primary and elective 
angioplasty had no significant measurable effect on either surface CD40L 
expression or sCD40L release. In contrast to PIVIA formation, CD40L expression 
did not appear to influence reperfusion following primary angioplasty for STEMI, 
and there was no demonstrable effect of early anti-platelet therapy. 
The finding that CD40L expression was lower in STEMI patients than those with 
stable angina may be consistent with previous data from Garlichs et al that 
demonstrated platelet surface CD40L elevation among patients with unstable 
angina relative to those presenting with acute MI (40). In that study MI patients 
had an associated increase in sCD40L release, with the authors suggesting a 
continuum of surface CD40L up-regulation and sCD40L hydrolysis that might 
reflect the severity of the plaque rupture, with greater hydrolysis of surface 
sCD40L once CD40L is maximally expressed. However, this latter finding was 
not replicated in the present study. This may have been a consequence of the 
use of serum rather than plasma samples in that study. Serum assays have 
been demonstrated to overestimate sCD40L levels in unstable coronary patients 
(231; 232), such that plasma assays are currently the preferred method of 
measuring platelet derived sCD40L (232). Indeed sCD40L levels in the study by 
Garlichs et al (40) were substantially higher than in either the cohort described 
here, or among ACS patients in other studies where citrated plasma was also 
used (87). Equally this disparity may be a result of differences in the study 
population. The present study included only acute STEMI patients, usually 
presenting early after symptom onset (median 2.5 hours), and commonly with 
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established thrombus. It is therefore possible that sCD40L and platelet CD40L 
were already sequestered in thrombus, and platelets may not have had the 
capability, or sufficient time to further up-regulate surface CD40L. 
The apparent lack of CD40L response to angioplasty also merits consideration. 
It is possible that sampling at 2 hours following the procedure may have been 
too late to detect changes in sCD40L. A number of studies have demonstrated a 
significant increase in sCD40L as early as 10 minutes following peripheral or 
coronary angioplasty (233; 234). On the other hand Furman et al also failed to 
demonstrate a change in sCD40L levels immediately after angioplasty or at 24 
hours among acute coronary patients presenting without ST segment elevation 
in the absence of GPRA therapy, and when GPRA therapy was included 
sCD40L fell significantly at both time points (87). 
It is also plausible that the lack of change in CD40L expression and sCD40L 
release among STEMI patients may have represented a balance between the 
dynamic processes of platelet activation by plaque rupture and injury, and 
stabilisation by combined anti-platelet therapy. A primary angioplasty control 
group treated without anti-platelet therapy could have addressed this issue, but 
was unethical given the established prognostic benefits of these therapies. 
However, the finding that CD40L and sCD40L also remained unchanged 
following elective angioplasty for CSA both in the presence and absence of 
abciximab militates against this argument. 
Differences between CD40L and PMA 
Unlike P selectin, CD40L expression appeared to behave differently to PMA 
levels in the experiments described here. Both PMA and CD40L have been 
suggested as markers of platelet activation, and as mediators of plaque 
instability, thrombosis and inflammation (34; 185; 220). Angioplasty in the setting 
of both stable and destabilised plaque was associated with increasing 
inflammation measured by IL-6 at each time point, consistent with previous 
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studies (235; 236). However, PMA formation was modified by coronary 
intervention whereas CD40L was not. This may simply be a reflection of the 
sensitivity of PMA in this study. Larger sample sizes might have unmasked more 
subtle changes in CD40L yielding similar results. The only previous study of 
platelet activation following primary angioplasty was substantially smaller than 
the current study (29). Subsequent studies measuring PMA and CD40L 
expression in ACS patients using flow cytometry have recruited similar or slightly 
larger patient populations (30-200 patients) (31; 32; 40; 87; 237) However, studies 
assaying soluble CD40L have utilised stored samples from large randomised 
studies (88) resulting in statistically powerful results. While it is difficult to draw 
definitive conclusions, the results presented here may intimate that although 
CD40L is involved in the mechanism of plaque rupture and thrombus formation, 
circulating levels are not reflective of disease severity in the setting of 
established STEMI, and are not modified by coronary intervention. Moreover, if 
CD40L is a potential therapeutic target, alternative therapies may be necessary 
in addition to clopidogrel and GPRA therapy to improve outcomes in STEMI 
patients specifically. 
Limitations 
This study has important limitations. The prospective observational study design 
investigated platelet behaviour in the setting of established clinical and 
pharmacological practice, leading to a number of confounding factors that may 
have influenced the results. In addition logistic difficulties with patient 
recruitment resulted in small sample sizes which may have particular relevance 
to the results of subgroup analyses. The findings must therefore be viewed as 
hypothesis generating, and a stimulus for more specific hypothesis driven 
clinical and basic science research. 
Specifically, it is not possible to separate the influence of the mechanical 
angioplasty process, and that of adjuvant anti-platelet therapy on platelet 
activation following angioplasty. It is possible that primary angioplasty may 
have 
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resulted in enhanced platelet activation in the absence of abciximab. As 
discussed earlier, it was deemed unethical to perform primary angioplasty 
without combined aspirin, clopidogrel, heparin and abciximab. The effects of 
simultaneous platelet suppression and activation could have canceled each 
other out, and may be relevant to the CD40L response in particular. In addition, 
as stated earlier, the CSA cohort was a heterogeneous group, almost half of 
which received abciximab therapy. Subgroup analysis in fact suggested that the 
abciximab did not influence the platelet response to elective angioplasty. 
However, it is possible that abciximab was administered in higher risk cases that 
might otherwise have demonstrated a heightened platelet response to 
angioplasty. 
In comparing the influence of early and late anti-platelet therapy in the setting of 
primary angioplasty, the effects of abciximab and clopidogrel cannot be 
separated. The clopidogrel loading dose was administered a median of 62 
minutes prior to intervention, suggesting that any effect is more likely to be the 
result of abciximab. This would be consistent with previous data in ACS patients 
suggesting that PIVIA formation in response to abciximab is independent of 
clopidogrel (87), and that suppression of surface expression of CD40L and P 
selectin following angioplasty in stable patients required early clopidogrel 
loading (236). Similarly, the influence of abciximab on platelet activation in the 
setting of CSA and STEMI cannot be directly compared due to the differences in 
the timing of administration of both this therapy and clopidogrel in each group. 
It has already been discussed that the small sample sizes investigated may 
have had particular relevance to subgroup analysis of the STEMI cohort. Given 
that the majority of STEMI patients achieved arterial patency (TIMI grade 2 or 3 
flow) post procedure, it is nonetheless impressive that PIVIA levels were 
predictive of improved epicardial and microvascular flow. However, it 
is possible 
that similar associations with other markers may have been missed. 
A larger 
study is therefore indicated before further conclusions can be drawn. 
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Moreover, the finding of an association between heightened PMA expression 
and impaired reperfusion does not imply causality. In addition it has already 
been discussed that the reduction in PMA formation at 2 hours following primary 
angioplasty in those receiving early anti-platelet therapy may have been a 
marker of successful reperfusion rather than a beneficial therapeutic effect. 
Finally, the sampling time points (2 and 24 hours post balloon inflation) were 
chosen to detect the peak activation following angioplasty based on previous 
studies (31). As few studies have investigated these markers in this patient 
subgroup, it is possible that a delayed or biphasic activation platelet activation 
response may have been missed. 
Future Research 
The results of the platelet studies described here should now form the basis of 
larger studies to test hypotheses generated from this observational work. 
In order to accurately compare platelet responses to coronary angioplasty in the 
setting of acute STEMI with stable coronary disease, an appropriately powered 
prospective study should now be performed. Subjects should be matched for 
age, sex, and coronary lesion location (e. g. proximal left anterior descending 
artery lesions), receiving standardised doses and timing of essential medical 
therapy (aspirin, clopidogrel, heparin) in order to control for confounding factors. 
STEMI patients should also be matched for symptom duration. The influence of 
abciximab therapy and timing of therapy could be further investigated through 
randomisation. Blood sampling should be performed at additional time points. 
In addition basic science research should now be performed to investigate 
whether there is a causal link between the platelet activation markers studied 
here and microvascular dysfunction in vitro following ischaernia and reperfusion. 
Using the preliminary clinical data obtained from this study, a grant proposal has 
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been developed to study the influence of PMA formation and CD40 - CD40L 
interactions on microvascular flow in the mouse mesentery using intravital 
microscopy. The individual effects of anti-platelet therapies on these interactions 
may subsequently be investigated. 
6.8 CONCLUSIONS 
In this small prospective observational study primary angioplasty for ST segment 
elevation myocardial infarction did not increase platelet activation. Lower platelet 
monocyte aggregate levels at presentation predicted improved epicardial and 
microvascular flow following intervention, supporting the concept that PMA 
formation reflects the severity of plaque rupture, and may promote 
microvascular dysfunction. Administration of early anti-platelet therapy with 
abciximab and clopidogrel reduced platelet monocyte aggregate levels 2 hours 
following intervention. This mechanism may contribute to the benefit of early 
abciximab facilitation observed in clinical trials. A larger study is now indicated. 
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CHAPTER 7 Comparison of Primary Angioplasty and Thrombolytic 
Strategies for the treatment of ST segment Elevation Myocardial Infarction 
in North East London: Clinical outcome, resource utilisation and hospital 
stay 
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7.1 ABSTRACT 
Thus far this thesis has described the development and delivery of a pilot 
primary angioplasty service in North East London. This chapter compares 
clinical outcomes and resource utilisation during the pilot programme with 
outcomes following the thrombolytic strategy. 
Methods 
Subjects 
105 consecutive patients with confirmed STEMI delivered to a network heart 
attack centre (N-HAC) within a network of six hospitals with a view to primary 
angioplasty were compared with 192 STEMI patients presenting to one of the 
participating centres utilising the thrombolytic strategy; 105 admitted prior to and 
87 following the instigation of the pilot primary angioplasty service. Data 
collection was prospective and non-randomised. 
Outcomes 
Clinical outcomes were assessed at median follow up of 19 (9-36) weeks. 
Analysis was by intention to treat. Major Adverse Cardiac Events (MACE) 
included death, non-fatal myocardial infarction (NFMI), stroke, and emergency 
revascularisation post discharge. Resource utilisation was measured by 
emergency readmission, the need for planned and unplanned cardiac 
catheterisation, and hospital stay during the index admission and subsequent 
cardiac hospital isations. 
Results 
The primary angioplasty strategy significantly reduced mortality and MACE 
compared to thrombolysis (4% and 15% primary angioplasty vs. 11 % and 25% 
thrombolysis, p=0.022 and 0.048 respectively). Stroke was reduced, though not 
significantly (1% primary angioplasty vs. 4% thrombolysis). The rate of NFMI 
was similar between groups (8% primary angioplasty vs. 7% thrombolysis, 
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p=NS). The need for unplanned cardiac catheterisation and emergency 
readmission was not reduced by the primary angioplasty strategy, with a similar 
number of readmissions occurring during follow up. Primary angioplasty reduced 
the length of inpatient hospital stay by a median 3 days (3 days (2-4) primary 
angioplasty vs. 6 days (4-9) thrombolysis, p<0.001). At the time of follow up the 
primary angioplasty strategy had saved 529 bed days per 100 patients treated 
when compared with thrombolysis, at the cost of 51 additional cardiac 
catheterisation procedures and 61 revascularisations. 
Conclusions 
Primary angioplasty utilising a network heart attack centre model significantly 
improves clinical outcomes compared with thrombolysis, and radically reduces 
hospital stay. However, strategies are still required to reduce emergency non 
cardiac readmissions and unplanned catheterisation procedure. Delivery of a 24 
hour seven day service should now be considered. 
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7.2 INTRODUCTION 
The preceding chapters of this thesis have described the development of a 
network primary angioplasty pilot service in North East London. A central 
hypothesis of the thesis was that primary angioplasty can be delivered safely 
and effectively in a United Kingdom population, with improved efficiency and 
clinical outcomes compared with thrombolysis. Effective delivery of therapy has 
been established utilising two complementary access strategies [chapter 5]. 
This chapter now compares clinical outcomes and resource utilisation during the 
pilot programme with outcomes following the thrombolytic strategy. 
7.3 METHODS 
7.3.1 Subjects 
Primary Angioplasty 
105 patients with confirmed STEMI were admitted to a network heart attack 
centre (N-HAC) either directly via ambulance or transferred from one of 5 
participating ME departments [chapter 5]. 103 underwent primary angioplasty 
(PA), one patient was referred for bypass surgery, and the other was treated 
medically. The service operated during working hours (0800-1700 on 
weekdays). 
Thrombolysis 
Outcomes were compared separately with two cohorts of patients with 
confirmed STEMI presenting to one of the participating network centres 
(centre 
E) [see chapter 2; Figure 2.1] utilising the thrombolytic strategy 
(TL). 87 
patients were admitted between April 2003 and April 2004 presenting outside 
the operating hours the daytime pilot primary angioplasty service 
(71- pilot'). In 
order to control for the potential selection bias caused 
by the differential hours of 
operation of each strategy, a historical cohort of 105 consecutive patients with 
confirmed STEMI admitted over a 24 hour seven 
day period between October 
2001 and October 2002 prior to the instigation of the pilot primary angioplasty 
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service was also investigated (71- pre pilot'). Baseline characteristics of the 
study cohorts are demonstrated in table 7.1. 
7.3.2 Outcomes 
Follow up data were available in 94% of cases for a median of 19 weeks (9-36) 
(table 7.1). Analysis was by intention to treat. Major Adverse Cardiac Events 
(MACE) included death, non-fatal myocardial infarction (NFMI), stroke, and 
emergency revascularisation post discharge as defined in chapter 2 [2-6 
Clinical Outcomes]. Emergency cardiac readmissions, planned (elective) and 
unplanned (emergency) cardiac catheterisation procedures and 
revascularisations were also recorded. 
Hospital stay during the index admission was compared, both inclusive and 
exclusive of hospitalisation following transfer to the cardiac centre where 
appropriate. Patients were discharged according to physician preference 
following thrombolysis. Following primary angioplasty early hospital discharge 
was permitted for uncomplicated patients at 48 hours [chapter 4; Table 4-4], 
with the remainder discharged according to physician preference. The duration 
of hospital stay following subsequent readmissions was also recorded for 
patients in the primary angioplasty and TL pilot cohort. 
7.3.3 Statistics 
Comparison of continuous variables between cohorts was assessed using non 
parametric tests due to the skewed distribution of data (Mann Whitney U and 
Kruskal - Wallis tests). Chi square and Fisher's exact test were used to compare 
categorical variables. 
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Table 7.1 Baseline characteristics of study cohorts 
Primary TL pilot TL pre pilot P 
Angioplasty 
(n=105) (n=87) (n=105) 
Mean age (sd) 59.4(12.6) 61 (14) 61 (13) NS 
Male sex 76 82 81 ISIS 
Smoker (%) 70 68 NS 
Diabetes 18 31 0.17 
Hypertension (%) 41 44 NS 
Ethnicity 
Caucasian 71 49 54 
Asian 26 37 40 
Black 2 6 4 
Other 1 8 2 
_ Prior MI 5(12.2%) 11(14.5%) - NS 
Prior Revascularisation 1(2.4%) 1(1.3%) NS 
" PCI 1 0 
" CABG 0 1 
Symptom duration at 110 (60-200) 174 (80-337) 0.004 
presentation med (10R) 
Symptom onset within 12 82% 84% - NS 
hours 
Treatment received PA 98% TL 80% 93% NS 
Anterior STEMI 44% 32% 39% NS 
Cardiogenic Shock 3% 2% 3% ISIS 
Peak CK med (IOR) 787 (427-1728) 680 (140-1228) NS 
Follow up weeks med 16(9-28) 17(8-28) 28(12-51) 0.004 
(IOR) 
Follow up available 103(98%) 77(89%) 98(93%) NS 
- Data not recorded 
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7.4 RESULTS 
7.4.1 Baseline Characteristics 
There were baseline differences between study cohorts. Firstly the duration of 
follow up was similar for the primary angioplasty and 'TL pilot' cohorts, but 
longer in the 71. pre pilot' group (Table 7.1). Nevertheless, the timing of MACE 
was similar between the three groups (median [IQR] 2 weeks [0-6] PA; 3 weeks 
[1-8] TL pilot; 3 weeks [2-12] TL pre pilot). Secondly the proportion of patients of 
Asian origin was higher in both the thrombolytic groups reflecting the catchment 
population of the admitting centre rather than that of the North East sector. This 
may also explain the higher proportion of diabetic subjects, although this was 
non significant. Finally symptom duration at presentation was shorter in the 
primary angioplasty cohort, although the proportion of patients presenting within 
12 hours was similar. 
7.4.2 Major Adverse Cardiac events 
7.4.2.1 Primary angioplasty versus thrombolysis 
Figure 7.1 demonstrates clinical endpoints for each cohort. MACE was 
significantly lower in the primary angioplasty cohort than in the pilot thrombolysis 
group, driven predominantly by a significant mortality reduction. MACE following 
primary angioplasty was also lower than the historical thrombolysis cohort, but 
did not reach significance. Stroke was lower in the PA group. However, non fatal 
MI was similar in all groups. Event rates were lower (though not significantly) in 
the historical thrombolytic cohort (TL pre pilot) than those admitted outside 
working hours after commencement of the pilot (TL pilot). 
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Figure 7.1 Major Adverse Cardiac Events at median follow up 19 weeks 
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7.4.2.2 Influence of multi-vessel coronary disease among patients 
assigned to primary angioplasty 
Of 103 patients undergoing primary angioplasty, 47 (46%) had multivessel 
coronary disease (more than one vessel with greater than 70% luminal 
stenosis). Of these, 33 (70%) underwent intervention to the culprit vessel only, 
with the remaining 14 (30%) undergoing immediate multi-vessel coronary 
angioplasty. There was no detectable difference in event rates between patients 
with multivessel and single vessel disease (Figure 7.2). There was a higher rate 
of non fatal MI among patients with single vessel disease compared with multi- 
vessel disease, although this did not approach significance. 
Among the subgroup of primary angioplasty patients with multi-vessel coronary 
disease, there was a higher rate of non fatal MI, unplanned revascularisation, 
and in turn MACE, in those patients undergoing culprit vessel revascularisation 
only during the index admission, although this did not approach significance in 
this small subgroup (Figure 7.3). Equally, among those patients undergoing 
single vessel angioplasty, there were no significant differences in outcome 
between patients with multi-vessel disease compared single vessel disease 
(Figure 7.4). 
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Figure 7.2 Major adverse events among 101* STEMI patients presenting to 
the Network Heart Attack Centre (N-HAC) undergoing primary angioplasty: 
Influence of multi-vessel coronary disease 
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Figure 7.3 Major Adverse Events among patients with multivessel 
coronary disease undergoing primary angioplasty (n=46): Influence of 
culprit versus multi-vessel coronary angioplasty 
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Figure 7.4 Major Adverse Events among patients undergoing single vessel 
primary angioplasty (n=87): Influence of single vessel versus multi-vessel 
coronary disease 
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7.4.3 Resource Utilisation 
Contrary to expectation, the number of emergency cardiac readmissions was 
not reduced by the primary angioplasty strategy (Figure 7.5). In addition the 
number of unplanned cardiac catheterisation procedures and emergency 
revascularisations were similar in all cohorts. 
The proportion of emergency readmissions with either troponin positive ACS or 
recurrent STEMI were similar in all cohorts (Table 7.2). However, a higher 
proportion of patients re-presented with a troponin negative chest pain 
syndrome from within the primary angioplasty cohort compared to those treated 
with thrombolysis, although this was not significant. 
The rate of inpatient transfer for cardiac catheterisation and subsequent 
revascularisation during the index admission and post discharge were similar in 
both thrombolytic cohorts (Table 7.3 and Table 7.4). By the end of follow up the 
primary angioplasty strategy had resulted in 51 additional cardiac 
catheterisations and 61 additional revascularisations per 100 patients treated 
compared to thrombolysis, when all planned and unplanned procedures were 
included. (Additional revascularisations were calculated using the combined 
average from the thrombolytic cohorts). 
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Figure 7.5 Emergency readmissions and unplanned cardiac 
catheterisation procedures at a median of 19 weeks follow up 
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Table 7.2 Diagnosis following Emergency Readmission 
PA n=22 TL pilot n=20 TL pre pilot n=18 
(21%) (26%) (18%) 
Chest pain syndrome 
13(59%) 8(40%) 8(44%) 
Troponin negative 
NSTE-ACS 
5(23%) 6(30%) 4(22%) 
Troponin positive 
Recurrent STEMI 3(14%) 3(15%) 2(11%) 
Other 
LVF 1 1 0 
Arrhythmia 0 1 0 
CVA 0 1 3 
Non Cardiac death 0 0 1 
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Table 7.3 Cardiac catheter procedures performed during the index 
admission and during follow up 
PA TL pilot TL pre pilot 
N=1 05 N=87 N=1 05 
INPATIENT PROCEDURES 
All 
Catheterisation 
100% 44(51%) 59(56%) 
Indication 
Ischaernia driven 1 (1%) 17(20%) 24(23%) 
Protocol driven 27(31%) 35(33%) 
PROCEDURES DURING FOLLOW UP 
PA TL pilot TL pre pilot 
N=1 03 N=77 N=98 
All outpatient 
22 (21 15(18%) 17(17%) 
Catheterisation 
Unplanned 
14(14%) 10(13%) 8(8%) 
Catheterisation 
TOTAL 
No Catheter 
studies per 100 121 68 72 
patients treated 
* Includes 6 cardiac catheter studies immediately prior to planned 'staged' non culprit 
PCI, 1 patient undergoing routine coronary angiography following a primary angioplasty 
to the left main stem, and 1 patient with recurrent stable angina. 
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Table 7.4 Revascularisation procedures performed during the index 
admission and during follow up 
PA TL pilot TL pre pilot 
N=l 05 N=87 N=l 05 
INPATIENT PROCEDURES 
Revascularisation 103(98%) 32(37%) 41(40%) 
PCI 103 27 37 
CABG 0 5 4 
PROCEDURES DURING FOLLOW UP 
All 
Revascularisation 13(13%) 10(12%) 12(12%) 
PCI 13 5 9 
CABG 0 5 3 
Emergency 
Revascularisation 8(8%) 6(8%) 6(6%) 
PCI 2 5 
CABG 4 1 
TOTAL 
Revascularisations 
48 51 
per 100 patients 
All PCI (11 CABG) (7 CABG) 
treated 
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7.4.4 Hospital Stay 
Inpatient hospital stay was significantly reduced by the primary angioplasty 
strategy by a median of 2 days compared to the historical cohort, and 3 days 
compared to thrombolysis during the pilot period (Table 7.5). 
Early hospital discharge was associated with a similar event rate post discharge 
to those discharged later (Table 7.6). A significantly higher proportion of those 
patients allowed home early required a subsequent unplanned cardiac 
catheterisation procedure, though this did not lead to an increase in repeat 
revascularisations. 
Although the number of cardiac readmissions was similar in both the PA and the 
'TL pilot' cohorts, the median duration of hospital stay for readmission following 
PA was substantially shorter (Table 7.5). The primary angioplasty strategy 
saved 529 bed days per 100 patients treated, when all index and subsequent 
hospital isations were included. 
206 
Table 7.5 Analyses of hospital stay during index admission and following 
readmission 
TL pre PA TL pilot 
pilot P N=1 05 N=87 
N=1 05 
INDEX ADMISSION 
Hospital stay 
Excluding cardiac centre NA 5(4-9.25) 4(1.5-6) <0.001 
Days: median (10R) 
Hospital stay including 
cardiac centre 3(2-4) 6(5-12) 5(4-9) <0.001 
Days: median (10R) 
I 
FOLLOW UP 
ALL READMISSIONS 27(26%) 23(30%) NS 
Hospital Stay 
2(1-7) 7(2-16) 0.049 
Days: median (10R) 
EMERGENCY 
22(21%) 20(26%) 17(17%) NS 
READMISSIONS 
Hospital Stay 
3(1-7) 6(1-15) NS 
Days: median (10R) 
TOTAL 
Hospital Stay 
3(2-5) 7(5-17) <0.001 
Days: median (10R) 
Hospital Days per 100 
613 1142 <0.001 
patients treated 
I 
- Data not recorded 
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Table 7.6 Effect of early discharge on event rate among patients allocated 
to primary angioplasty 
48 hr 
Discharge 
N=36 
> 48 hr 
Discharge 
N=66 
P 
Event Rate post discharge 
Composite MACE 4(110/6) 8 (12%) NS 
* Death 0 1(2%) NS 
* NFMI 3(80/6) 5(8%) NS 
Stroke 0 0 NS 
Emergency 
Revasc 
3(80/6) 5(8%) NS 
Resource Utilisation 
Emergency 
readmission 
9(25%) 13(20%) NS 
Unplanned Catheter 8(22%) 6(9%) 0.049 
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7.5 DISCUSSION 
7.5.1 Clinical Outcome 
These data demonstrate that the pilot primary angioplasty service was 
associated with a significant reduction in mortality and overall MACE when 
compared to contemporaneous and historical patient cohorts allocated to 
thrombolysis. Importantly mortality, and stroke rates were comparable to those 
observed in randomised controlled trials to date, with a slightly elevated rate of 
non fatal MI (127). However, the non-randomised and time dependent nature of 
this study necessitates some caution in interpretation. Trials comparing these 
reperfusion strategies have demonstrated only modest reductions in mortality 
with the major benefit emanating from a reduction in non fatal MI (127; 132). In 
the present study this situation was reversed, with a sizeable mortality reduction 
but a similar incidence of non fatal MI in all cohorts. 
It is possible that the mortality differences observed may have been 
exaggerated by patient selection rather than treatment per se. Whereas 
thrombolysis patients were investigated from one centre within the network, 
primary angioplasty patients were recruited from centres across North East 
London. Failure to transfer high risk patients from other participating Accident 
and Emergency departments for primary angioplasty cannot therefore be 
excluded. In addition the daytime operation of the primary angioplasty service 
may have further skewed the outcome in favour of this strategy. The Zwolle 
group have demonstrated improved outcomes following primary angioplasty 
during routine duty hours (209). Nevertheless, any bias favouring selection of 
low risk patients for primary angioplasty should have been reduced by the 
'accept all' protocol whereby patients were delivered to the N-HAC by A&E 
physicians or LAS crews without referral to medics or cardiologists [chapter 4]. 
Delivery of thrombolysis may also be less effective out of hours. Indeed, the rate 
of prescription of thrombolysis was lower in the contemporaneous 
'out of hours I 
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thrombolytic group compared with the historical cohort. In addition there was a 
lower MACE rate among the historical cohort despite longer follow up. Thus a 
low risk primary angioplasty cohort may have been compared with high risk 
thrombolytic groups, which will have been only partially redressed by inclusion of 
the historical thrombolytic group. Even so, the proportion of patients presenting 
with cardiogenic shock was similarly low in all three cohorts. 
The lack of a reduction in non fatal MI following primary angioplasty also 
warrants consideration. There have been wide variations in the reported rates of 
NFIVII following reperfusion therapy, depending on the regimen used and the 
definition of the endpoint (between 2 and 9% at 30 days) (238). In this study any 
elevation of troponin above the local reference value was included in the NFIVII 
endpoint, in accordance with the joint European Society of Cardiology (ESC) / 
American College of Cardiology (ACC) guidelines (44). It is likely that defining 
NFIVII using peak CK elevation (of 1.5 or 2 times the upper limit of the reference 
range) would have reduced the rate of NFIVII (239), although whether this would 
have been lower following primary angioplasty relative to thrombolysis remains 
uncertain. These data are not available as the centres investigated no longer 
use CK routinely for all cardiac admissions, and there is no standard cut off for 
troponin elevation, especially where troponin I assays are used (as is the case in 
the North East London Network). 
It is also likely however, that the rate of NFIVII among thrombolysis patients was 
lower than may be expected from a 'real world' STEMI cohort. This may have 
been a reflection of the fact that over half of the patients allocated to 
thrombolysis underwent cardiac catheterisation during the index admission, of 
whom above 70% were revascularised, thereby reducing the risk of subsequent 
re-infarction. 
it is also possible that the revascularisation strategy may have had an impact on 
the rate of non fatal MI in the primary angioplasty cohort. These patients 
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predominantly underwent culprit vessel revascularisation only. In those patients 
with multi-vessel disease this was associated with a higher rate of non fatal MI, 
and unplanned revascularisation compared with those undergoing complete 
revascularisation, though this was not statistically significant. Angiographic (17), 
angioscopic (18), and intravascular ultrasound (IVUS) (19) studies have 
previously established that multiple complex plaques coexist throughout the 
coronary tree in patients presenting with STEMI, though there is debate as to 
their prognostic importance (17; 19; 20). However, no definite conclusions can be 
drawn from this small subgroup of patients. A definitive answer to the question 
of multi-vessel versus culprit vessel angioplasty in STEMI patients with multi- 
vessel disease can only be appropriately addressed in the context of a 
randomised controlled trial. 
Finally the rate of non fatal MI could have been spuriously low in the 
thrombolytic cohorts. It is possible that some events may not have been 
captured. Whereas primary angioplasty readmissions were tracked at all centres 
across the network, thrombolysis patients were predominantly tracked through 
the referring centre only. Notably some primary angioplasty patients were 
readmitted to a network centre other than the centre of origin for the index 
admission. In addition follow up data were available for a higher proportion of 
primary angioplasty patients. 
7.5.2 Resource utilisation 
Contrary to expectation, the primary angioplasty strategy did not result in a 
reduction in emergency cardiac readmission, unplanned cardiac catheterisation, 
or unplanned revascularisation. The rate of readmission was however consistent 
with recent international registry data (43). Again the lack of difference between 
primary angioplasty and thrombolytic cohorts may have been a consequence of 
inpatient revascularisation in the thrombolytic groups resulting in fewer episodes 
of recurrent ischaernia following thrombolysis. However, a higher proportion of 
patients were readmitted with troponin negative chest pain from among the 
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primary angioplasty cohort, raising the possibility that many of these admissions 
may not have been ischaernic. The lack of an associated increase in 
revascularisation and shorter hospital stay following readmission among primary 
angioplasty patients supports this notion. However, the reason for a higher rate 
of non ischaernic chest pain readmissions following primary angioplasty remains 
unclear. 
The primary angioplasty strategy radically reduced the duration of hospital stay 
compared to thrombolysis. This difference in hospitalisation increased further 
when cardiac readmissions were taken into account. Furthermore, the saving of 
529 days per 100 patients treated with primary angioplasty was calculated in 
comparison with thrombolysis at the centre with the shortest STEMI 
hospitalisation within the network [see chapter 3 Table 3.2]. This suggests that 
the potential bed day savings compared to current practice across the sector 
would be considerably higher. 
The reduction in hospital stay was a consequence of the early discharge policy 
for uncomplicated patients following primary angioplasty combined with the 
prolongation of hospital stay caused by transfer to the cardiac centre for invasive 
investigation following thrombolysis [see chapter 3; 3.4 RESULTS]. The early 
discharge policy appeared safe, in that there was no difference in MACE 
compared to those discharged later. However, there was a significantly higher 
rate of subsequent unplanned cardiac catheterisation in the early discharge 
group, though not resulting in a commensurate increase in revascularisation. All 
patients allocated to early discharge were reviewed by the cardiac rehabilitation 
team prior to discharge, and invited to a follow up visit at the WHAC within 10 
days for physician and cardiac rehabilitation review, in order to ensure patient 
education and dose titration of secondary preventive therapy. It may therefore 
be surprising that this 'low risk' group required additional invasive investigations. 
It is possible that despite these measures, early discharge did not allow 
sufficient patient confidence or education, resulting in more frequent re- 
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presentations with non cardiac pain. In the context of an evolving pilot 
programme, and the associated early discharge protocol, there may have also 
been a desire among clinicians to perform early coronary angiography in such 
cases rather than leave uncertainty while arranging non invasive investigation. 
These data may suggest that selection of patients for early discharge may 
require criteria specific to the individual in addition to clinical criteria. 
As stated in chapter 5, the data presented here represent outcomes from an 
evolving rather than established service. Thus far the primary angioplasty 
service has demonstrated improved clinical outcomes compared with 
thrombolysis, with a major reduction in hospital stay. However, strategies are 
required to further reduce both ischaemic and non ischaemic readmissions 
following discharge. In addition favourable outcomes must be proven with 
expansion of the protocol outside working hours. 
7.6 CONCLUSIONS 
Primary angioplasty in North East London significantly reduced mortality and 
major adverse cardiac events among patients with STEMI relative to 
thrombolysis. However, strategies are still required to reduce emergency non 
cardiac readmissions and unplanned catheterisation procedures. Primary 
angioplasty saved 529 hospital bed days per 100 patients treated compared with 
thrombolysis, at the cost of 51 additional cardiac catheterisation procedures and, 
and 61 revascularisations. Delivery of a 24 hour seven day service should now 
be considered. 
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CHAPTER 8 General Discussion and Conclusions 
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8.1 SUMMARY OF FINDINGS 
This thesis has described the development, instigation and expansion of a pilot 
primary angioplasty service within a metropolitan population in North East 
London. The impact of protocol design on clinical outcomes and service delivery 
has been investigated, and resource utilisation compared with the thrombolytic 
strategy within a section of this population. In addition the influence of platelet 
activation as a possible biological mechanism determining the efficacy of 
reperfusion has been explored, and in turn the impact of service design, 
specifically the use of pharmacological facilitation, on platelet activation has 
been studied. 
The stimulus to redesign delivery of reperfusion therapy for patients presenting 
with ST segment elevation myocardial infarction (STEMI) was initially based on 
the increasing body of evidence that primary angioplasty was superior to 
thrombolysis in terms of clinical outcome (127), and has been discussed in detail 
in chapter 1 [1.6 Mechanical Reperfusion Therapy for ST segment Elevation 
Myocardial Infarction - Primary Angioplasty]. However, chapter 3 
demonstrated that existing delivery of reperfusion therapy in North East London 
using the thrombolytic strategy was associated with a significant burden of 
invasive investigation and revascularisation, resulting in substantial prolongation 
of hospital stay across the network. This was in spite of effective delivery of the 
therapy itself, and highlights the limitations of NSF targets focussed on 
prescription of therapy rather than clinical outcome. Moreover, chapter 3 also 
demonstrated inequities in both referral practice and access to tertiary cardiac 
services across the network. These findings suggested that there was an 
existing need to reassess the provision of reperfusion therapy within North East 
London, with the aim of improving access to cardiac catheterisation and 
revascularisation and reducing resource utilisation. This provided an additional 
rationale for development of a pilot primary angioplasty service locally. 
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The process of service design, instigation and expansion described in chapter 4 
was itself dynamic. An existing tertiary cardiac centre was selected to function 
as the network heart attack centre (N-HAC) for the period of the pilot. 
Partnership with the London Ambulance Service (LAS) was an essential feature 
of the process from the outset, and allowed the development an optimal 
pathway for rapid access to reperfusion therapy, using independent pre hospital 
diagnosis by LAS crews without the need for formal referral. However the impact 
and importance of an additional access strategy from ME departments within 
the network became apparent only once the pilot commenced. The latter 
protocol led to over 50% of all recruitment, and resulted in the development of a 
dedicated patient transfer system ('SCATS') by LAS [chapter 4]. In addition it 
afforded the opportunity to investigate the use of upstream anti-platelet therapy 
prior to transfer in the protocol. 
These two access strategies were compared in chapter 5. As expected, pre 
hospital diagnosis with direct ambulance catheter lab access significantly 
reduced the time to reperfusion in those undergoing a primary angioplasty 
procedure, when compared with A&E transfer. However, the 'accept all' no 
referral policy was associated with lower diagnostic accuracy for STEMI among 
patients delivered by LAS crews relative to their counterparts in A&E. The fact 
that many of those LAS patients without STEMI had a high risk NSTE-ACS 
suggests that this issue was a result of unfamiliarity with the protocol rather than 
an inability to recognise ACS patients with ST elevation. This finding 
demonstrates the necessity of continuing education for all stakeholders, and 
may imply that referral mechanisms such as ECG telemetry should be 
investigated to avoid unnecessary mobilisation of the WHAC team in future, 
particularly when expansion to a 24 hour protocol is considered. 
The most recent European and North American guidelines governing the 
management of ST segment elevation myocardial infarction recommends that in 
patients treated with primary angioplasty the door to balloon (DTB) time should 
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not exceed 90 minutes (136; 240). The direct access strategy achieved this 
target in 94% of cases. However this target does not refer specifically to patients 
transferred from distant centres. In this situation a European taskforce has 
recommended a target of 120 minutes (212), which was achieved in 65% of 
A&E transfer patients. In the North American guidelines transfer is not 
recommended if the delay to the primary angioplasty strategy (DTB-DTN) 
exceeds 60 minutes (136), at which point the mortality benefit may be lost (135). 
A&E transfer patients had a median delay of 69 minutes. Although this falls 
outside this window, it is well within the 93 minutes necessary to derive a benefit 
in MACE (135). While this may be acceptable, chapter 5 also highlighted that 
there may be opportunities to further streamline the patient pathway through 
participating A&E departments. 
Despite the delay incurred by the transfer strategy, clinical outcomes and 
myocardial infarct size were similar to those in the direct access group. This is 
interesting as 79% of ME transfer patients presented within 3 hours of 
symptom onset, when the outcome of reperfusion therapy is likely to be most 
time dependent (137). This is therefore likely to have been the consequence of 
pre transfer anti-platelet therapy with clopidogrel and abciximab, which was 
associated with a significantly higher frequency (more than double) of TIMI 
grade 3 flow in the infarct related artery at angiography prior to coronary 
intervention. The implication of this finding is that early reperfusion following pre 
transfer therapy compensated for transfer delay. The benefit of pre transfer 
therapy may also translate to the direct access cohort, such that the optimal 
future strategy may be the administration of therapy in the pre-hospital setting. It 
is important to recognise however that in terms of service delivery these 
strategies remain complementary. The development of the two protocols was 
borne of necessity. At inception direct access was preferred, offering the most 
rapid access to reperfusion. However, ME transfer remains essential to ensure 
access to therapy for self presenters, patients developing ST elevation in the 
department, and as a safety net for LAS crews where the diagnosis is uncertain. 
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Chapter 6 of this thesis investigated potential biological mechanisms that may 
determine outcome following primary angioplasty. Platelet behaviour was 
studied in a subgroup of 25 patients from the primary angioplasty cohort in order 
to investigate the influence of platelet activation on reperfusion following primary 
angioplasty, and the effect of early anti-platelet therapy on the platelet response 
to the primary angioplasty process. The markers studied included platelet 
monocyte aggregates (PMA) and CD40 ligand (CD40L), both of which 
themselves possess pro-inflammatory and pro-thrombotic properties, and have 
previously been implicated as promoters of plaque instability and 
thrombogenicity (185; 220). PMA formation at presentation but not CD40L 
expression determined the efficacy of both epicardial and microvascular 
reperfusion in addition to infarct size following primary angioplasty. Furthermore, 
early anti-platelet therapy resulted in a more rapid reduction of PIVIA post 
intervention, modifying the platelet response to resemble that observed following 
coronary angioplasty in the setting of stable coronary disease. These data 
support the concept that PIVIA reflect plaque thrombogenicity and may implicate 
them as direct mediators of microvascular dysfunction in the setting of STEIVIL In 
addition, reduction of PIVIA may provide a novel plaque stabilising mechanism 
explaining the benefit of early abciximab therapy prior to primary angioplasty 
observed in clinical trials (83; 126). These results could help explain why unlike 
abciximab, thrombolytic agents have been associated with adverse clinical 
outcomes when used to facilitate primary angioplasty (217). Thrombolysis also 
improves patency prior to intervention, but has been demonstrated to enhance 
other markers of platelet activation. Thus the assertion that the mechanism of 
benefit from pre transfer anti-platelet therapy was the result of early coronary 
reperfusion may be over simplistic. Further studies investigating PMA in the 
setting of thrombolysis could be considered to test this hypothesis. 
The central hypothesis of this thesis was that primary angioplasty could be 
delivered safely and effectively in a United Kingdom population, improving both 
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service efficiency and clinical outcomes compared with thrombolysis. The 
previous chapter compared clinical outcomes and resource utilisation during the 
pilot programme with outcomes following the thrombolytic strategy at one of the 
participating centres. Although this comparison was non randomised and 
involved relatively small sample sizes, primary angioplasty was associated with 
significant reductions in mortality and overall MACE. Interestingly however, there 
was no reduction in non fatal myocardial infarction, which has driven the MACE 
reduction in a number of clinical trials (127). The rate of non fatal MI was similar 
to that observed in previous primary angioplasty studies, but lower than might be 
expected among patients treated with thrombolysis. This may have been a 
consequence of 39% of thrombolysis patients undergoing revascularisation 
during the index admission, although this proportion was still lower than 
evidence would predict [chapter 2]. 
Disappointingly the pilot primary angioplasty service did not result in a reduction 
in emergency readmission, unplanned cardiac catheterisation, or emergency 
revascularisation. However, readmissions from among the primary angioplasty 
cohort were predominantly with troponin negative chest pain, and although 
many of these patients underwent invasive investigation, few required 
revascularisation. Notably, there were more readmissions among uncomplicated 
patients discharged early (at 48 hours). It is possible that 48 hour discharge may 
not have allowed sufficient education or confidence among some patients, 
leading to brief non ischaemic readmissions in the early post discharge period. 
The fact that nearly all of these subjects underwent angiography but not 
revascularisation is likely to reflect a clinical tendency to early invasive 
investigation of possible complications during the evolution of the pilot service. 
The major advantage of the primary angioplasty strategy in terms of resource 
utilisation was the radical reduction in hospital stay. This result was a 
combination of earlier discharge following primary angioplasty (even when 48 
hour discharge was excluded) and prolonged stay following thrombolysis, as 
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discussed in chapter 2. Furthermore, the reduction in hospital stay increased 
when emergency readmissions were included. The prolongation of repeat 
hospitalisation following thrombolysis is more difficult to explain but may indicate 
a greater degree of severity of MACE events including stroke and non fatal MI. 
Hospital stay was reduced by 529 days per 100 patients treated when compared 
to the centre with the shortest hospital stay within the network. The potential 
impact of hospital stay reduction across the North East London Cardiac Network 
is therefore considerable, particularly if translated to a 24 hour service. 
8.2 FUTURE DIRECTIONS 
8.2.1 Service Development 
The data from this thesis have demonstrated that within the confines of a 
daytime service during working hours primary angioplasty can be delivered in 
North East London safely and effectively, achieving published international 
guidelines, improving clinical outcomes, and radically reducing hospital stay 
compared to the thrombolytic strategy. These results provide convincing 
evidence that the service should now be adopted as the preferred reperfusion 
strategy for the North East London Cardiac Network on a 24 hour seven day 
basis. 
Temporal expansion of the protocol will provide important challenges. This 
initiative would make the North East London programme the largest primary 
angioplasty service in the UK, and the only one serving an entire hospital 
network with a population of nearly two million inhabitants. The pilot service has 
demonstrated areas where service delivery can be improved. These include the 
speed of transit through participating A&E departments, increasing the 
proportion of patients recruited directly via LAS, and increasing diagnostic 
specificity by these crews. These issues can be addressed rapidly through 
sustained education programmes for all stakeholders. ECG telemetry could be 
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investigated as a means of improving diagnostic accuracy further, and could 
form the basis of a pilot sub-study for selected LAS crews. 
In addition the move to a 24 hour service will also present new hurdles that have 
not yet been addressed. Outcomes will need to be maintained out of hours, 
when the cardiac catheter lab is not fully staffed, and where there is greater 
potential for reperfusion delay. Additional staffing will be required at the WHAC, 
an already problematic issue for fledgling district labs without on-call 
requirements. Changes in working practice will be required by medical all staff in 
order to deliver the service while meeting European working time directives. 
In addition to resolving working practices within the WHAC, 24 hour working will 
also affect LAS and A&E personnel across the network. The expanded use of 
the 'SCATS' protocol will result in more frequent movement of LAS crews out of 
their usual operational area, potentially compromising local response times for 
non cardiac emergencies. Meanwhile, although all participating A&E 
departments already function on a 24 hour basis, on site cover by senior A&E 
staff (registrars and consultants) may be reduced outside daytime hours. This 
might lead to a reduction in the diagnostic accuracy and appropriateness of 
inter-hospital transfers, and difficulties releasing staff trained in advanced life 
support to escort these patients with the ambulance crew. Finally the high 
turnover of junior medical staff across the six participating A&E departments will 
necessitate an ongoing programme of continued education to maintain 
familiarity with the protocol. 
8.2.2 Clinical Research 
The role of facilitation of primary angioplasty with anti-platelet therapy has been 
investigated in this thesis within the confines of a non randomised prospective 
observational study. As discussed in chapter 1 the role of facilitation remains a 
matter for debate [1.6.4 Pharmacological facilitation of 
Primary 
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Angioplasty]. Provision of a 24 hour service will allow the opportunity to 
investigate the nature and timing of facilitation in the setting of a randomised 
controlled trial. At present the weight of evidence is moving away from 
thrombolysis prior to primary angioplasty, favouring the use of upstream 
abciximab (126; 217). Recently however, anti-thrombin agents including 
bivalirudin have been proposed as an alternative to glycoprotein Ilb/Illa 
antagonists in the setting of coronary intervention (241). A randomised trial is 
currently being planned to operate in the North East London network comparing 
the use of upstream abciximab (with heparin in the catheter lab), with bivalirudin 
for STEMI either prior to transfer or in the catheter lab. In addition, the logistics 
of a sub study investigating pre-hospital administration of therapy by ambulance 
crews are being investigated. 
Although 48 hour discharge for uncomplicated patients was not associated with 
an increase in MACE, the safety of this protocol has not yet been established. A 
retrospective qualitative study of the patient experience following early discharge 
is planned in the first instance to investigate further the issue of frequent non 
ischaernic readmissions. Thereafter a randomised trial comparing early versus 
later discharge is required to prove equivalence of these strategies. 
8.2.3 Platelet Research 
As a consequence of the logistics of performing flow cytometry within six hours 
of venesection at multiple time points, the platelet studies presented in the thesis 
were limited by sample size. The results of the platelet studies described should 
now form the basis of larger studies to test hypotheses generated from this 
observational work. Firstly, a larger prospective study controlled for 
demographic, clinical and therapeutic characteristics is required to confirm the 
results of the studies presented in this thesis. Thereafter, the influence of PMA 
on microvascular dysfunction following reperfusion may be investigated further 
using a small animal model of ischaernia and reperfusion. A grant proposal 
has 
already been developed, investigating the influence of both PMA and 
CD40 - 
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CD40L interactions on microvascular flow in the mouse mesentery using 
interracial microscopy. 
Secondly, the finding that early anti-platelet therapy may modify the platelet 
response to balloon and stent insertion to resemble that of a stable plaque may 
suggest a plaque stabilising mechanism. In order to investigate the relationship 
between plaque morphology and platelet activation in STEMI, a protocol is 
currently being developed to correlate platelet marker expression at presentation 
with plaque morphology in vivo determined using advanced intravascular 
ultrasound technology (virtual histology, Volcano therapeutics, Rancho Cordova, 
CA). 
Finally, the use of an alternative anti-thrombotic regime prior to intervention 
suggests that a platelet sub study should be planned in conjunction with the 
bivalirudin randomised trial proposed above. Also, as has been suggested 
earlier, the impact of thrombolytic therapy on these markers could provide 
valuable information that may further elucidate the mechanism of benefit of 
abciximab over thrombolysis for facilitation of primary angioplasty observed in 
clinical trials. However, due to the success of the pilot service, the opportunity to 
recruit patients receiving thrombolysis no longer exists within North East London 
during working hours, and would therefore need to be performed elsewhere. 
8.3 CONCLUSIONS 
Despite effective delivery of thrombolytic therapy, this reperfusion strategy 
necessitates frequent early revascularisation, leading to prolonged 
hospital stay 
in North East London. Primary angioplasty can be delivered safely and 
effectively to this population using a regional heart attack centre model. 
Direct 
ambulance access to the catheter lab significantly reduces 
the time to 
reperfusion. Where this cannot be performed, upstream anti-platelet 
therapy 
with abciximab and clopidogrel prior to transfer 
from an Accident and 
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Emergency department may compensate for inter hospital transfer delays. The 
efficacy of reperfusion following primary angioplasty can be determined by the 
degree of platelet activation at presentation, and in turn platelet activation may 
be modified by early anti-platelet therapy. Within the limitations of a daytime 
service primary angioplasty improves clinical outcome compared to 
thrombolysis, and is associated with a radical reduction in hospital stay. Delivery 
of a 24 hour seven day service should now be addressed. 
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Direct anqioplastv Proposal 
Patients presenting with acute ST segment elevation MI (STEMI) via the 
London Ambulance Service (LAS) will have direct access to the London 
Chest Hospital for immediate angiography with a view to primary angioplasty 
where appropriate. 
Backwound 
The current strategy for treating patients presenting with acute (ST segment 
elevation) myocardial infarction (STEMI) at Barts and the London NHS trust 
is the administration of intravenous thrombolysis, to dissolve clot and reopen 
the occluded blood vessel (infarct related artery). The drug is most effective 
when given early, and thus reduction of the 'door to needle time' remains a 
National Service Framework directive. 
However, even with rapid effective administration of the newest combinations 
of thrombolytic and anti platelet therapies the percentage of patients 
presenting with ST elevation MI achieving good (TIMI-3) flow in the infarct 
related artery is no more than 60-70% [1,2]. In those who do achieve 
reperfusion, the rate of re-occlusion is also unacceptably high (6 -13% early, 
and up to 30% at 30 days) [3,4]. Despite this thrombolysis remains the 
predominant reperfusion strategy in the United Kingdom. 
Primary (or direct) angioplasty can provide TIMI-3 flow in 90-95% of cases, 
and is a superior reperfusion strategy where skilled operators are readily 
available [5,6,7], with improved outcomes for patients treated with stents and 
adjunctive glycoprotein Gpllbllla receptor antagonists [8]. Mechanisms of 
providing access to this therapy locally and nationally have not yet been 
investigated. 
Aims 
The aim is to examine our local provision of reperfusion therapy, and assess 
strategies to improve both delivery of treatment and patient outcomes. 
Therefore in addition to a pilot primary angioplasty service, this process will 
involve: 
Audit of current practice, to provide a context for prospective analysis 
(salient data presented in this document) 
Prospective audit of STEMI treatment with thrombolysis (at the Royal 
London and Newham General Hospitals) 
Implementation and audit of guidelines on the treatment of failure to 
reperfuse following standard thrombolytic therapy 
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We will compare reperfusion strategies collecting data prospectively, looking 
specifically at the following areas 
Clinical 
Delivery of treatment, with follow up of patient outcomes 
Logistic 
Address the practical issues related to service provision 
Financial 
Calculate the actual costs of each strategy (medications, consurnables 
etc. ) 
Calculate the financial impact on length of hospital stay, transfer time, 
and readmission rates for the Trust and for purchasers (early 
intervention may free beds in RLH and therefore decrease costs vs 
increased early costs of intervention) 
The data collected over the pilot period will inform recommendations on the 
style of service we should plan in the future. These options could include: 
Continuation of thrombolysis as primary treatment for STEMI, with no 
plan for primary angioplasty 
Continuation of thrombolysis as primary treatment for STEMI with an 
explicit rapid invasive response to failure to reperfuse 
A selective primary angioplasty service targeting those shown to be at 
high risk, or who benefit most (e. g. patients with anterior ST elevation) 
* Consideration of an expanded primary angioplasty service 
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Mechanism of pilot implementation 
Patient Selection 
" Chest pain onset <6 hours 
" ST elevation (identified by trained ambulance personnel) 
" LBBB excluded 
" No age limit 
Patient Population 
*6 participating ambulance stations serving Tower Hamlets 
* Royal London Hospital catchment area only 
Hours of operation 
" Blue Calls taken 0800 - 1600 Monday to Friday 
" Not on Bank Holidays 
" Not on audit days outside London Chest 
Logistics 
Blue call from LAS via designated phone in each lab - arrival time 6- 
15 minutes 
Catheter lab space identified (if >60 mins delay then thrombolysis to 
be given (responsibility of designated Registrar) 
Patient admission directly to the catheter lab holding area (not CCU) 
Inpatient stay at London Chest 
Translation issues pertaining to the large non-english speaking local 
population will be addressed by the on site trained interpreter(s) 
It is accepted that there may rarely be instances of incorrect diagnosis, 
or significant co-morbidity. These patients will need to relocate to A+E 
without cardiac intervention (urgent transfer policy agreed with LAS). 
In the intervening period we will be medically responsible for the 
patient. 
Start Date 
March 2003 
LAS currently ready 
Minor building work to be completed in catheter lab (shelving and drug 
cupboard in clinical area) 
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Current Activity at Barts and the London NHS trust 
Data from 1st Oct 2001 - 1st Oct 2002 Royal London Hospital 
Analysis of 1 years' data from RLH of patients who would fit the entry criteria 
for the proposed pilot study at LCH 
105 patients (age 21-91 mean 61,85 male) presented with chest pain and 
ST elevation on ECG (entry diagnosis definite or probable MI) 
82.5% presented via LAS (either directly or via GP) 
17.5% walk-in 
98 (93%) received thrombolysis 
2 failure of administration, 5 contraindicated 
98% of those eligible received therapy 
Agents used 34 SK (streptokinase) 
47 TnK (Tenectoplase) 
17 tPA (alteplase) 
Door to needle time 
53% <20mins 
74% <30mins* 
83.5% <40mins 
*Data from the MINAP report Jan- June 2002 show the Royal London 
Hospital reaches government targets on door to needle time (75% <30mins) 
(Royal College of Physicians, November 190 2002) 
1 primary angioplasty 
8/105 (7.8%) died in hospital (9 by 30days, 10 at 3months) 
1 death occurred in those not receiving lysis 
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STEMI Inpatient Transfers for Cardiac Catheterisation 
58/105 (55%) transferred as inpatients for angiography with a view to 
inpatient revascularisation 
5/7 who did not receive thrombolysis were transferred as inpatients, but only 
1 was transferred immediately 
(4 dead within 24 hours, prior to opportunity for PCI as a consequence 
of AMI) 
20/58 (34%) transferred day 0 or day 1 
11/20 were transferred as a consequence of failure to reperfuse following 
thrombolysis 
(NB. Of the 47/105 who were not transferred for inpatient angiography, a 
further 6 patients were identified with failed thrombolysis) 
Reason for transfer 
36'symptorns' including 11 failed thrombolysis, 4 re-infarct, and post 
infarct angina 
22 'protocol' pain free with high risk features 
(+l 0 booked for outpatient angiography) 
In total of 65% of all STEMI pts were referred for angiography 
3/10 of those patients referred for outpatient angiography were readmitted 
with an acute coronary syndrome before their booked angiogram 
date (2 
within 30 days). All 3 were listed for inpatient angiography and underwent 
angioplasty that admission. 
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Flow diaqram 
1 105 STEMI I 
7 no lysis 2 
1 98 thrombolysis I 
4 deaths < 24 
1 94 alive I 
18 no reperfusion 
3 Reinf arction >24 
20 post infarct anginci 
52 patients reperf use 
no ischaemia 
2 deaths 19 Predischarge 
+ETT/High risk 
31 low risk uncomplicated 7 
I Max 23 uncomplicated @3 months I 
ediate) 
71 IP CA 
(3 
deaths 
=O 
OP CA 
----10 
1 death 
The diagram shows 23/105 (22%) patients remained free of death, failure to 
reperfuse, reinfarction, recurrent ischaernia or invasive 
investigation/revascularisation at 3 months 
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Impact on Transfer time and Length of Hospital Stav 
Transfer 
time n=58 
Range Mean Median Mode 
Days 0-20 3.6 3 0 
Days 2-20* 5.3* 5* 6* 
*Excluding patients transferred on day 0 or 1 
Hospital Range Mean Median Mode 
stay 
Inpatient 1-36 8.1 6 5 
Cardiac 
Catheter 
n=58 
Inpatient 3-36* 9.8* 7* 5* 
Cardiac 
Catheter* 
n=38 
No Inpatient 0-24 5.43 5 4 
Cardiac 
Catheter 
n=37147 
*Excluding patients transferred on day 0 or 1 
Conclusion 
Even with effective delivery of thrombolysis reaching NSF targets, 
over half those patients admitted with STEMI were transferred for 
inpatient cardiac catheterisation. 
Over one third necessitated very early transfer for failed reperfusion, 
re-infarction or recurrent symptoms. 
The current strategy incurs actual transfer costs (i. e. additional 
ambulance and escort personnel) and bed day wastage driven by 
delays till transfer and ensuing prolonged inpatient stay. 
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Prooected Workload for Pilot 
1.10.01 - 1.10.02 
AMI patients arriving RLH between 0800 - 1700 56/105 (53%) 
82.5% arrived via London Ambulance service 
Projected STEMI admissions 5/7 days per week, over 1 year 40 
Projected STEMI admissions 5/7 via LAS over 1 year 33 
Expect mean 2.75 patients per calendar month 
Currently we perform inpatient catheter/PCI on 55% of these patients 
Current work predicts 1.5 patients per calendar month are already 
being treated invasively Mon-Fri 0800 - 1700 
Additional workload will be 1.25 patients per calendar month 
This would not be expected to have a major impact on current workload, or 
compromise treatment of patients waiting for inpatient catheterisation with 
non-ST segment elevation acute coronary syndromes. 
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Backwound 
As you may be aware, The London Chest Hospital (LCH) opened its Direct 
Access pilot primary angioplasty service to blue calls from London 
Ambulance Service (LAS) in April 2003. The service offers daytime access for patients presenting with ST segment elevation Myocardial Infarction 
(STEMI) to immediate angiography with a view to immediate culprit vessel 
angioplasty. 
Based on Audit data from patients presenting to the Royal London Hospital 
(RLH) A&E with chest pain and ST elevation from October 2001-2002, we 
expected that 2-4 patients to present via LAS per calendar month during the 
hours of operation of Monday - Friday 0800-1600 hours (see the attached Acute 
M1 discussion document 25.11.2). 
Thus far we have in fact received fewer patients than expected, though it is 
still early days. In addition there is a desire to meet the needs of those 
patients who self-present to A&E or develop ST elevation in A&E during 
these hours. This has stimulated the development of a protocol for early 
transfer and angiography for this patient group. 
There is a large body of evidence supporting primary angioplasty as the 
preferred reperfusion strategy for STEMI patients when compared with 
thrombolysis (23 randomised controlled trials to date) (1). There is further 
strong evidence that it is also safe and effective to transfer STEMI patients 
from a non-invasive centre to an intervention centre with a view to primary 
angioplasty(2; 3). In these studies no thrombolytic therapy was administered 
prior to transfer. Furthermore patients with transfer times of up to 3 hours still 
had reduced event rates when compared to patients treated with on site 
thrombolysis. There is also emerging data to support a 'facilitated' 
angioplasty approach where pharmacological therapy (including either 
reduced dose thrombolysis, glycoprotein IIbIIIa receptor blockade, or a 
combination) is administered initially to increase the likelihood of arterial 
patency, followed by immediate angiography and angioplasty (4; 5). We await 
the data from ongoing trials to elucidate the optimal combination. However, 
although there is some data to support a strategy of full dose thrombolysis, 
followed by 'rescue' angioplasty for patients who do not achieve acceptable 
ST segment resolution (6), this is associated with an elevated bleeding risk. 
Our interpretation of this data is that patients self-presenting to RLH A&E 
would be best served by being transferred as early as possible from RLH to 
LCH without antecedent thrombolysis. All patients meeting 
inclusion/exclusion criteria would be offered immediate transfer to LCH for 
angiography with a view to PCI where appropriate. This would be performed 
with a call to LAS via the existing emergency transfer telephone. The 
ambulance service can provide crews rapidly via this mechanism, in order to 
deliver the patient directly to the cardiac catheter lab table in no more than 30 
minutes following arrival in A&E. The protocol has the advantage of including 
patients with contraindications to thrombolysis. 
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The following document contains a draft protocol to facilitate transfer of these 
patients. This has been designed to integrate with the existing DIRECT AMI 
protocol (a copy of which is enclosed), and the current RLH guidelines for 
management of ST segment Elevation MI. They represent a framework for 
discussion that may be adapted to meet the needs of the patients, and the 
A&E and Cardiology departments. 
1. INCLUSION / EXCLUSION CRITERIA 
The following criteria mirror the DIRECT AMI LAS criteria. 
Hours of operation: 
Monday to Friday 0800hrs - 1600hrs 
Patients arriving after 0730 can be included as they would be expected to 
receive catheterisation by 0800. Patients arriving after 1600 precisely should 
not be offered immediate transfer, and should therefore receive usual therapy 
(i. e. thrombolysis where indicated) 
INCLUSION CRITERIA: 
" Patients with Chest Pain suggestive of ACS 
Most recent sustained pain (>20 minutes) within 6 hours 
" ECG showing ST Elevation in TWO or more contiguous leads 
AT LEAST 2 mm ANTERIOR LEADS 
AT LEAST 1 mm non-anterior LEADS 
" Orientated and Conscious 
EXCLUSION CRITERIA: 
Left Bundle Branch Block - LBBB on 12 Lead ECG 
Unconscious Patients 
Cardiogenic Shock (BP < 85mmHg) 
Confused 
Previous CVA with dense herniplegia / other severe disability 
Patients in Cardiac Arrest 
Intubated patients 
NB. While Cardiac Arrest and Cardiogenic Shock are exclusion criteria for 
this immediate transfer protocol, they may of course be discussed on an 
individual case basis with the on call Cardiology SpR. 
2. DIAGNOSIS 
The diagnosis of definite or probable STEMI will be made in the usual 
manner, based on symptoms and ECG. 
However this ECG must be corroborated by a second senior physician 
(SpR or Consultant in Accident and Emergency or Medicine) 
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3. BLOOD SAMPLING 
The usual samples should be taken before thrombolysis, but with the addition 
of a group and save sample. 
In addition, blood should be taken for research purposes into the bottles 
provided as for all ACS patients. Patients can be consented formally 
following venesection by a member of the cardiac research team (as per 
ethics committee approval). These samples are particularly relevant in this 
patient group. 
4. PRE-TRANSFER THERAPY 
" Aspirin 300mg should be administered if it has not already been 
given in the ambulance. 
" Clopidlogrell 300mg should be administered. 
" Abciximab (Reopro) should be given if readily available, but must not 
delay patient transfer. 
" Analgesia can be administered as per usual protocols 
5. MECHANISM OF REFERRAL 
Once the patient has been identified as a transfer candidate, the plan to 
transfer for immediate angiography should be discussed with the patient, and 
the possibility of angioplasty. The patient does not need to be formally 
consented at this stage (this will be performed by a SpR at LCH). However 
on rare occasions where patients strongly object to invasive therapy, they 
can be excluded without proceeding further. 
The ECG and PATIENT MUST BE REVIEWED BY the A&E SpR or 
consultant before referral takes place. The patient does not need to 
be discussed with the on call medical team. 
A call should be made to LAS via the existing emergency transfer 
phone in A&E. The attending ambulance will then inform LCH of the 
transfer via Ambulance Control using the existing BLUE PHONE and 
giving the usual CASMEET information (see Direct AMI protocols 
book). This will occur as the ambulance leaves for LCH giving a 10 
minute warning. 
Provided the patient fulfils inclusion/exclusion criteria in the opinion of 
the A&E SHO and SpR (or consultant), the patient does not need to 
be discussed with the on call Cardiology SpR. 
All other patients NOT MEETING THE ABOVE CRITERIA who are felt 
to be potential early transfer candidates MUST BE DISCUSSED IN 
THE USUAL MANNER WITH THE ON CALL SPR AND MUST NOT 
BE SENT TO LCH DIRECTLY. THIS PROTOCOL IS DESIGNED 
FOR S TEMI ONLY. 
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Under rare circumstances where on arrival the patient is not felt to warrant 
angiography, a cardiology SpR will inform A&E immediately. The patient will 
usually be transferred back to A&E. 
6. TRANSFER 
The patient will be transferred with a physician in attendance. Where 
necessary an English speaking relative should be allowed to accompany the 
patient. 
7. ARRIVAL AT LCH 
On arrival at LCH the patient will be transferred directly to catheter lab 
recovery, and treated as per the DIRECT AMI protocol. 
The patient's existing notes and ECGs should be attached to the DIRECT 
AMI ICIP, which should be used for all other clinical entries. 
The patient will remain an inpatient at LCH. 
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8. FLOW CHART 
DIAGNOSIS OF ST SEGMENT 
ELEVATION ACUTE MI 
I FULFILLS INCLUSION/ EXCLUSION 
YES 
INFORM PATIENT OF 
TRANSFER OPTION 
AGREE 
"7ý-z 
NO 
USUAL A&E TREATMENT 
DISAGREE 
Take Blood. Then Administer: 
" Aspirin 300mg (if not already) 
" Clopiclogrel 300mg 
" Abciximab (Repopro) when 
available 
CALL LAS 
TRANSFER PATIENT 
to LCH with physician 
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The Current Direct Angioplasty Pilot Service at 
London Chest Hospital 
Patients presenting with acute ST segment elevation MI (STEMI) via the London Ambulance Service (LAS) currently have direct access to the London 
Chest Hospital for immediate angiography with a view to primary angioplasty 
where appropriate. This pilot service is open to emergency 'blue' calls 0800- 
1600 hours weekdays, bringing patients who would normally be taken to the 
Royal London A&E. 
Back-wound 
Rationale for Primary Angioplasty 
The current UK strategy for treating patients presenting with acute (ST 
segment elevation) myocardial infarction (STEMI) is the administration of 
intravenous thrombolysis. The drug is most effective when given early, and 
thus reduction of the 'door to needle time' remains a National Service 
Framework directive. 
However, even with rapid effective administration of the newest combinations 
of thrombolytic and anti-platelet therapies the percentage of patients 
presenting with ST elevation MI achieving optimal (TIMI-3) flow in the infarct 
related artery is no more than 60-70% (1; 2). In those who do achieve 
reperfusion, the rate of re-occlusion is also unacceptably high (up to 30% at 
30 three months) (3) . 
Despite this thrombolysis remains the predominant 
reperfusion strategy in the United Kingdom. 
Primary (or direct) angioplasty can provide TIMI-3 flow in 90-95% of cases, 
and has been demonstrated to be a superior reperfusion strategy when 
compared with thrombolysis (4), with improved outcomes for patients treated 
with stents and adjunctive glycoprotein Gpllbllla receptor antagonists (5-7). 
Mechanisms of providing access to this therapy locally and nationally have 
not yet been investigated. 
Rationale for Expansion 
The Pilot service opened to 'Blue Calls' from LAS in April 2003. Based on 
audit data from patients presenting to the Royal London Hospital (RLH) A&E 
with chest pain and ST elevation from October 2001-2002, we expected that 
2-4 patients to present via LAS per calendar month during the hours of 
operation (Monday - Friday 0800-1600 hours). 
Thus far we have in fact received fewer patients than expected, though it is 
still early days. In addition there is a desire to meet the needs of local 
patients presenting via LAS from within neighbouring A&E catchment areas. 
This has stimulated discussion regarding the expansion of the pilot service to 
Newham Hospital Catchment area. Our aim is to expand the number of 
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patients treated to that originally expected. Newham is in close proximity to 
LCH, and also served by LAS crews trained in 12 lead ECG recognition. 
Safety of transfer from Newham Catchment area to LCH 
Recently published data have demonstrated that it is safe to transfer STEMI 
patients from a non-invasive centre to an intervention centre with a view to 
primary angioplasty (without administration of antecededent thrombolysis at 
the referring centre), and that this strategy is more effective than on site 
thrombolysis (8-10). In these studies transfer times of up to 2 hours were 
permissible, with a mean of 30 minutes. This excludes the time spent in a 
district hospital before transfer. Transfer times from the NGH catchment 
would reliably be expected to be below 30 minutes. Furthermore, with a 
strategy of pre-hospital diagnosis and patient delivery directly to LCH 
catheter lab, there would be no delay through NGH A&E. Thus we feel that it 
is safe to transfer patients diagnosed with STEMI directly to LCH, even if they 
are within closer reach of NGH A&E at the point of diagnosis. 
Aims 
The aim of the pilot is to examine our local provision of reperfusion therapy, 
and assess strategies to improve both delivery of treatment and patient 
outcomes. Therefore in addition to the pilot primary angioplasty service, this 
process involves ongoing audit of current practice, and prospective 
comparison of patient outcomes following treatment with usual therapy 
outside the hours of operation. 
We are already collecting data prospectively using for the MINAP database. 
In addition we intend to collect data looking specifically at the following areas 
Clinical 
Delivery of treatment, with follow up of patient outcomes, including 
ECG evidence of reperfusion 
Logistic 
Addressing the practical issues related to service provision 
Financial 
Calculation of the actual costs of each strategy (medications, 
consurnables etc) 
Calculation of the financial impact on length of hospital stay, transfer 
time, and readmission rates for the Trust and for purchasers (early 
intervention may free beds in RLH and therefore decrease costs vs. 
increased early costs of intervention) 
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The data collected over the pilot period will inform recommendations on the 
style of service we should plan in the future. These options could include: 
Continuation of thrombolysis as primary treatment for STEMI, with no 
plan for primary angioplasty 
Continuation of thrombolysis as primary treatment for STEMI with an 
explicit rapid invasive response to failure to reperfuse 
A selective primary angioplasty service targeting those shown to be at 
high risk, or who benefit most (e. g. patients with anterior ST elevation) 
9 Consideration of an expanded primary angioplasty service 
A21 
Discussion Document Direct AMI June 2003 
Current Mechanism of Pilot implementation 
Patient Selection 
Inclusion Criteria 
Chest pain onset <6 hours 
ST elevation (identified by trained ambulance personnel) 
Conscious 
No age limit 
Exclusion Criteria 
" Unconscious 
" Cardiogenic Shock despite filling(BP < 85mmHg) 
" Conf used 
" Previous CVA with dense hemiplegia / other severe disability 
" Patients in established Cardiac Arrest 
0 Intubated patients 
Ambulance Crews 
6 participating ambulance stations serving Tower Hamlets and 
Newham 
Currently only Royal London Hospital catchment area. At present if the 
patient is nearer to NGH they go there. 
Hours of operation 
" Blue Calls taken 0800 - 1600 Monday to Friday (in order to ensure the 
last patient would be on the table before 1700 
" Not on Bank Holidays 
" Not on audit days outside London Chest 
Logistics 
" Blue call from LAS via designated phone in the cath lab - arrival time 
6-15 minutes 
" Catheter lab space identified (if >60 mins delay then thrombolysis to 
be given - responsibility of designated Registrar) 
Patient admission directly to the catheter lab holding area (not CCU) 
" Inpatient stay at London Chest 
" Translation issues pertaining to the large non-english speaking local 
population will be addressed by the on site trained interpreter(s) 
It is accepted that there may rarely be instances of incorrect diagnosis, 
or significant co-morbidity. These patients will need to relocate to A+E 
without cardiac intervention (urgent transfer policy agreed with LAS). 
In the intervening period we will be medically responsible for the 
patient. 
Start Date 
9 Opened April 2003 
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Projected Workload contributed by Newham 
Backwound Audit Data 
(Data from 1st Oct 2001 - 1st Oct 2002 Newham General Hospital) 
104 patients (age 34-97 mean 63; 74 male) presented with chest pain and 
ST elevation (entry diagnosis probable or definite MI) - LBBB excluded 
90 (86.5%) admitted via LAS 
84 (81%) received thrombolysis 
8% too late, 7%risk haernorrhage 
DTN (mean 73, median 30 mins) 
39% < 30mins 
42% < 40mins 
Cardiac Catheterisation 
22 (20%) transferred for inpatient cardiac catheter 
31 (30%) listed before discharge for outpatient cardiac catheter 
Total 50% referred for invasive investigation 
6/104 died (5%) in hospital 
Workload 
43% (45) presented within the period 0800-1600 
Actual number admitted via LAS and within pilot time window 38/104 (36.5%) 
Project 27 patients within this time window - 5/7 days a week 
2.3 patients p. c. m 
Application of exclusion criteria, and account for audit days, bank holidays 
and unforeseen closures will further reduce this number. 
Thus we would expect to supplement recruitment by a maximum of 
2 patients per month 
I 
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Comparison with Barts and the London NHS trust 
Audit Data for the same period 
(Data from 1st Oct 2001 - 1st Oct 2002 Royal London Hospital) 
105 patients (age 21-91 mean 61,85 male) presented with chest pain and 
ST elevation on ECG (entry diagnosis definite or probable MI) 
82.5% presented via LAS 
98 (93%) received thrombolysis 
2 failure of administration, 5 contraindicated 
Door to needle time 
74% <30mins* 
83.5% <40mins 
Cardiac Catheterisation 
58 (55%) referred for inpatient cardiac catheter 
10 (9.5%) listed prior to discharge for outpatient angiography 
65% of all STEMI pts were referred for angiography 
8/105 (7.8%) died in hospital 
Projected Workload 
AMI patients arriving RLH between 0800 - 1700 56/105 (53%) 
82.5% arrived via London Ambulance service 
Projected STEMI admissions 5/7 days per week, over 1 year 40 
Projected STEMI admissions 5/7 via LAS over 1 year 33 
Expect mean 2.75 patients per calendar month 
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1. INTRODUCTION 
The purpose of this paper is to 
Introduce the concept of Primary Angioplasty for acute myocardial infarction (AMI) 
Document progress with regard to the 'pilot' London Chest direct 
transfer initiative for patients presenting with ST elevation to the London Ambulance Service from the Royal London catchment 
population 
Review audited outcomes of this pilot 
Propose developments in working practice which would be necessary to introduce a 24 hour 7 day service 
2. CLINICAL RATIONALE FOR PRIMARY ANGIOPLASTY 
Introduction 
Thrombolytic therapy remains the predominant reperfusion strategy for ST 
segment elevation myocardial infarction (STEMI) in the United Kingdom with 
government policy directed towards optimising thrombolytic delivery. The 
drug is most effective when given early, and thus reduction of the 'door to 
needle time' remains a National Service Framework directive. 
However the superiority of primary angioplasty over thrombolysis has now 
been demonstrated in multiple randomised trials dating back to the early 
1990s (1). With the data currently available from 'real world' trials employing 
contemporary interventional techniques it is necessary for health providers to 
address the logistics of delivering primary angioplasty to the majority of their 
STEMI patients. 
Problems With Thrombolysis 
While the large multi-centre randomised controlled trials of the 1980s and 
early 1990s demonstrated that thrombolysis saves lives, this was only when 
compared to aspirin alone (2-6). Newer bolus preparations such as 
tenecteplase and reteplase have greater clot specificity, and are easier to 
administer. However, their efficacy is similar to standard preparations, and 
prognostic benefits have remained much the same (7-9). With optimal 
therapy only 50-70% of patients achieve complete effective patency (TIMI-3 
flow) in the infarct related artery (7; 8; 10), and even where thrombolysis is 
effective the rate of early reocclusion remains unacceptably high (6-13% 
early, and up to 30% by 30 days) (11; 12). 
Furthermore, a significant proportion of patients are ineligible for treatment, 
and perhaps more importantly, a significant number who are eligible are 
denied treatment. The MIR and MITRA registries (21,092 patients) 
demonstrated that 48% of STEMI patients did not receive reperfusion therapy 
- 29% being ineligible, and 19% with no obvious contraindication (13). 
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Primary angioplasty can achieve TIMI-3 flow in 90-95% of cases, and treats both the occlusive thrombus and the ruptured plaque. Meta analysis of the 
short-term results of 10 randomised controlled trials conducted prior to 1997 
demonstrated a mortality of 4.4% with angioplasty versus 6.5% using 
thrombolysis (p=0.02), with the composite endpoint of death or non fatal MI 
of 7.2% vs. 11.9% respectively (p<0.001) (14). Stroke was also significantly 
reduced. Long-term follow up data from Zwolle group (15) demonstrated an 
absolute mortality reduction of 11% (13% angioplasty vs. 24% streptokinase) 
after a mean of 5 years. Patients presenting with cardiogenic shock fare 
better following primary angioplasty (16), and it is the only reperfusion 
strategy available to those ineligible for thrombolysis. 
Since the publication of these studies percutaneous coronary intervention 
(PCI) has evolved. Stenting following primary angioplasty reduces six month 
major adverse cardiac events (MACE) when compared with balloon 
angioplasty alone (POBA) (17), with further improvements in outcome with 
the addition of Glycoprotein receptor antagonist therapy (18). As yet it is not 
clear whether there may also be a role for pre-procedural thrombolysis (either 
alone or in combination with GPRA therapy) to 'facilitate' primary angioplasty. 
Results of ongoing trials such as FINESSE and ASSENT IV will address this 
issue in due course. What is clear is that contemporary primary angioplasty 
necessitates a combined mechanical and pharmacological approach. 
Transfer for Primary Angioplasty 
Until recently the problem with primary angioplasty has been the requirement 
that patients have immediate access to on-site cardiac catheter lab facilities 
and experienced operators. It has therefore been perceived to be impossible 
to offer such therapy to all infarct patients. This has been challenged with the 
advent of landmark trials demonstrating the safety and efficacy of acute inter- 
hospital transfer for primary angioplasty from district general hospitals 
(DGHs) without such facilities to a regional cardiac centre. 
DANAMI-2 (19) randomised regional centre and DGH patients to on-site 
thrombolysis with tPA or primary angioplasty with stenting in most cases 
(93%). This was a high-risk group of patients with >4mm ST elevation and 
with symptoms for up to 12 hours. The composite endpoint of death / 
reinfarction / stroke was significantly reduced in the PCI group (13.7% versus 
8.0% p=0.0003). Remarkably, this outcome was observed allowing transfer 
times (time from first presentation to arrival at the cardiac centre) of up to 3 
hours. The results are all the more striking as primary angioplasty was not 
available in 2 of 5 participating centres prior to the study, and operators were 
trained during a pilot period. 
PRAGUE-2 (20) has provided further support for a primary PCI transfer 
strategy. It randomised DGH patients to on-site thrombolysis with 
streptokinase or transfer for PCI. Although the mortality reduction (10% 
thrombolysis (TL) vs. 6.8% PCI) did not reach significance across all patients, 
it became significant in patients who presented greater than 3 hours following 
onset of symptoms (15.3% TL versus 6% PCI P<0.02). This is in 
keeping 
with the exponential deterioration in efficacy of thrombolysis with 
increasing 
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symptom duration that we might expect, which appears significantly 
attenuated with PCI (21). 
A recent meta-analysis of 23 trials comparing primary angioplasty and 
thrombolysis (22) included all these transfer studies, and other trials 
employing current interventional techniques (12 using stents and 8 using 
GPRA therapy). Mortality following PCI was significantly reduced (whether or 
not cardiogenic shock patients were included), as was stroke and non-fatal 
MI (figure 1). This is contemporary primary angioplasty in a wider group of 
patients than previously described. 
Summary 
Clinical evidence clearly demonstrates that primary (or direct) angioplasty is 
a superior reperfusion strategy when compared with thrombolysis, yet this 
service is not routinely available in England. 
Figure 1. Keeley et al. Meta analysis of 23 randomised trials of Primary Angioplasty 
versus Thrombolysis 
Adapted from Keeley EC, Boura JA, Grines CL. The Lancet 2003; 361: 13-20 
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3. PILOT PROJECT 
NORTH EAST LONDON 
PRIMARY ANGIOPLASTY DAYTIME - WEEKDAY ONLY SERVICE APRIL 2003 - JANUARY 2004 
BACKGROUND 
The key to providing the earliest possible reperfusion is pre-hospital 
diagnosis and delivery of patients directly to a dedicated team in the catheter 
lab, bypassing delays in Accident and Emergency. In DANAMI-2 the door to 
balloon times for transfer patients were comparable to and in some cases 
shorter than those presenting to a cardiac centre. While this seems a positive 
result demonstrating rapid patient transfer, it also suggests significant delays 
in regional centre A&E departments. 
Many NE London ambulances have ECG capabilities, with crews trained in 
12-lead ECG recognition. We propose a 'direct access' strategy where crews 
can deliver suitable patients diagnosed in the field directly to the catheter lab. 
However, where patients present themselves directly to hospital, there will 
also be a mechanism to rapidly transfer these patients in addition. This latter 
group will have anti-platelet therapy administered in the A&E pre-transfer. 
This model has been the basis of a pilot primary angioplasty programme that 
is currently operating on the London Chest Hospital site. It opened to London 
Ambulance Service (LAS) calls in April 2003, offering a daytime weekday 
only service to three East London hospital catchments. Data collected and 
experience to date are included in this proposal, informing the development 
of the 24-hour seven-day service. 
Taking this proposal forward require changes in working practice. It will also 
necessitate investment. This business case sets out the alterations in 
working practice, projected workload and costs. 
Initial 'pilot' 
Patients presenting with STEMI via the London Ambulance Service 
(LAS) from the catchment population of Tower Hamlets would have 
direct access to the London Chest Hospital for immediate angiography 
with a view to primary angioplasty. 
This was based on pre-hospital diagnosis of STEMI by trained 
participating LAS crews with on board 12 lead ECG capabilities. 
The service was initially open to patients presenting via LAS, between 0800- 
1600 weekdays, and only within the Royal London Hospital (RLH) catchment 
area. 
Based on audit data previously presented it was expected that we would treat 
2.75 patients pcm, and a maximum of one patient per week. 
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Our actual experience was that LAS delivered only 4 patients in the first four 
months, 2 of whom were confirmed as STEMI on arrival. This was a result of 
a combination of factors including frequent closure (bank holidays, audit 
days, British Cardiac Society, Euro PCR live case day), and missed direct 
presentations to A&E. 
Extended 'pilot' 
Two additional initiatives were adopted to increase patient numbers to the 
previously expected level (average one patient per week). 
An immediate transfer protocol from RLH A&E for STEMI patients 
(opened August 18 th) 
Expansion to include patients picked up by LAS in the Newham and 
Homerton hospital catchment (opened August 14 th) 
We will expand to accept A&E transfers from Newham and Homerton 
in early 2004. 
These initiatives were adopted in collaboration with LAS and RLH A&E, and 
with consultation of Newham Hospital Cardiology and A&E departments, 
Newharn PCT, and the North East London Cardiac Network board. 
In addition there has been a commitment from the LCH cardiologists and 
cath lab staff to avoid any weekday closures unless essential. 
Service Delivery and Patient Experience Outcomes of Pilot 
Figures 2 and 3 demonstrate the 19 admissions to LCH thus far. 
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FIGURE 2: SOURCE OF PRESENTATION 
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FIGURE 3: OUTCOME ACCORDING TO ECG / CLINICAL DIAGNOSIS 
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12/19 patients were diagnosed as definite ST elevation events. The table 
below demonstrates the rapid instigation of treatment on arrival. Patients are 
rapidly assessed by a cardiologist, and transferred to the catheter lab table, 
where angiography is performed with angioplasty as necessary. 
EFFICACY OF Mean (mins) Median Range 
DELIVERY 
Arrival to table 16.4 15 10-30 
N=1 2 
Door (LCH) to 42.6 38 19-104 
balloon 
N=1 1 
All procedures were successful. There was one (femoral) in-hospital 
complication necessitating prolonged hospital stay, but no additional therapy. 
Evaluation of pilot 
While the number of patients treated is small, it has been demonstrated that 
primary angioplasty can be delivered effectively at the London Chest Hospital 
with favourable door-to-balloon times, in-hospital outcomes, and early 
discharge. This has been achieved with the development of explicit protocols 
for direct access and A&E transfer respectively. There is also an 
infrastructure for interdisciplinary collaboration (between LAS, Cardiology and 
A&E), and ongoing support from the Cardiac Network, with frequent feedback 
to PCTs involved. To date no major logistical problems (such as bed 
occupancy, or cath lab availability) have been experienced. 
At present the pilot service recruits patients during daytime hours (0800- 
1600) on weekdays as follows: 
1. Direct access of LAS crews from Royal London (RLH), Newham 
(NGH) and Homerton (HOM) catchments. 
2. STEMI transfers from the RLH A&E. 
This will expand to accept A&E transfers from Newham and Homerton in 
early 2004. 
The protocol used for the pilot phase sets out clear and specific inclusion and 
exclusion criteria, and transfer mechanisms. It lends itself to being adopted 
by a wider catchment on a 24-hour basis and to include other hospital 
A&Es, 
with adaptations outside normal working hours. 
Since opening to direct access admissions for RLH catchment 
in April 2003, 
the programme has gradually expanded to receive RLH A&E transfers and 
subsequently direct admissions from Newharn and Homerton. 
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4.24-HOUR, SEVEN DAY SERVICE PROPOSAL 
BACKGROUND 
Based on the success of the pilot project it is proposed that this extended into 
a 24 hour 7 day service in a two phased approach: 
PHASE 1 
The proposal is an adaptation of the existing pilot protocol, with changes to 
cater for out of hours staffing and working practice. 
The first phase would involve a modified protocol for receiving patients out of 
hours (5pm-8am) for the existing participating hospitals, Royal London, 
Newham and Homerton. 
1. Recruitment and transfer 
The method of recruitment will remain as per the existing protocol. The 
service will continue to accept all patients that fulfill inclusion and exclusion 
without formal referral. 
1. Transfer from home 
Paramedic ambulance crews make the diagnosis using on board 
12 lead ECG equipment, and transfer directly to the London Chest 
Hospital 
This will continue for the 3 hospitals in East Central LAS sector 
(RLH, NGH, HOM) 
2. Rapid critical transfer from A&E Departments 
a. This will occur in the East Central LAS Sector when: 
Paramedic crews are not available to make diagnosis 
Paramedic crews are uncertain regarding suitability of the patient 
Patients self present to A&E 
Patients develop new ST segment elevation in A&E 
A&E transfers - Pre transfer therapy 
The existing protocol for pre transfer therapy with a glycoprotein Ilb/Illa 
receptor antagonist bolus (abciximab - ReoPro TM), and clopidogrel will be 
administered to patients form RLH, HOM, NGH. These patients would usually 
be expected to undergo cardiac catheterisation within 60 minutes. 
Out of Hours Transfer Protocol 
Calls received between 0800-1600 on weekdays will be received according 
to the current Pilot Primary Angioplasty Protocol. 
Calls received after 1600 will be dealt with as follows: 
The call will be diverted to CCU automatically and received by a 
nominated senior nurse bleep holder. 
The AMI bleep will be activated as usual. This will alert the out-of-hospital 
cardiac team. 
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The patient will be received onto CCU, NOT INTO THE LAB, and assessed by a resident SHO and subsequently the non-resident specialist registrar (SpR) on call, pending arrival of the on call catheter lab team. Maximum call to arrival time must not exceed 1 hour, as per trust guidelines. 
All procedural aspects will be performed as per the existing protocol. 
Proposed Starting Date 
Subject to being able to recruit to the additional posts required to cover the 
on-call component of the service, it would be possible to begin from the 1.4.04. 
PHASE 2 
Expansion of recruitment to three further hospital catchments: King George 
Hospital (Ilford), Oldchurch and Whipps Cross. 
Rapid "critical" transfer from A&E Departments as described above will be 
the ONLY transfer method from the further hospitals (KGH, OCH, WX). 
These patients will receive anti-platelet pharmacotherapy starting in A&E 
before transfer, to give them a better than 75% chance of having TIM13 flow 
on arrival 
A&E transfers - Pre transfer therapy 
1/2 dose TPA (or TNK or Reteplase) is proposed for patients from OCH, WX, 
KGH. These patients may less reliably undergo catheterisation within 60 
minutes. 
Implications for LAS sectors 
The initially proposed hospitals lie in the Central LAS sector (NGH, HOM, 
RLH), the others in the northeast sector. Moving vehicles between sectors 
may lead to a shortage of local emergency vehicles. The LAS is committed to 
the pilot and to addressing this problem, but this is not felt to be achievable in 
the timescale proposed for the implementation of Phase 1, hence the 
proposal of Phase 2 involving the other 3 hospitals. There is a commitment 
from LAS to provide the critical transfer service to this patient group as soon 
as is feasible. 
Patients from further other catchment areas including North central London 
and Essex sectors would be accepted as part of the service, subject to the 
appropriate ambulance service being able to commit to the extended 
geographical transfer times arising through redirecting transfers to the 
London Chest Hospital. 
Proposed starting date: 
This would be dictated according to the progress of discussions with the A&E 
Departments in other hospitals and the LAS in relation to the impact of the 
service development on their ability to meet their own performance targets. 
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Patient Numbers 
The projected workload is based on audit data from the six participating 
hospitals (Table 1). This information is now 2 years old and more recent 
information is being gathererd. 
TABLE 1 
Admissions with 
definite or Probable 
STEMI 
October 2001-2002 
Inpatient 
angiogram 
No. (%) 
Outpatient 
Angiogram 
Planned 
No. 
KGH 114 51(45) 30 
NGH 104 22(21) 31 
RLH 105 59(56) 12 
OCH (est)* 130 70(54) - 
HOM (est)* 70 50(71) 
WX (est)* 100 55(55) 
TOTAL 523 309(59) 
* Est = Estimations pending full data collection 
Thus we would initially predict receiving 1.4 patients per day (10 patients per 
week). 
However, based on initial experience from the pilot programme we will also 
expect to receive some Non-ST elevation Acute Coronary Syndrome (NSTE- 
ACS) patients. 
Figures 2 and 3 represent recruitment from April 2003 - January 2004 
These data demonstrate that we must cater to receive up to 25% more 
patients than these figures predict. 
This would result in 654 patients per year 
(1.8 patients per day, 12.6 patients per week) 
Calculation of costs is therefore based on receiving an average of 2 
patients per day. 
It should however be made clear that a minimum of 50% of these 'additional' 
procedures are already being performed at BLT during daytime hours as 
query proceed' cases. The majority from these particular hospitals are 
performed on the London Chest site. This means that there is the existing 
catheter lab capacity to commence the proposed service with 
immediate 
eff ect. 
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5. NON FINANCIAL BENEFITS ARISING THROUGH PROJECT 
Hospital bed day savings 
At present evidence suggests patients who remain uncomplicated following 
STEMI should be eligible for discharge after 4 days. However in practice 
patients are kept in much longer. In a recent study Kaiser Permanente, a 
non-profit health maintenance organisation in California, reported an average hospital stay for acute myocardial infarction in the year 2000 of 4 days 
compared with 5 days for US Medicare patients and 9 days for NHS patients 
(23). 
Previous Royal London Hospital Experience 
Our own experience based on audit data (October 2002-3) is displayed 
below (table 2). The overall mean stay was 7.9 days. 
Notably, the 56% of patients requiring inpatient cardiac catheterisation had a 
prolonged stay, driven by delays in inter hospital transfer. The mean stay 
increased to 9.6 days when transfers for early (<48 hours) ischaernic 
complications were excluded. 
N Mean Median Range 
Referred for 59 All 8.1 6 1-36 
Inpatient 
Angiography 40/59 urgent 9.6 7 3-36 
transfers excluded 
Not referred Data for 31/39 6.4 5 2-24 
for Deaths excluded 
angiography 
Hospital Discharge - Advantages of Primary Angioplasty 
Uncomplicated patients following primary angioplasty may be discharged on 
the third day of admission (24). Our own pilot primary angioplasty protocol 
allows for discharge of uncomplicated patients at 48 hours. This is based on 
the fact that all risk stratification (with angiography and echocardiography) is 
performed within this period, and evidence that the vast majority of major 
complications occur within this time period, with further problems occurring at 
a relatively constant rate out to 30 days (25). 
In addition, recent evidence demonstrates that the rate of re-admission with 
non-fatal myocardial infarction following primary angioplasty is significantly 
reduced relative to thrombolysis (26). 
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Hospital Discharge - Experience from London Chest Pilot Primary 
Angioplasty Programme 
Since opening to calls from LAS 19 patients have been delivered to LCH with 
a view to primary angioplasty. 12 were diagnosed with definite ST elevation, 
11 of whom underwent primary angioplasty. 
Mean hospital stay was 2.9 days (one patient stayed nine days following a femoral complication (table 2). 
In addition 5 patients with non-ST elevation syndromes were admitted, 4 of 
whom underwent angiography, 3 undergoing PCI. The mean hospital stay for 
these patients was 1.2 days. If they had presented via A&E, these patients 
would normally have been listed for later routine inpatient transfer and 
angiography. 
Table 2 PILOT PRIMARY ANGIOPLASTY: duration of hospital stay 
PATIENTS MEAN STAY MEDIAN STAY RANGE 
_STEMI 
n=12 2.9 2 1-9 
NSTE-ACS n=5 1.2 1 1-2 
Non Cardiac n=2_ 
_ 
NA 
If we extrapolate these data to our projected 1 -year (six-hospital) population 
we would expect major savings in terms of hospital stay. 
654 patients @ mean 2.9 Days 1896 hospital days 
654 patients @ mean 7.9 Days 
Days saved 
Days Saved per 100 patients 
5166 hospital days 
3270 
500 
This is a conservative estimate based on the Royal London Hospital mean 
hospital stay, and assuming all 654 primary angioplasty patients would incur 
a'STEMI'stay. 
Benefits To Local Hospitals 
Savings on the cost of thrombolytics in the local hospitals (data is 
currently being collected). 
Reduction in the number of patients presenting to local A&E 
Departments, thus reducing the pressure around meeting targets. 
Improved efficiency of bed usage will be delivered in beds on each of 
the provider trusts within NE London sector. Transfer data are 
currently being examined from an audit relating to this. 
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A small proportion of patients (25-30% of local transfers) have an ACS 
without ST elevation but have continuing pain. These patients could be transferred immediately and be investigated/treated immediately 
using the same team. This would give the on-call teams a more 
realistic workload amd would drastically reduce transfer times. 
6. SUMMARY 
We have demonstrated that we currently deliver a working daytime 'Regional 
Heart Attack Centre' model for primary angioplasty in East London which 
benefits both patients and Trusts in terms of speed of care and length of 
hospital stay. The existing protocol requires minimal change in order to offer 
a 24-hour 7 day service to a wider population. We have addressed the 
mechanisms for delivering this service to ensure we are able to deliver an 
evidence-based and cost-effective service. 
In addition to the direct benefits of this reperfusion strategy to patients, the 
programme will reduce Accident and Emergency waiting times, hospital stay, 
and readmission rates. These potential benefits will be prospectively audited 
during the first year of the service. 
The proposal has been developed in partnership with the LAS, NEL Cardiac 
Network and the relevant acute hospital Trusts, and if approved would be an 
excellent example of successful working across a network area to the nebefit 
of the patient. 
Next Steps 
The proposal will be taken to the North East London Cardiac Network to 
obtain the support of key stakeholders. 
Directors of A&E Departments in the local hospitals will be consulted in 
relation to the impact of the proposal on their existing working practise. 
Due to the benefits of the proposal to all parties it is not anticipated that there 
will be any irresolvable concerns. 
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7. COSTS: PHASE 1 
1. CATHETER LAB CAPACITY / CONSUMEABLES 
It is expected that we will perform approximately 550-560 DIRECT AMI 
procedures per year. 
(Pilot data (Figure 2+3) predict catheter studies on 85% of transfers, PCI for 
70% of transfers). This work will be spread throughout the 24-hour seven-day 
period. However it will be offset by a reduction in STEMI inpatient transfers 
undergoing daytime catheter/query proceed studies (which currently make up 20-25% of all inter-hospital transfers). As seen in table 1 above, this should 
account for at least half of the total number, which means that the catheter 
lab capacity is readily available. 
ESTIMATED ADDITIONAL WORKLOAD 300 procedures maximum 
50-65% of these will be performed out of hours. Therefore we would not 
expect to need additional daytime lab capacity. 
2. BEDS / ASSOCIATED WARD STAFF 
There must be sufficient capacity to accept 2 patients per day, with an 
average hospital stay of 2.5 days. 
We recommend 3 additional dedicated AMI transfer beds. 
CAPITAL EXPENDITURE -3 additional fully equipped beds 
WORKS Cost 
Monitors, Oximetry 
Oxygen Supply, Suction E45,000 
_ TOTAL C459000 
REVENUE 
These beds will require 1: 3 nursing, necessitating 5.8 additional nurses. 
3. EMERGENCY STAFF 
Catheter Lab 
While existing on call arrangements can be preserved, there will be a 
significantly increased workload. Staff may be expected to be called on 50- 
75% of evenings. In such cases they will not be expected to work the 
following day (morning) in line with EWTID. This will necessitate recruitment 
of staff. 
The staffing proposed will enable cover for out of hours activity on a daily 
basis. 
a. Nursing 
2 additional catheter lab nurses are required 
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b. Radiographers 
Radiographers already perform a 24 hour on site service. 
There is therefore no additional cost. 
c. Technicians 
2 additional catheter lab technicians are required 
Phvsicians 
a. Senior House Officers - the current SHO rota will be preserved. There 
are no additional cost implications. The SHO will be the first medical contact 
for the patient. This will be of additional training value to the respiratory SHOs 
who participate in this rota. At times where multiple inpatients require 
immediate attention, help may be sought from on call anaesthetic staff. 
b. Specialist Registrar - The current SpR rota will also be preserved, 
remaining non-resident. 
c. Consultants - There will be a dedicated AMI intervention on call rota 
comprising all DGH interventionists serving the participating hospitals, and 
local interventionists serving RLH. This will be based on the London Chest 
site, operating independently of which centre is on call for non-STEMI 
emergencies. 
(As experience with this system progresses, it is expected that senior 
interventional fellows will gain sufficient experience to operate independently 
without on site consultant supervision, subject to achievement of an agreed 
competency level) 
Surgical Cover will be agreed across both sites (LCH and St. 
Bartholomew's), as STEMI patients very rarely require immediate surgical 
intervention. Therefore there will be no impact on the surgical rota. 
4. FOLLOW UP 
A dedicated clinic will follow all patients at 6 weeks. Subsequent follow up will 
revert to local hospitals. 
CLINIC COST (estimated for 10 patients per week) 
Cardiac rehabilitation and diabetic care will be handed back to the local 
hospital. 
5. AUDIT 
The whole patient population will be subject to regular and continuous audit 
and as such will require dedicated audit/data collection staff support. 
This is 
mandatory, and will require IT support. 
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A dedicated fellow (Senior SpR grade) will continue to oversee and implement the project, with responsibility for continued data analysis, and 
quarterly reports to the participating hospitals, BLT trust and the Cardiac 
Network Board. In addition, it is proposed that a coordinator for the project is 
appointed. 
COSTS: PHASE 2 
It is not possible to accurately detail the costs involved in Phase 2 until the 
full implications of the area expansion for LAS have been determined. 
However, additional costs will include: 
" LAS costs 
" An additional 2 beds and nursing staff 
" The cost/availability of staff from transferring hospitals to accompany 
patients being transferred from A&E. Over 70% of these would 
usually transfer to BLY anyway but the change to an acute rather than 
planned transfer may have a cost implication 
" It will not be necessary to further increase the on-call staffing for the 
catheter labs from Phase 1 
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Costings for direct AMI paper 
Area WTE Cost 
CTU 
Nurse grade F 2 81,650 
Nurse g ade E 2 72,910 
Nurse grade D 2 68,310 
222,870 
Labs 
Additional posts 
Nurses (grade E) 2 70,150 
Technician (MT04) 2 83,260 
SpR? 1 70,929 
224,339 
On call payments (above those 
currently paid) 
Assumes 3 
hrs per night 
Nurse 19,391 
Technician 16,920 
36,311 
Other pay costs 
Outpatients 
Standard cost for 1 outpatient 
clinic per week 
10,000 
Project coordinator 1 31,740 
Research Fellow (no on call 
duties) 
1 52,836 
Total revenue costs 578,096 
Capital costs 
Monitoring for 3 beds 45,000 
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APPENDIX le 
DIRECT AMI UPDATE October 2004 
The Primarv AnqioDlastv Pilot Service at Barts 
and the London NHS Trust 
Progress Report and Proposed Expansion to serve the North 
East London Cardiac Network 
Elliot J Smith and Martin T Rothman on behalf of the Primary Angioplasty 
Working Group 
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1. Introduction 
At present the pilot primary angioplasty service treats patients diagnosed with ST segment 
Elevation Myocardial Infarction (STEMI) diagnosed within 'East Central London' within 
working hours. In practice this means any patient diagnosed with STEMI within the catchments 
of the Royal London Hospital, Homerton University Hospital and Newham University Hospital 
between 0800 and 1600 Monday to Friday. This represents the pilot phase (phase 1) of the 
project, which was designed to demonstrate the feasibility, efficiency, safety and efficacy of a 
Regional Heart Attack Centre (RHAC) model of infarct management in our metropolitan UK 
population. 
Patients are identified either by specially trained London Ambulance Service (LAS) crews in 
the community or by any of the three participating A&E departments and taken immediately 
to the cardiac catheter lab at the London Chest Hospital without referral, where the occluded 
coronary artery can be reopened mechanically by angioplasfy, rather than receiving standard 
thrombolytic therapy. 
The success of the pilot has led to the desire to offer this service to all STEMI patients within the 
North East London Cardiac Network. In practice this would mean accepting STEMI patients from 
within the catchments of Whipps Cross Hospital, Oldchurch Hospital and King George Hospital 
in addition to the existing areas (Figure 2). 
Phase 2 of the process will expand the service geographically, but will continue to operate 
during working hours only. This will ensure there is a smooth learning curve similar to that 
experienced by the existing LAS crews and A&E departments. 
Phase 3 will allow transition to a 24 hour seven day service. This will be the first coordinated 
RHAC Network service in the United Kingdom. 
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2. Objectives of the Scheme 
The objectives of the scheme are to: 
1. Provide equity of access to state of the art evidence based care (primary angioplasty) 
for all heart attack patients in Northeast London, irrespective of postcode. 
2. Deliver immediate coronary intervention wherever necessary with speed, efficiency, and 
equity of access. 
3. Provide an integrated patient journey through the network, from pre-hospital diagnosis, 
through the RHAC, and with a network wide rehabilitation and education process 
coordinated between the RHAC and local DGH. This will ensure a patient centred 
approach well beyond the initial intervention. 
3. The Primary Angioplasty Pilot at Barts and the London NHS Trust 
Phase 1- The Pilot 
The pilot primary angioplasty service opened in April 2003, initially serving only the local 
population (the Royal London Hospital), operating during working hours only (weekdays 0800- 
1700). We sought to provide data as to the safety and feasibility of a RHAC model for all STEMI 
patients in Northeast London (and Essex). The pilot has since expanded and currently treats 
patients presenting not only to BLT, but also STEMI patients diagnosed within the catchments of 
Homerton and Newham hospitals during working hours. The pilot has proven successful in terms 
of service delivery, safety, and patient outcomes, with key benefits including a radical reduction 
in hospital stay. Patients are received directly into the cardiac catheter lab, and the culprit artery 
opened rapidly where necessary. Data are summarised below: 
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A. EXPERIENCE TO DATE 
Total Number of patients delivered to LCH for consideration of Primary Angioplasty, with 
discharge diagnosis, and treatment received. 
Home 110 
34 AMBULANCE 
DIRECT 
LAS pre-hospital 
diagnosis 
36 
A&E 
I Newham I 
A&E diagnosis 
7() 
LONDON CHEST 10 (141/6) 
I NON CARDIAC 
48 (69Yo) 12 (17'Yo) 
DEFINITE STEMI NSTE-ACS 
It It 
47 4 
PRIMARY ANGIOPLASTY for 
ANGIOPLASTY NSTE - ACS 
B. EFFICIENT DELIVERY OF THERAPY 
TABLE 1: Patients are rapidly assessed, moved to the catheter lab table, and angioplasty 
performed. 
N=41 STEMI Mean (scl) 
Arrival at LCH to Cath Lab table 16 mins (7) 
Arrival LCH to Balloon inflation 39 mins (11) 
RoyalLondon 
-w- 
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C. IMPROVED OUTCOMES FOLLOWING PRIMARY ANGIOPLASTY 
Outcomes follovWng Primary Angioplasty versus 
30- 
Thrombolysis 
27 
25- 
20--1 
*ä-ýO 15 
10- 
5- 
0 
The black columns represent patients presenting to the RHAC during the pilot service diagnosed 
with definite ST segment Elevation Myocardial Infarction. The Grey columns represent STEMI 
patients assigned to thrombolysis during the pilot period (i. e. performed out of hours). The third 
column shows all patients with STEMI treated in a 12 month period prior to the instigation of 
primary angioplasty. Follow up was for a mean of 21 weeks. 
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D. IMPACT ON HOSPITAL STAY 
Uncomplicated patients are discharged at 48 hours. 80% of all patients admitted are discharged 
by day 3. 
The table demonstrates that hospital stay is radically reduced following primary 
angioplasty. 57% of thrombolysis patients were transferred for inpatient coronary 
angiography, which further prolonged hospital stay. 
Hospital Stay (days) 
Primary 
Angioplasty 
n=41 
Thrombolysis 
(during pilot) 
n=76 
Thrombolysis 
(pre pilot) 
n=96 
ALL Patients 
3.1(1.4) 8.5(6) 7.3(5) 
Mean (scl) 
NOT Transferred for inpatient 
7.2(5) 5.6(4) 
angiography NA 
Mean (sd) 
n=35 n=39 
Transferred for inpatient 
9.2(6.8) 8.2(6.6) 
angiography NA 
Mean (sd) 
n=41 (54%) n=57 (59%) 
Awards for the Pilot Service (Phase 1) 
These achievements have been recognised by the Department of Health, with the service 
receiving the regional award for outstanding achievement in Emergency care at the Health and 
Social Care Awards 2004 1. In addition our team is one of three nominees for the Cardiology 
award at the Hospital Doctor Awards 2004, and one of four finalists for the Health Services 
Journal Awards 2004 in the category 'Improving Patient Access. ' 
Geographical and Temporal Expansion (Phases 2 and 3) 
We now propose to expand the service to provide firstly geographical 
(Phase 2), and secondly 
temporal equity (Phase 3) for STEMI patients diagnosed anywhere within the 
North East London 
Cardiac Network. The service aims to treat all patients presenting with suspected 
STEMI via the 
RHAC model, within the catchments of the existing participating 
hospitals (Royal London, 
Homerton, and Newham Hospitals), in addition to those of King 
George (Ilford), Oldchurch 
Hospital, and Whipps Cross Hospitals. 
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Phase 2 
The London Ambulance Service with Barts and the London NHS Trust will offer this service to 
the three additional catchments and their respective ME departments from Jan 4 th 2005. The 
service will continue to operate on weekdays (excluding bank holidays) receiving STEMI patients 
diagnosed at the centre of origin between 0800 and 1600. It is anticipated that Phase 3 (a 
24-hour seven-day service) will commence later in 2005. 
4. Implications to Participating District Hospitals and respective 
Accident and Emergency Departments 
Key Benefits 
All patients presenting with chest pain and ST segment Elevation will be treated initially at Barts 
and the London NHS Trust. In addition all outpatient follow up will be performed at the RHAC. 
This will have the following key advantages: 
1. Reduction in district hospital admissions with ACS by 25-30% 
2. Reduction in waiting time for inter-hospital transfer of high risk Non-ST-elevation ACS 
(as 30% of patients listed for transfer are admitted with STEMI) 
3. Reduction in ME presentations with STEMI by 50%. (Based on experience within the 
current network, 50% of patients are admitted to the RHAC directly via LAS from the 
community). 
4. A guarantee that those STEMI patients that still present to ME will never incur 
prolonged waits in ME (as they will be transferred immediately without referral). 
Cost and Projected Workload 
1. Pre transfer therapy: 
Patients admitted to ME will require one dose of clopidogrel orally, and a bolus dose of 
abciximab. They will not require thrombolysis. The net cost is c. E100 per patient 
compared with aspirin and thrombolysis. 
However, this cost will be incurred in only half the current total number of patients 
receiving thrombolysis (as explained above). Furthermore, less than 25% of these 
patients will require an inpatient stay at the district hospital (following transfer back to the 
DGH after primary angioplasty. The majority are sent home from the RHAC). 
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2. Procedures 
Audit data from Barts and the London NHS Trust demonstrate: 
(Follow up of 105 patients admitted with chest pain and ST elevation October 2001-2000) 
68% of patients ultimately undergo angiography following presentation with STEMI 
48% of patients undergo revascularisation (90% undergoing angioplasty). 
Recent data from the primary angioplasty pilot: 
90% of patients presenting to the RHAC undergo immediate angiography 
80% of patients presenting to the RHAC undergo immediate revascularisation (all 
angioplasty) 
Projected Workload 
Across the Network over 24 hours, a maximum of 700 patients would be expected to 
present to the RHAC per annum. Based on the data above: 
90% undergo immediate angiography: 
vs. 68% 
630 
476 
Additional angiographic procedures (6 Trusts) 154 
Additional angiographic procedures per Network Trust per year 26 
80% undergo revascularisation (all coronary angioplasty): 560 
48% undergo revascularisation (all coronary angioplasty): 336 
Additional angioplasty procedures (6 Trusts) 224 
Additional angioplasty procedures per Network Trust per year 
37 
Thus the absolute increase in invasive investigation and revascularisation 
as a 
proportion of all revascularisation is small. 
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5. Service Model 
The Phase 2 service model is outlined below. This is a geographical extension of the 
existing service. A sample A&E Transfer form is included (Appendix A). 
A. PRE-HOSPITAL 
1. All Patients diagnosed with possible STEMI fulfilling entry criteria (Table 3) within the 
Northeast London Cardiac Network will have immediate and direct access to a Regional 
Heart Attack Centre (RHAC) for primary angioplasty. 
2. Patients will be selected by trained LAS crews making a pre hospital diagnosis using on- 
board 12 lead ECG equipment, and without referral. LAS crews will have clearance to 
bypass the nearest ME in favour of the RHAC 
3. STEMI patients presenting to any A&E department within the network will also have 
access to the RHAC via immediate LAS transfer - also without referral. These will be 
performed as 'critical transfers' giving them a 999 priority. These patients will have the 
opportunity to receive pre-transfer therapy where possible, facilitating rapid treatment at 
the RHAC. 
a. Patients presenting first to an Accident and Emergency department will receive 
oral clopidogrel and intravenous abciximab (a glycoprotein Ilb/Illa receptor 
antagonist) prior to transfer, in addition to the usual aspirin. 
4. The RHAC will be based on the London Chest Site 
5. First notification of an incoming STEMI patient will be performed by the incoming LAS 
crew, irrespective of their origin (i. e. from the community or a participating ME 
department). The call will be received via a designated telephone line in the catheter lab 
(0800-1600). On receipt of the call, a 'DIRECT AMI' bleep will be sent to the receiving 
team (SpR, SHO, Cardiac physiologist, cath lab nurse, radiographer, porter, security, 
and bed manager). 
B. ON ARRIVAL AT THE RHAC 
6. The patient will always be received into the catheter lab, and assessed by the resident 
SpR, and a decision taken as to suitability 
7. Unless contraindicated, all patients will receive aspirin, clopidogrel, and abciximab 
(reopro) prior to angiography (unless already administered). 
8. Angiography will be performed according to the usual primary angioplasty protocol. 
Culprit vessel angioplasty and stenting will be performed where appropriate, with other 
vessels treated at the operator's discretion 
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C. INPATIENT STAY 
9. Patients will remain monitored on CCU for 24 hours 
10. Uncomplicated patients (age<75, successful angioplasty, moderate or better LV 
function, free from arrhythmia) will be discharged home at 48 hours 
11. Patients expected to stay more than 48 hours will be transferred back to their local 
hospital under the care of the local cardiology team 
12. Patients will receive all prognostic therapy prior to discharge unless contraindicated 
D. FOLLOWING DISCHARGE 
13. All patients will be reviewed within one week of discharge by the local cardiac 
rehabilitation service. Data will be sent electronically from the BLT rehabilitation team. 
Clinical problems can be assessed by the local cardiology team, but will always be 
communicated via the local rehabilitation team to the BLT rehabilitation team and 
thereby to the coordinating 'Direct AMP SpR. This will ensure rigorous data flow. 
14. All patients will be reviewed once at BLT 8 weeks following discharge in a nurse led 
doctor supervised clinic (coordinated through the cardiac rehabilitation team). This will 
be the only formal outpatient follow up. 
15. Data will also be collected at 6 months and 1 year via telephone questionnaire. 
16. This will provide the only network wide coordinated rehab programme for STEMI. 
17. Data will be entered onto a designated server, with regular downloading to the CCAD / 
MI NAP database. 
Table 3: Inclusion and Exclusion Criteria 
INCLUSION CRITRIA EXCLUSION CRITERIA* 
Chest pain; Sustained cardiac pain 
within the preceding 12 hours 
- ST segment Elevation on ECG 
* Orientated, conscious 
o Age 2: 18 years 
. Left Bundle Branch Block 
- Cardiogenic Shock 
. Intubated / ventilated 
- Established Cardiac Arrest 
Confused/ reduced conscious 
level 
Previous Stroke with dense 
hemiplegia 
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6. Conclusion 
The pilot primary angioplasty service has already proven safety, efficiency and clinical 
effectiveness operating during daytime hours and serving a network of three feeding hospital 
catchments, and has been recognised by the Department of Health for its achievements in 
improving emergency care. The service has the support of the North East London Cardiac 
Network Board, Barts and the London NHS Trust Chief executive, the London Ambulance 
Service and all currently participating ME departments. 
We now propose expansion of the existing protocol geographically during working hours on 
weekdays. This will offer significant benefits not only to the patients but also the participating 
Trusts, in reducing inpatient hospital stay, and interhospital transfer delays, with a negligible 
increase in procedural activity. We look forward to offering this daytime service from Tuesday 4 th 
January. A 24-hour service is ultimate goal of this initiative, and will represent the final phase in 
the development of this service. 
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The map demonstrates the phase 1 (current) catchment and the proposed phase 
2 
catchment. The participating Hospitals are shown, with the expected number of 
STEMI 
patients seen per year highlighted. 
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